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Abstract
This Thesis provides evidence that raised plasma growth hormone (GH) 
levels play an intrinsic metabolic role in Type 1 diabetes. Physiological and 
functional aspects of G H  pulsatility has been examined under standardized 
conditions.
Diabetic subjects have prolonged G H  clearance characteristics: Bolus 
G H  half-life {tVi) measurements and distribution volume (DV) are increased 
(meanjf SEM tVz 13.6^1.1 vs control 8.9+.0.54 mins, p<0.05; DV 6.1+.0.4 vs 
control 3.54+.0.32L, p < 0.005). Short-term euglycaemia, hyperglycaemia or 
hyperinsulinaemia do not influence GH decay. The time-mode of G H  
exposure critically extends G H  half-life (60min exposure tVz 25.7±2.1 mins; 
steady state (12h exposure) tVz 28.59^1.8 mins) describing an asymptote.
The dynamics of G H  secretion are also altered: Deconvolution analysis 
of adolescent plasma GH profiles confirm increased G H  secretion rate (median 
(range) 1.88(0.56-3.81) vs. control 0.62 (0.32-1.92) m U/m in, p <0.05) and altered 
dominant pulse periodicity (90min versus control 135min, p <  0.025). 
Exaggerated GH secretion persists despite overnight euglycaemic clamp. 
Pirenzepine (anticholinergic) reduces mean GH secretion (reduction of 63%, 
range 9.3-82.8%) suggesting the presence of an increased cholinergic tone exists 
in diabetic subjects; pirenzepine did not alter periodicity which remained 
shortened at 90minutes. During insulin-varying clamp and somatostatin 
suppression, trough plasma G H  levels correlate with mean plasma insulin 
(r=0.52, p = 0.016); ambient glucose levels have no effect.
The pulse signal was differentiated: GH pulsatility (3 pulses, mean peak
31.5 (range 26.5-36.9) mU/L) is primarily responsible for an oscillatory increase 
in insulin requirements occuring 135min after a GH pulse (r=0.21,p< 0.001) 
and lasting 240min; both pulses and continuous GH (8-lOmU/L) contribute to 
stimulation of ketogenesis (within Ih of GH exposure); the GH pulse.
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predominantly by continuous G H  tone, raises free fatty acid levels. GH 
stimulated metabolites rise despite optimum insulin provision for euglycaemia.
GH disturbances of amplitude and pulsatility fuel insulin resistance, 
raising insulin requirements; hyperinsulinaemia antagonizes G H  suppression 
summative to an existing raised cholinergic tone. Both mechanisms 
exacerbate G H  release, aggravating G H  levels further; this stimulates release 
of ketones, fatty acids and worsening insulin resistance leading to a spiralling 
cycle of deteriorating metabolic control.
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ABBREVIATIONS (ALPHABETICAL)
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(30HB
Clamp
N G
NI
H G
HI
DV
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GHBP
GHRH
IGF-1
IGF-BP
NEFA
PIR
SRIH
SI Units
tVz
acetoacetate 
3 (3-hydroxybutyrate
maintaining set levels of glucose or insulin in order to carry out 
studies
Normoglycaemic clamp: blood glucose set at 5 m m ol/L 
Normoinsulinaemic clamp: plasma insulin at 8-15 m U /L 
Hyperglycaemic clamp: blood glucose set at 12mmol/L 
Hyperinsulinaemic clamp: plasma insulin at 50 m U /L
Distribution volume: the physiological space where a hormone 
or drug distributes in order to clear from the circulation
Growth hormone implies endogenously secreted hormone or 
measured plasma level
r-hGH recombinant human growth hormone exogenously 
administered
Growth hormone binding protein 
GH releasing hormone 
Insulin-like growth factor -1 
IGF binding proteins
non-esterified fatty acids or free fatty acids
Pirenzepine: an anticholinergic drug
somatotrophin releasing inhibitory factor or exogenous 
somatostatin (1-14)
mU milliunits 
pg micrograms
kg kilograms
GH in this Thesis is measured as mU/L. O ther authors using 
micromols/L can use conversion factor (1 pmol = 2mU)
Half-life: time taken to decay to half-plasma levels after initial 
entrance into blood circulation
diabetic In this Thesis this refers to Type 1 (insulin-dependent)diabetes
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CHAPTER 1
INTRODUCTION
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1.0.0
G R O W TH  H O R M O N E  A N D  PH Y SIO LO G ICA L A D A PTA TIO N S
Complex interactions exist between growth hormone (GH) and diabetic 
metabolism (Sonksen 1993). In adolescent subjects the precise pathology may 
be obscured by multiple hormone and metabolic change, manifesting with 
unpredictable effects in this age group. The scientific knowledge of the GH 
axis over the last 20 years has emerged with contradictory theories, 
particularly as there are multiple levels of hormone action, with complex 
feedback and control mechanisms, from gene expression to regulation of 
mature peptide action. Clarifying the subsequent role of GH secretion and 
action in Type 1 diabetic adolescents remains an outstanding challenge and of 
interest to both researchers and clinicians alike.
1.0.1 C ontrol of norm al G H  secretion
GH is secreted from somatotrophes, which are found in increased numbers in 
the lateral wings of the pituitary, identified by specific immunological staining 
of large secretory granules (Wilson 1988). Now that direct measurements 
(animals) or specific antibody techniques are being employed (humans), a 
better picture is emerging of G H  control. Major transmitters being involved 
are GH releasing hormone (GHRH), synthesised mostly in arcuate nucleus 
(ARC) neurones (Tannenbaum 2001), and somatostatin (SRIH), synthesised in 
hypothalamus within the periventricular (PVe) and ARC neurones 
(Carpentier 1996).
G H R H  and SRIH are present in portal vessels at concentrations that stimulate 
or inhibit GH release and GH gene transcription ÇBluet-Pajot 1998). GH RH  
stimulates both GH synthesis, by increasing the transcription rate of the GH 
gene and GH release (Mayo 2000, Cunha 2000). After binding to somatotroph- 
specific GHRH receptors, functionally distinct receptor proteins are generated 
by alternative RNA processing mechanisms (Miller 1999). In contrast
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somatostatin exerts its physiological actions by its own specific receptors (six G- 
protein-coupled receptors) which are widely expressed in the pituitary, brain, 
and the periphery (Csaba 2001, Dournaud 2001).
O ther neuropeptides synthesised in ARC neurones, such as galanin, or in 
ARC interneurons, such as neuropeptide Y (NPY), are able to modulate 
synthesis and release of G H RH  and SRIH into the hypothalamohypophyseal 
portal system. Gonadal, and adrenal steroid hormones also affect the GHRH- 
SRIH balance and a differential distribution of sex steroid receptors in the 
ARC and the PVe is likely to account for the different pattern of GH 
secretion seen in male and female animals and humans (Van den Berg 1996). 
Sex-steroid hormones (oestradiol and androgens) during normal puberty 
augment GH seccretory burst mass 1.8-3.5 fold, whereas ageing and 
hypogonadism mute the amplitude of pulsatile GH output.
In addition, at other hypothalamic and suprahypothalamic levels, 
neurotransmitters, neuropeptides such as opiates, gut hormones, 
corticotropin releasing hormone (CRH) and thyrotropin releasing hormone 
(TRH) further regulate the secretion of G H RH  and somatostatin.
An ultradian rhythm  in GH secretion is recognised (Wagner 1998). The 
secretion of GH is strongly influenced by the sleep or wake state 
(Brandenberger 2000). Data suggest a differential somatostatinergic control of 
GH release with a lower somatostatinergic tone in the hypothalamic area(s) 
involved in sleep regulation and sleep-related GH release than in the area 
controlling daytime G H  secretion (Van Cauter 1998). However, the concept 
of a dual control of daytime and sleep-related GH secretion remains to be 
directly demonstrated.
Cholinergic muscarinic pathways play an important role in G H  secretion 
(Goni 1997) particularly in the sleep release of GH (Peters 1986). Previously 
muscarinic agonists were shown to stimulate basal GH release and enhance GH 
responses to GHRH (Massara 1986, Torsello 1988, Panzeri 1990). Conversly, 
antagonism of endogenous cholinergic pathways, with muscarinic receptor
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blocking drugs such as mescolapine or atropine or pirenzepine causes a striking 
reduction in the slow wave sleep related GH release (Peters 1986) and virtually 
abolishes the GH responses to L-dopa, apomorphine, glucagon, FK-33-284 
arginine, physical exercise, clonidine and GHRH (Massara 1986). However, 
other authors have found that pirenzepine completely abolished the normal 
sleep-induced GH surge without affecting plasma G H RH  levels (Page 1987a), 
Futhermore, the GH response to insulin-induced hypoglycaemia is largely 
spared during cholinergic muscarinic receptor blockade, although the reasons 
for this are unclear (Evans 1985a). Thus, the cholinergic influence on GH 
control is complex.
Some studies have shown that muscarinic antagonists block an 
inhibitory effect exerted by acetylcholine on SRIH release from the 
hypothalamus (Richardson 1980, Mazza 1994). Others have shown that 
pirenzepine does not exclusively act via release of somatostatin, but may act 
through inhibition of GHRH function. Such increase in SRIH concentration 
could reduce or block the stimulatory effect of exogenously administered or 
endogenously released GH RH  on G H  secretion. In contrast, G H  responses to 
hypoglycaemia may be mediated by reduced SRIH release that might override 
the effects of cholinergic muscarinic blockade. In partial support of this 
hypothesis the inhibitory effect of atropine on GH responses to G H RH  in 
normal rats was abolished by pre-treatment with anti-somatostatin antibodies 
(Locatelli 1986). Although muscarinic and nicotinic cholinergic pathways 
generally play opposite regulatory roles (facilitatory and inhibitory 
respectively), the effect on GH secretion may be different in vivo compared 
with in vitro models.
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1.0.2 The effects of metabolic factors on G H  secretion
Modulation of GH secretion by humeral factors such as glucose, free fatty acids 
and ketone bodies were previously thought to leave the basic temporal pattern 
of GH secretion relatively unaffected (Quabbe 1985).
Glucose deficiency causes a rise in plasma GH concentration which has an 
important role in glucose counter-regulation (Wurzburger 1990). The 
mechanism by which hypoglycaemia causes GH release is unclear: some 
authors suggest the pathway is probably largely independent of GHRH; others 
have shown that G H RH  and hypoglycaemia do have additive effects on G H  
release when administered together (Page 1987b). After prior G H RH  
administration, the subsequent GH responses to GH RH  are abolished while 
GH responses to hypoglycaemia are still preserved and seemed to be enhanced 
(Vance 1986). Vance et al (1986) provided some evidence that hypoglycaemia 
increases GH by reducing somatostatin release from the hypothalamus. 
However, the mechanism that predominates is still not clear as it is possible 
that there is contribution both from release of hypothalamic G H RH  or other 
factors with GH releasing activity, and by reduction of SRIF release.
Whereas hypoglycaemia stimulates GH release, an increase in blood glucose 
levels in normal subjects reduces basal and stimulated GH levels. Elevation of 
the blood glucose concentration reduces the GH response to a number of 
stimuli (Penalva 1989) and this suggests that hyperglycaemia may act by 
eliciting somatostatin release from the hypothalamus. Non-suppression by 
hyperglycaemia has been demonstrated in the GH response to arginine, 
exercise, sleep, L-dopa and GHRH-mediated secretogogues.
In vivo studies in normal subjects suggests that insulin does not have a major 
direct role in GH regulation. Early studies using step wise increases in insulin 
infusion in normal adults, but without taking precautions to maintain a stable 
blood glucose, failed to demonstrate a change in GH concentration until the 
blood glucose had fallen by fifty per cent (Sonksen 1972). However, although 
there was no immediate GH response to insulin when the hypoglycaemia was
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blocked by glucose administration, a late rise in plasma G H  was seen some 
three hours after a bolus of insulin with blood glucose maintained at 4 mrhol 
per litre (West 1977). This rise is analogous to the late rise seen after oral glucose 
ingestion and suggests that this response may be mediated either by a direct 
stimulatory effect of insulin or by an altered glucose flux in tissues after the 
initial accelerated glucose disposal. Which of these events have taken place has 
not been established.
Free fatty acid administration to normal subjects reduces G H  release: this 
effect is probably due to increased somatostatin release since free fatty acids 
reduced GH responses to G HRH in normal rats but not in rats treated with 
anti-somatostatin antibodies (Imaki 1986). However, this does not exclude an 
additional direct pituitary action (Casanueva 1987).
Administration of free fatty acids (NEFA) to normal subjects reduces the GH 
response to a variety of different stimuli including hypoglycaemia, physical 
exercise, L-dopa, clonidine, arginine, sleep and GHRH which is also seen in 
patients with elevated NEFA and/or triglycerides (Imaki 1985). Lack of free 
fatty acids is also a stimulus to GH release (Quabbe 1972).
Ketone bodies also seem to be involved in the modulation of GH release, since 
ketone body administration will almost entirely abolish the G H  response to 
lack of free fatty acids (Quabbe 1983).
Insulin-like grow th factor-1 (IGF-1) acts as a negative feedback in the 
somatotropic axis inhibiting G H RH  and stimulating somatostatin at the 
hypothalamus or pituitary or both.
Daily GH hormonal profiles are thus the product of a complex interaction 
between the output of the circadian pacemaker, periodic changes in behaviour, 
light exposure, neuroendocrine feedback mechanisms, gender, age and the 
timing of sleep and wakefulness. The interaction of these factors can affect 
hormonal secretory pulse frequency and amplitude. The variable interactions 
between GH and other hormone and metabolic factors all require consideration 
particularly when examining subjects in-vivo.
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1.0.3 G H  pulsatility
In the normal state, the pulsatile nature of GH secretion from the pituitary 
gland causes circulating GH levels to fluctuate widely. During much of the 
time, plasma GH is undetectable (trough or baseline levels) by current 
radioimmunoassays and punctuated by secretory episodes, resulting in plasma 
peaks of varying height, which primarily occur at night. Episodic pituitary 
hormone secretion generally reflects episodic stimulation by the hypothalamic 
releasing factors. However, direct measurements are difficult and in humans 
essentially impossible, as dilution of the small portal circulation into systemic 
blood reduces peripheral concentrations of hypothalamic releasing factors to 
unmeasurable values. Thus, the assessment of the pattern of GH pulses in 
peripheral blood is usually the only clue to the pattern of hypothalamic 
secretion although this is clouded by the distortions of clearance, mixing, 
responsiveness of the pituitary and measurement error. Methods of examining 
hormone secretory profiles are many (Bright 1999, Langendonk 2001) and the 
various methods are appraised in Chapter 4.
In human subjects GH secretion is known to be oscillatoiy (Ovesen 1998) but 
the proposed mechanism of pulsatility differs between authors. Originally 
studies in perifused rat pituitary cells have led to the postulation that 
hypothalamic somatostatin withdrawal sets the timing and duration of the GH 
pulse and GHRH activity sets the amplitude of the pulse (Tannenbaum & Ling 
1984, Weiss 1987). When continuous or intermittent G H RH  infusion was 
given in adult male human volunteers, augmentation of consistent repeatable 
GH responses only occurred after withdrawal of somatostatin, suggesting that 
the generation of regular pulsation of GH is dependent on somatostatin changes 
(Hindmarsh 1991). Similarly, acromegaly is caused by excess G H  release but 
remains episodic in the presence of continuous G H RH  suggesting that 
hypothalamic somatostatin (SRIH) secretion is preserved (Gelato 1990).
Authors previously concluded that a concomitent rise in G H RH  levels is 
required during periodically quiescent somatostatin levels (Plotsky & Vale
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1985, Cronin 1987, Ho 1993). In contrast, when using a continuous high dose 
synthetic SRIH (Octreotide) to create a constantly raised somatostatinergic tone 
and a sensitive chemiluminometric assay to measure endogenous GH, both GH 
pulse frequency and the response to GH RH  and GHRP-6 stimulation was 
unchanged compared to a constant saline infusion and these authors concluded 
that somatostatin withdrawal was therefore not critical to G H  pulse initiation 
(Dimaraki 2001). Conversely, others have shown that G H  pulsatility can be 
generated in normal volunteers by the combination of continuously raised 
GHRH and intermittent SRIH (Achermann 1999). This suggests that GH RH  
stimulates GH synthesis and replenishment of stored G H  pools, even during 
high SRIH tone when GH is effectively modulated by somatostatinergic 
restraint. Paradoxically, intermittent somatostatin also facilitates somatotrope 
cell responses to secretagogic stimuli, thus amplifying pulsatile G H  secretion. 
The neurophysiological regulation of G H  is thus complex (Veldhuis 2001).
O f the total GH secreted, 8-12% manifests as a low basal rate of GH 
release, controlled by facilitative action of G H RH  and GHRP and inhibitory 
action of SRIH. The abrupt rise of the GH pulse itself maintains its own 
homeostasis by a time-delayed signal feedback to the central regulatory centres, 
subsequently on ARC neurones acting via specific G H  receptors, to activate 
SRIH and to subdue G H RH  (Peng 2001). Thus GH itself is able to inhibit 
the amplitude of GH secretory episodes and to increase their frequency (Mass 
2000). This auto regulatory loop contributes to the time-dependent 
physiological pulsatile dynamics of the GH axis. More slowly, the IGF-1 
feedback axis at varying IGF-1 concentrations dampens G H  secretory pulse 
amplitude by a delayed negative-feedback action. The mechanism of action of 
SRIH, as an inhibitor is therefore complex as it may directly inhibit GH release 
from the pituitary, or act at the level of insulin-like growth factor-I, IGF-I or 
even at the level of GH releasing hormone. Thus, G H RH  and GHRP are 
stimulatory and SRIH, GH and IGF-1 are inhibitory feedback signals to GH 
pulsatility.
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1.0.4 G H  actions
Endogenous GH consists of 191 amino acids and both growth-promoting and 
diabetogenic properties are intrinsic to the molecule.
The am plitude and frequency of the GH pulse signal has been shown to be 
advantageous for growth (Bick 1992, Achermann 1999). Data from rats also 
suggest that trough  concentrations are as important as peak concentrations 
when interpreting the G H  signal (Agrawal 2001), particularly as trough levels 
may relay alterations of the G H  binding protein (GHBP). The GHBP is 
thought to correpond to the extracellular, ligand-binding domain of the GH 
receptors (GHR) in tissues, reflecting GH receptor status (Amit 2000). The 
high affinity GHBP is the circulating ectodomain of the G H R and is 
produced in many tissues, particuarly liver, either by alternative GHR 
mRNA splicing (rodents) or by proteolytic cleavage from the GHR (humans) 
and parallel GHR expression (Baumann 2001). In general low levels of 
GHBP occurs in conditions associated with G H  resistance such as 
malnutrition and diabetes (Menon 1992, Radetti 1997), conversely obesity is 
associated with elevated levels. GHBP binds about half of the circulating GH 
under basal conditions but is easily saturated at high G H  levels. It has 
complex functions including a circulating buffer/reservoir function for GH, 
prolongation of plasma GH half-life, competition with GHRs for GH, and 
probably unproductive heterodimer formation with the GHR. The net effect 
of these partly enhancing and partly inhibitory functions on G H  action in 
vivo is complex, difficult to ascertain and varies with age and between species.
In the male rat GH secretion is characterised by regular GH peaks of 
high amplitude, and their GH receptors and GH-binding protein are low 
whereas female rats have a more continuous secretion and their GH receptors 
and GH-BP are high. The mechanism appears to be that each surge of GH 
results in individual pulse-related turnover of receptor internalisation and 
recycling and this is accompanied by a parallel increase of serum GH-BP
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activity, which is competitive and cyclical. The GH and receptor wave is then 
responsible for an individual secretion pulse of IGF-1 (Bick 1990). 
Furthermore, this author showed that when physiological doses of G H  were 
infused into hypophysectomised rats either as pulses (1.5u/kg/day, every 
5minutes for 3 hours for 5 days) or continuously, the pulsatile GH pattern 
maximally stimulated growth and induced a cyclical change in the levels of 
hepatic cell membrane receptors and circulating GH-BP, whereas G H  receptors 
and GH-BP were enhanced maximally by continuous GH levels and weight 
gain was poor (Bick 1992).
The mechanism of the nitrogen retaining (anabolic) effects in humans appears 
to be that the GH pulse signal triggers tissue-specific gene expression, 
promoting skeletal and muscle growth. An abrupt rise in circulating GH 
concentrations stimulates rapid internalization of the GH receptor in peripheral 
target tissues and evokes second messenger nuclear signalling. Discrete GH 
peaks stimulate linear (skeletal) growth and drives muscle IGF-1 gene 
expression more effectively than basal GH exposure. Assessment of prepubertal 
children has also suggested that peak levels of G H influence growth rate and the 
IGF-1 axis, although elevated trough levels do influence growth, but only when 
GH peaks are low (Achermann 1999).
Removal of the first 42 residues of the intact hormone, the amino 
terminal portion of hGH, enhances its diabetogenic properties (Lewis, 1991). 
Since the late 1920's it has been recognised that pituitary extracts and later 
purified GH are capable of producing major alterations in the metabolism of fat 
and carbohydrate. Although these early studies show that GH is a powerful 
diabetogenic hormone, the picture became rather less clear with the 
demonstration of both insulin-like and insulin antagonistic effects of GH 
(Davidson 1987). MacGorman and her colleagues, using G H  infusion and 
providing constant background insulin levels in humans, showed that GH has 
an early transient insuIin-Hke effect (MacGorman, 1981) which was evident on 
both the liver, reducing endogenous glucose production, and peripheral tissues
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increasing glucose uptake but this effect was reversed in two hours. Following 
a subsequent glucose infusion, increased hyperglycaemia compared with control 
was observed due to impaired suppression of hepatic glucose production and to 
reduced glucose clearance. In another study using normal subjects, longer 
term GH administration for four days produced significant carbohydrate 
intolerance but with no change in insulin binding to monocytes, suggesting that 
GH causes insulin resistance.
GH also has a lipolytic effect (Richelsen 1997). Free fatty acids (NEFA) 
concentrations increased two hours after GH suggesting that the lipolytic 
activities of GH are intrinsic properties of the molecule administration (Sirek 
1967, Hart 1984). However, other studies show that the lipolytic activity may 
only become apparent after either modification of the molecule in vivo or 
activation of a lipolytic intermediate and dispute the notion that G H  itself 
causes lipolysis. For example, in animals, amplification of adipose tissue 
response by G H  (bovine somatotrophin) was seen only after excitement 
(intensive handling) or epinephrine administration, suggesting that adrenergic 
stimulation of adipose tissue promoted NEFA response (Boisclair 1997). 
Thus, this amplification of adipose tissue response must be considered when 
conducting intensive studies as even the minimal excitement associated with 
blood sampling can confound results regarding lipid mobilization.
GH also has acidogenic and basogenic actions. Acid-base and nitrogen 
homoeostasis are interdependent through the co-ordinated action of growth 
horm one/IG F-1 on substrate fluxes. Growth hormone's acidogenic action, as 
a consequence of promoting fatty acid utilization yields protons required for 
driving hepatic glutamate production. Subsequent peripheral retrieval of the 
salvaged glutamate requires insulin-like growth factor-1 (IGF-1) activated 
uptake and acid-base homeostasis. In addition to the nitrogen sparing 
acidogenic effect, GH is also basogenic in combination with IGF-1 and acts 
on the kidney to maintain acid-base balance (Welbourne 1997).
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1.0.5 G H  secretion during fasting
The well-established physiological metabolic responses to G H  can change 
markedly in conditions of reduced nutritional supply or metabolic stress. 
Work in animals indicates alterations of the G H  secretory pattern  by fasting 
and prevailing metabolic conditions (Tannenbaum 1979, Breier 1986). 
Withdrawal of food in both male and female guinea pigs changed the G H  
secretory pattern dramatically (Fairhall 1990). The normal episodic GH 
secretory pattern (large GH peaks occurring at 3.6 +.0.4h intervals over a low 
(0.5-1.5 pg/L, 1-3 mU/L) baseline secretion was altered to a pattern of more 
continuous GH output, characterised by a 10-fold elevated baseline secretion 
(5-15 pg/L, 10-30 mU/L) with no large secretory episodes or troughs. 
However, the elevated GH secretion in these fasted animals could be inhibited 
by continuous infusion of somatostatin.
Augmentation of GH release pattern is also seen in humans. During 
their studies in humans. Ho KY (1988) showed that while the increase in 
integrated GH concentrations had occurred by the first fasting day there was a 
further increase in the non-pulsatile component of GH release from four fold 
on the first fasted day to ten fold on the fifth day.
Fasting (or calorie deprivation) also augments GH response to GHRH: 
In animal studies, somatostatin, given at low dose, abolishes the G H  response to 
GHRH in the fed state but not in the fasted state. Higher doses of SRIH were 
needed to abolish the G H RH  response in the fasted state. However, 
pirenzepine (anticholinergic) administration lowered the G H RH  response in 
both fed and fasted states, although this inhibition was less evident in the fasted 
state (Rigamonti 1998).
Thus, it has been suggested that during fasting there appears to be an augmented 
GHRH secretion and somatotrope refractoriness to somatostatin to enable this 
enhanced secretion. Metabolic abnormalities associated with food deprivation 
may also act directly on the hypothalamus on the neuroendocrine control of 
the releasing factors that regulate GH (Laughlin 1996, Stoving 1999). For
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instance, insulin injections (1, 2 or 6 u iv) inhibited spontaneous GH pulses in 
normally fed animals, but has little effect on the high continuous G H  tone 
during fasting. This and other metabolic factors need consideration when 
exmining neuroendocrine control.
1.0.6 G H  action during fasting
The presence of a nutrition dependent component of GH action would be 
beneficial to man since anabolic processes can proceed only in the presence of 
adequate nutrition. Decreased nutrition not only leads to elevated G H  
secretion, but it also reduces hepatic G H  receptor (GHR) number and plasma 
levels of IGF-1, Circulating glucose and IGF-1 are both known inhibitors of 
GH secretion and anabolic effects of IGF-1 would have to be minimal during 
starvation since circulating and tissue concentrations of this growth factor are 
low. IGF-1 levels are restored with refeeding but both adequate protein and 
energy intake are necessary to return IGF-1 levels to normal (Caregaro 2001). 
Elevated G H  normally improves the partitioning of nutrients by increasing 
protein synthesis and decreasing protein degradation. Changes in the relative 
concentrations of IGF binding proteins (IGFBPs) in plasma also have a role in 
muscle protein synthesis (Svanberg 2000).
The qualitative changes in the pattern of G H  release seen with 
prolongation of fasting may also play an important role in mediating the well- 
documented switch from a predominantly gluconeogenic to a lipolytic source 
of metabolic fuel. The first relates to the maintenance of glucose supply 
through an increase in hepatic glucose production and second the provision of 
an alternative energy source by increasing fat mobilisation and oxidation 
thereby indirectly sparing body protein. Authors disagree as to whether GH 
directly or indirectly mediates these homeostatic mechnisms.
The role of fat-derived substrates in the regulation of gluconeogenesis 
during fasting has been examined in normal 4 day fasted volunteers treated 
with Acipimox (antilipolytic drug) or placebo for 8 hours (Fery 1996).
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During both fasted and non-fasted states, free fatty acids did not exert a 
direct stimulatory role on gluconeogenesis, but acted indirectly through an 
ability to modulate hormone changes, particularly growth hormone and 
insulin. Ketone-clamp experiments in Acipimox-treated fasted subjects also 
showed that during fasting, both ketones and NEFA suppressed 
gluconeogenesis but by different mechanisms (Fery 1996). The mechanism is 
thought to be that during starvation ketoacid production, as the consequence 
of incomplete fatty acid oxidation and ketone excretion, swamps the 
basogenic limb of G H  and full-blown metabolic acidosis prevails. Under this 
condition growth hormone's effectiveness in sparing nitrogen for anabolic 
processes is curtailed as glutamate (emanating from the liver) and glutamine 
(derived from muscle proteolysis) are directed to the kidneys, supporting 
ammoniogenesis: nitrogen balance is now sacrificed for acid-base
homeostasis. Underlying this state is an intracellular acidosis that may 
contribute to insulin resistance and developing hyperglycaemia in response to 
growth hormone.
This complex interplay of fasting and nutrients triggers a dramatic alteration 
in GH secretion and G H  action.
Differentiating the GH Signal, BRP 2002 27
1.0.7
G RO W TH  H O R M O N E  A N D  TYPE 1 DIABETES
1.0.8 G H  secretion
GH levels may be high in subjects with Type 1 diabetes (Hansen 1970, Salgado 
1996). Comparison of G H  pulsatility in twelve hour plasma G H  profiles in 
subjects with Type 1 diabetes with those of non-diabetic controls have yielded 
conflicting results: some authors suggest an exaggeration of GH release with an 
increase in the number of GH pulses in diabetic subjects (Asplin 1989, Halldin 
1998, Asplin, 1989) while others saw no difference (Molnar 1972). The 
amplitude of the G H  pulses was consistently increased in most studies (Horner 
1981, Batch 1992, Edge 1990), as was the mean integrated twenty-four hour GH 
concentration (Hayford 1980, Zadik 1980). Edge (1990) described overnight 
GH profiles in adolescent subjects with Type 1 diabetes and compared findings 
to puberty-matched control subjects. This author confirmed that the higher 
circulating level of G H in Type 1 diabetes is due to both an increased GH pulse 
amplitude (mean peak (SD) 35.5 ±4.2  mU/L) and a higher baseline (non- 
pulsatile component 5.01 ±0.62 mU/L). Other authors showed that while a 
difference in raised G H  level was seen in prepubertal diabetic subjects, when 
compared with controls, there was no difference during puberty (Nieves-Rivera 
1993). The current mechanism of this hypersecretion is accepted as mediated 
by feedback drive from low insulin-like growth factor (IGF-1) (Clayton 1994, 
Savage Dunger 1996, Bereket 1999). The first (initial) phase of insulin- 
dependent diabetes mellitus is characterised by the absence of insulin, high GH 
levels and low plasma IGF-1. The pituitary GH response to exercise and other 
stimuli is exaggerated. The second phase of disease ('C-peptide positive phase') 
is characterised by the return of some residual beta-cell insulin secretion, 
increased levels of GH compared to non-diabetic subjects, physiological IGF-1 
levels and near normal pituitary GH responses to different agents. The th ird
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phase of the disease is characterised by complete loss of endogenous insulin 
secretion, very high plasma GH levels, low normal plasma IGF-1 but impaired 
hepatic IGF-1 generating capacity. The control mechanisms of pituitary GH 
secretion (long loop negative feedback and auto-feedback) are disturbed 
(Wurzburger 1996). Despite this accepted mechanism, the neuroendocrine 
mechanisms regulating G H  secretion in Type 1 diabetes are still debated 
(Miller 1992, Muller 1995, Salgado 1996).
1.0.9 Mechanism of G H  hypersecretion
Insight into the hypothalamic control of GH in human subjects with diabetes 
has previously been gained indirectly and remains contradictory. The dilemma 
is partly because previous studies have used animal models, chiefly the rat, and 
induced experimental diabetes. Animal work has established that SRIH, rather 
than GHRH, plays an active role in modulating GH secretion in diabetic rats 
(Ndon 1992). In a rat model of diabetes (Goto-Kakizaki or GK rat), Ismail 
(1995) has shown that somatostatin release mediates a blunted G H  response to 
G H RH  in GK rats and that reduced hypothalamic cholinergic signalling to 
the somatostatinergic neurone may mediate the increase in somatostatin 
release. This view is supported in part by the results from in vitro studies in 
which cholinergic muscarinic blockade with pirenzepine (FIR) caused dose- 
related stimulation of somatostatin release from normal rat hypothalami but 
was without effect on GK rat hypothalami. The cause of this alteration in 
hypothalamic function is, at present, unknown.
Extrapolation of these findings to the human condition is not always valid and 
often adds confusion due to the intrinsic differences between the species, 
particularly in relation to the physiology of GH. For example, G H  induces 
its own receptors in the rat (Baxter 1984a) but down-regulates its receptors in 
man (Murphy 1984). Stress and hypoglycaemia are both accompanied by 
suppression of GH levels in the rat (Painson 1985) again in contrast to the 
observed effects in man. Experimental diabetes in the rat is characterized by
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low levels of GH and Insulin-like growth factor-1 (IGF-1) (Maes 1983) but in 
man, poorly controlled diabetes is characterized by normal or low IGF-1 levels 
despite raised circulating levels of GH (Amiel 1984). A better understanding of 
the precise role of GH in controlling diabetic metabolism can be obtained only 
by observations in human subjects in vivo.
GH  secretion in humans has been previously studied after 
administration of various pharmacological stimuli, either singly or in 
combination. Observations have shown that GH responses in diabetic adult 
subjects are increased following the administration of a number of 
pharmacological and physiological stimuli including hypothalamic stimuli 
(Topper 1985) and pituitary stimuli (Giampietro 1987). However, it is clear 
from clinical studies that responses to exaggerated pharmacological 
stimulation may not represent subjects in their usual physiological state.
The amplitude of G H  pulses in Type 1 diabetic subjects was increased 
in most studies and it has been noted that the baseline GH concentration from 
which the GH pulses arise, was higher in diabetic compared to non-diabetic 
subjects. The mechanism behind this remains contradictory. Some authors 
suggest that exaggerated G H  levels are due to primarily to GHRH-mediated 
effects. In contradiction, others have shown that GH responses to G H RH  did 
not change either during fasting or in subjects with Type 1 diabetes. 
Furthermore, data suggest that independently, both G H RH  and GH-releasing 
peptide-6 (GHRP-6) releasing mechanisms are unaltered in subjects with Type 
1 diabetes (Villas-Boas Weffort 1997). The enhanced spontaneous GH secretion 
is therefore unlikely to be due to marked alterations in somatotrope 
responsiveness to hypothalamic G H RH  (Kopelman 1988).
Although some studies in subjects with Type 1 diabetes related the 
problem of increased G H  release simply to poor glycaemic control (Press 
1984a), others showed no short term  effects of ambient glucose concentration 
on. G H  responsiveness (Ismail 1991). Acute changes in metabolites may also 
produce different effects on GH secretion when compared with chronic
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changes and this needs to be explored further in subjects with Type 1 diabetes 
where alterations in glucose, insulin and intermediary metabolism are in 
constant flux. As the various mechanisms of GH control are deduced from 
animal models and elucidated in clinical studies primarily involving adults, it 
must be remembered that children and adolescents with Type 1 diabetes may 
have alterations in the control of G H  release and require careful assessment. A 
further study recently has showed that fasting insulin levels and abdominal 
visceral fat were consistently important predictors of integrated 24-hour GH 
concentrations, independent of age group, gender or other variables (Clasey 
2001). Thus a powerful relationship, with bi-directional feedback, exists 
between fasting insulin, visceral fat and IGF-1.
Thus, equivocal evidence exists regarding the sensitivity of the pituitary gland 
in Type 1 diabetes: GHRH may be increased or reduced suppression of GH 
occurs due to metabolic or hormonal factors causing a reduced somatostatin 
release.
1.1.0 Impact of G H  hypersecretion
Although some authors claim that the actions of GH is not of critical 
physiological significance (Laursen 1995), there is ample evidence to suggest 
that discrete pulse alteration influences somatic and metabolic changes. Some 
previous studies in Type 1 diabetic subjects concluded that glucose disposal did 
not correlate with counterregulatory hormones or plasma NEFA, or 
antecedent glycaemic control (Davis 1992) but others showed that raised GH is 
accompanied by a decrease in insulin sensitivity in the liver and muscle (Moller 
1991). Consistent evidence now shows that increased plasma concentrations of 
GH in Type 1 diabetes impairs metabolic control (Press 1984a, Orskov 1985, 
Gerich 1986), is implicated in the development of the dawn phenomenon 
(Campbell 1985a) and be relevant to the development of microvascular disease 
(Olsen 1999, Flyvbjerg 1997, Cummings 1998, Landau 1998) that often becomes 
evident at around the time of puberty.
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The mechanism of in-vivo G H  effects on carbohydrate and lipid 
metabolism is still unclear in Type 1 diabetic subjects. There is good evidence 
that circulating GH has effects on glucose metabolism. Hypoglycaemia is 
observed in GH deficient children who also demonstrate low insulin levels to a 
standard glucose challenge while maintaining normal blood glucose levels 
(Hopwood 1975). GH replacement in these patients normalises plasma glucose 
levels and abolishes hypoglycaemia by increasing hepatic glucose production 
(Bougneres 1985).
The insulin-like effects of G H  involve enhanced glucose utilisation 
(probably at the glucose transport step) and anti-lipolysis. They can be 
demonstrated in-vitro but are clearly easier to show if the tissue has had little or 
no recent prior exposure to GH. As the tissues in diabetic patients are exposed 
to frequent bursts of endogenous secretion of the hormone, the insulin-like 
effects of GH are not important physiologically. The anti-insulin-like effects 
of G H  are more important and involve impaired glucose utilisation, inducing a 
refractory state to the insulin-like effects of the hormone and stimulate lipolysis.
Insensitivity to the actions of insulin is now believed to be a common 
feature of Type 1 diabetes (Olefsky 1985). A reduction of 30 to 60% in the 
metabolic response to a given insulin stimulus has been reported in diabetic 
adults when compared with matched normal subjects (Simonson 1985). The 
development of insulin resistance may be dependent on duration of the diabetes 
as it is present before treatment is started (Yki-Jarvinen 1986), disappears after 
treatment of less than three months duration (Gray 1986) and is significantly 
greater after five years than one year duration.
The mechanism of the insulin resistance in Type 1 diabetes is still unclear 
(Schliess 2000), although GH and other counter-regulatory hormones such as 
epinephrine (Walters 1992) and androgens (Ebeling 1995) have been implicated. 
Further evidence regarding the role of metabolites is also emerging: Insulin 
resistance with inhibition of glucose disposal in Type 1 diabetes is also observed 
after hyperglycaemia (Del Prato, 1997) and hyperlipidaemia (Balkau 1998).
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GH stimulates lipolysis, providing glycerol as a substrate for gluconeogenesis 
and free fatty acids (NEFA) which impair tissue glucose oxidation (Johnston 
1985, Neilsen 2001). In normal men high fatty acids have been shown to affect 
the ability of insulin to suppress endogenous glucose production (Bisschop 
2001). Further studies in Type 1 (insulin-dependent) diabetic subjects suggest 
that the mass-action effect of free fatty acids inhibits insulin mediated glucose 
disposal in muscle and stimulates gluconeogenesis in the liver, leading to 
insulin resistance. Current thinking shows that even physiological increases 
in plasma NEFA levels cause insulin resistance in both diabetic and non­
diabetic subjects (Boden 2001).
While increased nocturnal lipolysis has been associated with elevated G H  in 
the absence of insulinopenia or hyperglycaemia (Hagstrom-Toft 1997), some 
authors have shown that peripheral insulin resistance was only observed in the 
presence of a combined increase in total lipid and NEFA oxidation but not 
during an isolated Increase in NEFA oxidation, whereas hepatic insulin 
resistance could be induced even by a moderate increase in NEFA availability 
(Laville 1995). NEFA causing hepatic insulin resistance results in increased 
rates of endogenous glucose production in relationship to the prevailing degree 
of insulinaemia. However, this is not the only mechanism. G H  may induce 
insulin resistance through non-NEFA dependent mechanisms but these cellular 
mechanisms remain to be elucidated.
A complex picture thus exists regarding the role of GH, glucose, insulin 
and NEFA in the metabolic derangement of insulin resistance.
1.1.1 Insulin resistance, G H  and Puberty
During puberty there is an amplified secretory burst mass resulting in 
heightened GH pulse amplitude and duration (Zadik 1985, Veldhuis 2000). Sex 
steroids have also been associated with the different facets of altered G H  pattern 
-  an elevated basal GH secretion and pulsatility is associated with oestrogens 
(Pincus 1996) and amplified G H  secretory burst mass and higher plasma IGF-1
Differentiating the GH Signal, BRP 2002  33
associated with rise in testosterone (Veldhuis 1996a,b, 1998). However, short 
term fasting (Maccario 2000) abolishes these gender differences. Distinctive 
mechanisms of G H  release may be altered during puberty but the evidence 
from normal subjects is contradictory. For example, repeat G H RH  
administration in a group of children in puberty did not lead to inhibition of 
the subsequent G H  response, and may even have increased it (Ghigo 1989); 
whereas in a study of normal adolescents, GH responses to G H RH  did not 
change throughout puberty and was similar to those of adult women except for 
in boys where the response in mid-puberty was lower than those in either pre­
puberty or adult men (Gelato 1986),
There is evidence that a physiological adaptation in insulin resistance 
occurs with the onset of puberty (Moran 1999, Hoffman 2000). A combination 
of hormonal and metabolic factors may contribute to this adaptation (Goran 
2001). Insulin, being an anabolic hormone, is essential for appropriate tissue 
development, growth and maintenance of whole body homeostasis. Insulin 
regulates glucose homeostasis at many sites, reducing hepatic glucose output 
(via gluconeogenesis and glycogenolysis) and increases rate of glucose uptake 
into striated muscle and adipose tissue. The cellular site of the insensitivity to 
insulin action appears to be subsequent to insulin binding with its glyco-protein 
receptor on the cell surface. The clearance of circulating glucose in tissues 
depends on insulin-stimulated translocation of glucose transporter (GLUT-4) 
isoform to the cell surface. Insulin resistance occurs when either the normal 
circulating concentrations are insufficient to regulate these processes 
appropriately or the maximal response to insulin is reduced by a rate-limiting 
step in insulin action (Scheen 1996).
Insulin doses during puberty in subjects with Type 1 diabetes, even when 
adjusted for body weight, often exceeds those in both younger children and 
adults. These changes parallel those observed in normal children where despite 
comparable levels of fasting blood glucose, normal adolescence have higher 
fasting concentrations of insulin than those found in younger children and
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adults. These findings in both diabetic and non-diabetic adolescents could be 
explained by a reduction in insulin sensitivity during puberty.
Amiel and colleagues have provided some evidence for this by using the 
euglycaemic clamp technique (Amiel 1986), they showed a marked reduction 
(by 33 to 42%) in insulin stimulated glucose metabolism in pubertal compared 
with pre-pubertal diabetics, and noted similar changes in normal siblings. 
Diabetics at all ages were again remarkably insulin resistant compared with 
matched normal control. It seems likely that these changes in insulin resistance 
are related to hormonal changes, which are occurring during puberty. This 
includes elevated levels of growth factors and sex steroids and increased pulsatile 
GH release.
Several syndromes of hyperandrogenaemia are associated with insulin 
resistance (Prelevic 1997) and plasma dihydroepanandosterone sulphate 
(DHEAS) concentrations have been reported to correlate with fasting and 
glucose stimulated insulin responses during puberty but not in pre-puberty 
(Smith 1989a). However, a simple relationship between the levels of sex 
steroids and insulin resistances is unlikely since adults have a lower insulin 
resistance than during puberty (Caprio 1989), despite having higher circulating 
levels of sex steroids. Furthermore, the rate of insulin mediated glucose 
metabolism in normal women does not appear to be affected by the phase of 
the menstrual cycle, despite large differences in sex steroids levels. It is much 
more likely that sex steroids may act synergistically with other factors to 
contribute to the insulin resistance of puberty.
Another possible mediator is IGF-1 and indeed the reduced insulin 
sensitivity during normal puberty is associated with raised IGF-1 
concentrations (Caprio 1989). This does not however imply a causal 
relationship but is more likely to be the result of parallel response to another 
factor such as increase in GH levels. The IGF-1 molecule has structural 
homology with insulin and has insulin-like metabolic effects in vivo and so is 
unlikely itself to cause insulin resistance (Guler 1987). However, in diabetics
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there is evidence for the presence of inhibitors of IGF-1 action, particularly 
IGFBP-1 (Taylor 1987). These may also inhibit some of the actions of insulin 
(Avasthy 1986) and be a contributor to insulin resistance although it remains to 
be determined whether these inhibitors are important during puberty.
Insulin requirements increase because of rapid growth in puberty, even when 
corrected for body weight. Amiel and her colleagues demonstrated an inverse 
correlation between mean 24-hour levels of GH and the insulin stimulated 
glucose metabolism during their clamp studies, when diabetic and non-diabetic 
adolescents were analysed together. They suggested that the physiological 
increase in insulin resistance at puberty may be related to GH levels (Amiel 
1986). In the study of Beaufeure and colleagues in a group of eight well- 
controlled diabetic adolescents a correlation was seen between the insulin 
infusion rate required to maintain normoglycaemia in the early part of the 
night and nocturnal GH release (Beaufrere 1988). This observation was also 
confirmed by others when a direct relationship with mean plasma G H  levels 
and plasma free insulin levels was seen (Edge 1990a, Hindmarsh 1988a). These 
studies strongly imply that GH is the mediator of the insulin resistance of 
puberty.
O ther factors such as insulin antibodies, degree of insulization and 
exercise may affect insulin resistance in diabetes but there is no trend in these 
parameters with puberty thus they are unlikely to be the cause of the 
substantial increase in insulin resistance during puberty compared with younger 
children and adults.
The major site of insulin resistance is likely to be skeletal muscle. Plasma free 
insulin concentrations achieved with the hyper-insulinaemic clamp technique 
are sufficient to effectively suppress hepatic glucose production and hepatic 
glucose uptake only accounts for a small part of the clamp glucose disposal 
(DeFronzo 1983). Since adipose tissue accounts for only a small proportion of 
glucose metabolism and insulin sensitivity is directly related to muscle mass and 
inversely proportional to adiposity (Yki-Jarvinen 1983) skeletal muscle is
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probably the major site of insulin sensitivity. Thus, although hepatic and 
peripheral insulin insensitivity has been reported in Type 1 diabetes, the 
majority of clinically important glucose resistance must reside in peripheral 
tissues. Circulating GH is therefore implicated in the insulin resistance of 
puberty and thus are additive with the effects of diabetes on insulin insensitivity 
during puberty.
1.1.2 Nocturnal G H , insulin requirem ent and Dawn Phenom enon
Increased plasma GH levels may have insulin antagonistic effects overnight 
with greatest manifestation in the early morning hours. Clarke and colleagues 
(1980) reported that insulin requirements for normoglycaemia in six adults with 
Type 1 diabetes were two to three fold higher between 06.00-09.00 hours than 
between 24.00-06.00 hours. This increase in basal insulin requirement was 
termed the 'Dawn Phenom enon'. Schmidt and co-workers also used the 
term to describe the early morning rise in blood glucose concentrations on 
conventional insulin regimes, when increases in insulin requirements were not 
being met (Schmidt 1981). Following these reports the dawn phenomenon was 
demonstrated in many studies of adults with Type 1 diabetes (Skor 1983) and 
with non insulin-dependent diabetes (Bolli 1984b).
However, many of these early studies were carried out using the artificial 
pancreas, which was later shown to produce aggregation and loss of available 
insulin from the infusion solution after prolonged use (Brennan 1985). Because 
of this artefact it appeared that there was an increase in insulin clearance that 
contributed to a major extent to the increased requirement in the dawn hours 
(Dux 1985).
Studies using a Harvard Pump, which did not demonstrate the loss of insulin 
from the insulin infusion, have shown that dawn phenomenon does occur in 
adults with Type 1 diabetes but without the increased insulin clearance or fall in 
plasma insulin concentrations seen with the artificial pancreas (Campbell 1986).
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The increase in insulin requirement was actually less than one third of that 
found in previous studies (De Feo 1986). These studies concluded that changes 
in insulin sensitivity are implicated in the pathogenesis of the dawn 
phenomenon and demonstrated that the dawn phenomenon was very 
reproducible from day to day in adults with Type 1 diabetes (De Feo 1986).
Several studies measuring overnight blood glucose and plasma insulin 
profiles in normal adults have failed to demonstrate any change in dawn 
parameters (Simon 1988). In contrast, an increase in hepatic glucose ou tpu t in 
the early morning has suggested that a dawn phenomenon does occur in normal 
adults. Bolli and colleagues showed that rates of glucose production, glucose 
utilisation and insulin secretion all increase after 05.30 hours in normal 
volunteers suggesting the presence of a dawn phenomenon initiated by increase 
in glucose production (Bolli 1984a). O ther authors report an increase in plasma 
insulin clearance similar in both non-diabetic and diabetic adolescent subjects, 
while normal blood glucose levels did not change during the dawn period 
(Arslanian 1992). However, the dawn rise in blood glucose levels has been 
reported in diabetic adolescents during a constant rate overnight infusion of 
insulin (Edge 1990b, Dunger 1991).
The search for possible causes of this early morning reduction in insulin 
sensitivity initially focused on cortisol since the dawn phenomenon occurred at 
the time as the physiological pubertal rise in cortisol concentrations (Trumpet 
1995). However, abolition of the cortisol rise with metyrapone and 
dexamethasone did not inhibit the early morning increase in insulin 
requirement (Skor 1983), and the rise of cortisol appears to be too late to affect 
early morning insulin sensitivity (McMahon 1988). Plasma glucagon 
concentrations have been shown not to increase overnight and, in the absence 
of hypoglycaemia, plasma catacholamines do not reach levels at which they 
begin to exert significant metabolic effects (Campbell 1985a). The dawn 
phenomenon in Type 1 diabetic subjects has been shown to begin earlier 
(03.30am) and due to both an accelerated glucose production and impaired
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Utilization and not associated with cortisol, adrenaline or glucagon changes nor 
changes in insulin clearance (Campbell 1985b).
This leaves G H  as the most likely candidate for the major role in the 
dawn phenomena. Early studies suggested that the alterations in glucose 
metabolism were initiated by the nocturnal surges in G H  (Campbell 1985b) but 
these studies were carried out with the artificial pancreas (Biostater) and so 
doubt can be cast on their conclusions (Clemens 1982). However, when 
nocturnal GH was suppressed in adult diabetics using either somatostatin (De 
Feo 1986) or the anti-cholinergic drug methscopolamine (Davidson 1988), the 
dawn phenomenon was reduced by more than 70% or even abolished.
The dawn phenom enon may occur regardless of pubertal stage or glycaemic 
control in children and adolescents with Type 1 diabetes (Kobayashi 1997). 
Further studies in elucidating the cause of the dawn phenomenon provide 
contradictory evidence regarding GH. In a small group of extremely well 
controlled adolescent diabetics Beaufrere and colleagues (1988) found no 
correlation between the extent of the dawn phenomenon and the nocturnal 
GH secretion. Similarly, in normal volunteers following octreotide 
administration with replacement of nocturnal rise of GH, no effects were seen 
on glucose, glucose production, disappearance or substrate oxidation following 
breakfast (Nielsen 1998). Contrary to this, in a large group of adolescents with 
average glycaemic control, overnight GH parameters were correlated with 
raised increased insulin requirements and higher blood glucose values in the 
early morning (Edge 1990a). However, the mechanism has not been clarified. 
Although non-esterified fatty  acids are thought not involved to be in the 
dawn phenomenon (Boyle 1992), some studies show that NEFA have 
suppressive effects on peripheral glucose metabolism by inhibiting peripheral 
glucose oxidation and glycolysis (Bonadonna 1989, Walker 1991).
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1.1.3 G H  and lipolysis and ketogenesis
Clinical observations in normal subjects show that free fatty acids do rise in the 
night (Wildenhoff 1974) but the acute lipolytic action of G H  is usually limited 
by a compensatory rise in insulin secretion. However, during chronic (24h) GH 
exposure, consistent lipolytic effects are seen (Metcalfe 1981). Lipogenesis and 
lipolysis, which modulate fatty acid concentrations in plasma and tissues, are 
under hormonal control. In Type 1 diabetes, fasting NEFA levels are increased 
and there is both in vitro and in vivo evidence that G H  helps to sustain 
nocturnal lipolysis in Type 1 diabetes. When compared to healthy control 
volunteers, Type 1 diabetic patients on their usual intensive insulin regime, 
have been shown to have a significantly exaggerated evening-night rise of 
NEFA (increased by three-fold) (Hagstrom-Toft 1997). This author found 
that nocturnal G H  levels were also elevated in diabetic subjects and correlated 
to nocturnal lipolysis and adipose blood flow. Despite normal 24hour 
glucose levels, nocturnal rises in NEFA, GH and lipolysis were seen. Thus, 
nocturnal NEFA and lipolysis may be due to elevated GH but does not 
appear to be due to insulinopenia or hyperglycaemia.
Although circulating concentrations of non-esterified fatty acids 
(NEFA) are altered in intensively treated insulin-dependent diabetic subjects 
and a circadian change in NEFA concentrations has been noted, the 
mechanism of NEFA production directly by GH is still not clarified. When 
studying the regulatory effects of G H  on lipid oxidation using specific 
bioassays to measure mitochondrial GH receptors in fibroblasts, G H  was 
shown to directly stimulate fatty acid oxidation independent of insulin-like 
growth factor-I (Leung 1997). In addition, both preadipocytes and mature 
adipocytes do possess specific G H  receptors. GH may therefore mediate both 
direct effects and act indirectly through the GH-mediated secretion of IGF-1 
in adipose tissue. The prime mode of G H  action in causing lipolysis has not 
yet been established in Type 1 diabetes.
Differentiating the GH Signal, BRP 2002  40
In Type 1 diabetic subjects, the early-night peak of ketone 
concentrations have been associated with overnight GH release (Edge 1993) 
and the early-morning fasting ketone level is mainly determined by insulin 
levels. This ketogenic effect is also seen in Type 1 diabetic subjects who had 
euglycaemia, maintained with insulin infusion, were changed over to 
somatostatin and GH infusions and after only six hours on GH, when 
concentrations had reached those seen in poorly controlled subjects, plasma 
ketone increased markedly while blood glucose remained unchanged (Gerich 
1976, Keller 1984). Hyperketonaemia may result from increased lipolysis 
(muscle and fat tissues) with increased free fatty acids supply for ketogenesis or 
from a primary action of GH on hepatic ketone body production or decreased 
peripheral utilisation. The primary mechanism is not clearly determined. 
Turnover studies performed in fasted and diabetic subjects suggest that a 
production rate of ketones just exceeding the clearance rate, causes a 
progressive build-up in ketone concentration by further antagonism of muscle 
clearance (Balasse 1989).
During fasting, both FFA and ketone bodies tend to suppress 
gluconeogenesis, but there is no consensus on the exact mechanism of ketone 
production and action (Fery 1996). Moller (1990) during his studies on 
forearm technique in Type 1 diabetic subjects, suggested that the main 
regulatory effect of isolated hyperketonaemia appeared to be a direct negative 
feedback inhibition of lipolysis. When comparing a 32hour short term fast in 
diabetic subjects and controls, the rate of development of ketosis, metabolic 
acidosis, NEFA and glycerol turnover increased progressively in both 
conditions, but the rate of rise of ketones was extremely accelerated when 
insulin deficiency occurred with fasting conditions (Burge 1993). However, 
these authors attributed elevated levels of glucagon and catecholamines on 
lipolysis as leading to the development of ketones. Further work reveals that 
following acute administration of GH in conscious dogs, while there was 
only a transient increase in NEFA at 20minutes, ketone body concentrations
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were significantly elevated after 120-180 min independent of N EFA  (Okuda 
2001). In summary it is not clear whether in Type 1 diabetes the stimulation 
of lipid oxidation and ketogenesis is a continuous direct effect of G H  or 
whether it is driven by increased substrate supply secondary to  lipolysis.
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1.1.4
SUMMARY AND HYPOTHESES
Although GH secretion is controlled primarily by GHRH and SRIH, the 
inter-relationship with other metabolic factors is complex. In particular, 
profound alterations in GH control are seen during fasting where a 
change in GH amplitude and pulsatiliiy may mediate metabolic 
alterations, such as lipolysis and ketogenesis. The dissociation between 
GH and IGF-1 production suggests that the metabolic events in 
nutritional deprivation parallel that seen in Type 1 diabetes. This model 
can used to explore various hypotheses of GH control and actions. At 
present it remains unknown whether the GH changes are primary or 
secondary and whether GH mediates metabolic effects directly or via 
mediators as the weight of current literature provides evidence to suggest 
either mechanism. In diabetic subjects, the raised GH levels and effects on 
nocturnal insulin resistance, NEFA and ketones can be separately 
evaluated by metabolic studies.
To clarify whether the changes in GH and metabolic alterations exist as 
specific physiological adaptations, such as seen in starvation or whether a 
pathological process continues to sustain a deteriorating scenario in the 
Type 1 diabetic subject, I have proposed a series of hypotheses to be tested 
by specific experimental conditions.
The three specific hypotheses that are suggested in this Thesis are based 
on the following
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Observation
An altered pattern of raised GH in adolescents with Type 1 exists. The 
mechanism of raised GH requires exploration. Although GH clearance 
could differ to normal adolescents due be to alterations in GHBP, or 
glycaemic or msuhnaemic states, the generation of the basic underlying 
pulsatile pattern of GH release may also be influenced by an imbalance 
of interactions between neurotransmitters and metabolites.
Hypothesis 1
GH hypersecretion exists in adolescents with Type 1 diabetes subjects and 
is a prime abnormality of GH control
Experimental Procedure
1. Examine GH clearance characteristics (half-life decay kinetics and 
distribution volume of exogenous GH) in Type 1 diabetic subjects and 
compare to reported control values.
2. Describe the characteristics of overnight GH secretion (mean, peak, 
pulsatility) by using mathematical methods comparing puberty- 
matched subjects (Type 1 diabetes and control groups).
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Observation
Enhanced pulsatile GH secretion may result from alterations in SRIH, 
GHRH or cholinergic pathways or feedback of several potential 
metabolites on GHRH and somatostatin release. The direct role of insuhn 
and glucose on GH control is still unclear.
The modulation of GH release by metabolic factors, particularly insuhn 
and glucose, may have a greater regulatory role during fasting (nutrient- 
insufficient) state.
Hypothesis 2
Type 1 diabetes subjects haye GH alterations similar to the physiological 
adaptation observed in prolonged calorie deprivation. GH pulse (peak 
and suppression levels) are influenced by insulin and glucose levels.
Experimental Procedure
1. Clarify the alterations of spontaneous overnight GH secretion and 
during euglycaemia or after altering cholinergic tone.
2. Identify the influence of insulin (eg hyperinsulinaemia) and glucose 
(eg hyperglycaemia) on endogenous GH suppression by using 
somatostatin. Assess the metabohc influence on GH rebound pulse 
secretion.
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Observation
It is unclear as to whether GH mediates metabolic effects directly or via 
mediators to cause poor metabolic control namely hyperglycaemia, 
insulin resistance, hyperketonemia and lipolysis. The components of the 
GH pulse that cause metabolic derangement remains unclarified.
Hypothesis 3
The importance of an abnormal GH signal is to directly cause metabolic 
deterioration in the Type 1 diabetic subject
Experimental Procedure
1. Reconstruct a GH pulse protile representative of the GH levels seen in 
adolescent diabetic subjects
2. Simulate such a physiological plasma GH profile under standardised 
conditions.
3. By reconstructing a plasma GH profile into its separate components 
(pulsatility versus continuous signal), the direct relationship of GH 
pulse characteristics on insulin resistance, lipolysis and ketogenesis 
can be compared during in-vivo  study conditions.
In this Thesis, 1 examine GH kinetics, secretion and actions in-vivo  by a 
series of studies described in detailed in Chapter 2 involving adolescents 
and young adults with Type 1 diabetes.
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CHAPTER 2
EXPERIMENTAL PROCEDURES
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2.0.0
PRINCIPLE M ETHODS
This Thesis reports on three experimental protocols that were devised in order 
to clarify questions in section 1.1.5.
Experiment 1 G H  clearance study (subjects recruited by BRP)
Aims: Establish three metabolic conditions of glycaemia and insulinaemia 
(clamps) in order to examine
a) Decay characteristics of GH  (rhGH ) half-life and distribution volume
b) GH suppression during somatostatin infusion
c) GH rebound secretion after somatostatin suppression
Experiment 2 G H  secretion study (subjects recruited by D r J Edge)
Aims: Analyse spontaneous overnight plasma GH profiles in adolescent
subjects to perform
a) Distribution analysis to calculate the mean, peak and trough plasma GH 
level representative of adolescents with Type 1 diabetes
b) Deconvolution analysis to calculate secretory rates in Type 1 diabetes and 
control subjects during puberty
c) Determine effects of euglycaemia on spontaneous GH secretion
d) Effects of anticholinergic (pirenzepine) on GH secretion
Experiment 3 G H  signal study (subjects recruited by BRP)
Aims: Examine the metabolic effects of the GH pulse by separating its 
components of pulse signal and continuous signal
a) Effects on insulin sensitivity
b) Changes representing the Dawn phenomenon
c) Effects on lipolysis and ketogenesis
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The recruitment of the patients, the general procedure for the studies and 
practical techniques are common to the different analyses in this thesis and to 
avoid repetition details are given in this chapter. In all studies using exogenous 
rhGH, Genotropin (Kabi, Stockholm) was used. The practical techniques, 
assay methods and analyses were the same in each of the studies and are 
provided in Appendix 2 and 3. Any specific methods or modifications are 
given in the relevant Chapter.
2.0.1 Subject recruitm ent & ethics
Three groups of subjects who were recruited from the Paediatric Diabetic 
Clinic and Young Adult Clinic at John Radcliffe Hospital, Oxford between the 
years 1988-1992. Patients recruited were those who had had a diagnosis of Type 
1 (insulin-dependent) diabetes for a minimum of 2 years (to ensure endogenous 
insulin secretion was negligible) and were being treated with subcutaneous 
insulin and had no evidence of other medical diseases such as cystic fibrosis.
The Central Oxford Research Ethics Committee had approved all studies 
before recruitment began. Initial contact was at clinic attendance to explain the 
reason for carrying out the study and a standard letter was provided to eligible 
subjects and their respective parents to read. Thereafter, telephone contact 
was made 1-2 weeks later to discuss the information leaflet and any further 
clarification on practical procedures. All studies were carried out at the John 
Radcliffe Hospital, Oxford. Application and information letters were submitted 
to the Central Oxford Research Ethics Committee for ethical approval prior to 
each study protocol. Written information was provided to volunteers, their 
parents and to subjects’ GP with further verbal discussions if subjects were 
interested in participating (see Appendix Information: A l). Written and verbal 
informed consent was obtained from subjects and guardian/parent with a 2- 
week period of reconsideration. As most patients needed to attend on at least 
three occasions, doubtful patients were not recruited. Later subject exclusion or 
withdrawal is detailed in Appendix 2c.
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2.0.2
G H  CLEARANCE STUDY
2.0.3 Study design
The secretion, half-rate of elimination and volume of distribution controls the 
concentration of a hormone in the circulation. Firstly, an assessment of the 
clearance of GH from the circulation is required.
The study design is illustrated in Figure 2.1a.
GH half-life was determined by (lOOmU rhGH) bolus after somatostatin 
suppression of endogenous G H  in six patients each under three clamp 
conditions:
(a) Normoglycaemia and normoinsulinaemia (NG)
(b) Hyperglycaemia and normoinsulinaemia (HG)
(c) Normoglycaemia and hyperinsulinaemia (HI)
Each subjects’ clamp occurred in random order, separated by an interval of at 
least one week. In one patient (G) the normoglycaemic hyperinsulinaemic 
clamp was not performed. A computer programme was used to achieve stable 
clamping (Appendix 5). The different clamp conditions permitted analysis of 
the effects of short-term metabolic changes such as hyperinsulinaemia and 
hyperglycaemia on GH half-life.
This study protocol provided information on the effect of somatostatin on GH 
suppression under different insulinaemic and glycaemic states and allowed the 
analysis of GH rebound release after the termination of the SRIH infusion.
2.0.4 Subject characteristics (GH clearance study)
Six young adults (three females and three males ’'"BCDEFG) median age 21.5 
years (range 14.9 -25 years) with Type 1 (insulin-dependent) diabetes mellitus
Subject A B Jkc D , E ' F G Median
Age
yearsL-
* 14.76 17.8 21 24 2Z8 25 21.5
" r !
■ ■
■ 'T - : .Sex ; * F M M F M F -
Weight kg + 643 61.0 71.4 77.5 80^ 9 543 67.8
Height cm * 162.3 167 174.2 172.5 169.5 166 168.5
Surface area * 1.7 1.68 1.85 1.92 1.94 1.58 1.77
BMI
kg/m^
* 24.4 21.8 2T6 26.0 283 19.6 22.6
HbAi % * 9.2 15.8 10.4 8.8 9.7 12.6 10.1
Duration Diabetes 
years
* 9.43 6.1 10 20 14 15 12
Insulin Dose 
u/kg/day
* 1.0 1.47 0.92 0.64 0.92 038 0.92
Table la  Dem ographic data o f subjects B-G attending M orning Studies
* Subject A was excluded from further analysis.
s  RIF 50 |tg/m /h infusion l Rebound Period
S RIF bolusl GH bolusl
0730h
GLAMP CONDITIONS NG or 6
2 5 10  ^ 10 (min) Blood samples |
90 : 120 150 180
I— I— I— I— I— I— I
0800b
270
Clock time TIME (minutes)
Figure la  Study design: G H  clearance
G H  half-life: after withdrawal of long acting insulin at 36hours before 
study, subjects were admitted at OZ.OOh for canulation.
Baseline samples were taken between t = 0-30mins. Somatostatin (S) 
(bolus 50pg and infusion) was commenced at OS.OOh and clamp 
conditions achieved t = 30-150mins. Growth horm one(GH) lOOmU was 
administered at t = 90 and frequent blood samples taken to assess decay.
Clamp:
N G  = normoglycaemic H G = hyperglycaemic, H I= hyperinsulinaemic
G H  suppression: tw o periods t60-90 and tl20-150mins were analysed 
during 3 clamp conditions and somatostatin infusion.
G H  rebound: at t=150m ins somatostatin was ceased; clamp conditions 
maintained until t = 270mins to assess G H  rebound secretion.
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were studied (Table 2.1a: Demographic data (B-G)). The median duration of 
disease was 12 years (range 6-20 years). Each diabetic patient received insulin 
(median 0.92 units per kilo per day, range 0.86 to 1.5) three to four times daily. 
They were on no other medication apart from insulin. All were in good health 
apart from their diabetes and there was no evidence of any long term diabetic 
complications in particular retinopathy or microalbuminuria as predictor of 
clinical diabetic nephropathy (Morgensen 1990), Based on arithmetic means of 
5 to 10 glycosylated haemoglobin (HBAI) measurements over the previous two 
years in each patient, the mean H bA i was 11% (range 9.2 - 15.6%; reference 
range 5.6 - 8.2%).
’^ Subject A was excluded as following this study various technical 
improvements were made.
2.0.5 Clinical Protocol
Preparation
All subjects had close telephone contact during withdrawal of long and medium 
acting insulin and an individual written regime was supplied to enable adequate 
glucose control with short acting (Actrapid) insulin.
G H  clearance study illustrated in Figure 2.1a
Following an overnight fast and omitting evening insulin, subjects were 
admitted to hospital at 07.00 hours. An indwelling intravenous polyethylene 
cannula and a double lumen catheter were inserted under local anaesthetic 
(Figure A, Appendix 2) and subjects maintained in a resting position for 
15minutes. A continuous blood sampling withdrawal system was utilised 
(Figure B, Appendix 2). During the study no food was allowed but water was 
provided ad libitum.
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Basal measurements for insulin, glucose and GH were started fifteen minutes
after insertion of the cannula and thereafter at ten-minute intervals (07.30,
07.40, 07.50, and 08,00). The clamp was started at 08.00 hours
1. GH suppression: Endogenous GH secretion was suppressed by a bolus of 
somatostatin (SRIH) (somatostatin 1-14, 50 micrograms, Serono SpA, Italy) 
followed by an infusion of somatostatin (SRIH 50 pg/mVh)
2. Clamp: Insulin (Actrapid HM, Novo-Nordisk Gentofta, Denmark) was 
infused at a rate of 0.2 mU/kg. min to generate normoinsulinaemia with 
plasma insulin levels of 57-107 picomol/L (8 - 15 mU/L) or at a rate of 0.7 
m U /kg/m in to achieve elevated plasma levels of 360 picomol/L (50 
mU/L). Blood glucose levels were maintained at 5 mmol/L for the 
normoglycaemic and 12 mmol/L for the hyperglycaemic clamp 
respectively. Having reached a stable clamp conditions, each clamp was 
maintained for at least two hours at the steady state for the duration of the 
whole study.
3. Samples: Initially blood glucose concentrations were measured at one to 
three minute intervals until a stable clamp was achieved.
Samples for insulin and GH were taken at ten to fifteen minute intervals 
throughout the whole study (Figure 2.1a).
4. GH  bolus half-life: A bolus injection of the exogenous monomeric 
22kDa recombinant human GH (r-hGH, 50pg (lOOmU) Genotropin) was 
given at t==90mins. Following the r-hGH bolus, samples for GH were 
taken at two minute intervals for twenty minutes followed by two and 
three samples of five and ten minutes intervals respectively.
5. GH suppression and rebound: Examination of endogenous GH suppression
by SRIH at t = 90mins and at t=150mins under 3 clamp conditions is 
reported in Chapter 5. One hour after the recombinant GH bolus, the 
somatostatin infusion was terminated in order to analyse the endogenous 
GH rebound release (Chapter 5). Insulin, GH and glucose measurements 
were obtained at ten-minute intervals for the last two hours of the studies.
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2.0.6 Experimental conditions 
Clamp
Clamp conditions were established by 90mins and were maintained throughout 
the whole study period (90-270mins): mean jf sem plasma glucose was 5.3_+0.1, 
5.3+_0.1 and 12.1±0,l mmol/L during normoglycaemic (NG) (n=6), 
hyperinsulinaemic (HI) (n=5) and hyperglycaemic (HG) (n=6) clamps 
respectively.
Study period (t90-150min) - Bolus half-life study
The insulin infusion during the normoinsulinaemic (0.2 m U/kg/m in) and 
hyperinsulinaemic (0.7 m U/kg/m in) clamp studies (t90-150min) induced mean 
jfsem steady state plasma insulin concentrations of 36.4 mU/1 (NG) and 
(HG) and 92.2 mU/1 (HI) respectively.
Study period (t90-270min) -  GH suppression and rebound
Meanj^sem plasma insulin levels were N G  36.2 jf 6.2 and H G  30.9 4^ 6; versus
HI 77.52 +_7.4 m U /L (p< 0.001) clamps respectively.
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2.0.7
GH SECRETION STUDY- PROCEDURE 2
GH is secreted in a pulsatile fashion, so that multiple measurements over time 
during a 24-hour interval are required to assess endogenous release. However, 
daytime measurements require standardization of physical activities, meals and 
mobility and I have therefore analysed overnight plasma G H  profiles. Evans 
(1987) concluded that in adults 15-20 minutes sampling was the lowest 
frequency that would identify all the major GH secretory episodes.
2.0.8 Study design
GH profile data were analysed in adolescents with Type 1 diabetes under 3 
conditions and compared to controls. All subjects (diabetic and controls) had 
12hour profiles from 20.00-0800h. The G H  profile data have been the subject of 
a previous discussion (Edge 1990a) and the raw data re-analysed by Distribution 
Analysis.
2.0.9 Subject characteristics (GH secretion study)
Fifteen-minute integrated plasma GH samples were obtained from 29 diabetic 
adolescents (15 male, 14 female) and 34 healthy children (siblings: 17 male, 17 
female) enrolled as control subjects in overnight studies (Table 2.1b). 
Adolescent diabetic subjects had had a diagnosis of Type 1 (insulin-dependent) 
diabetes for more than one year and were taking no other medication other 
than insulin. Normal adolescents who were healthy siblings of diabetic children 
were enrolled as control for overnight GH studies. All adolescents had height 
and weight measured for the study session and the height velocity was 
calculated over a six-month follow-up period. Pubertal stage was assessed by the 
method of Tanner 1962 (breast stage was used in girls and genital stage used in
Subjects Type 1 Diabetes Control (normal healthy)
M edian  values
No 29 34
Age years 13.6 13.1
range L ^ 10.5-16.5 9.1-20.1
Sex 15M 14F 17M 17F
BMI kg/m^ 19.1 18.9
range 15.8-23.9 14.5-26.3
Puberty Stage 1 6 9
2-3 12 13
4-5 11 12
C ourtesy  o f  J  E dge
Table lb  Demographic data of diabetic and control adolescents attending for 
overnight (20.00-08.00h) plasma GH profiles in order to perform Deconvolution 
analysis to estimate secretory rates.
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boys). Skeletal age was assessed in diabetics as part of the annual review of 
growth and development.
The two groups were comparable in age (median age: diabetics 13.6y, range 
10.5-16.5; controls 13. ly, range 9.1-20.9y), stage of puberty (as assessed by 
method of Tanner 1962) and weight (median Body Mass Index: diabetics 19.1, 
range 15.8-23.9; controls 18.9, range 14.5-26.3). Diabetic subjects had a median 
glycated haemoglobin (HBAi) concentration of 10.6% (range 8.4-19.5) and had 
had Type 1 diabetes for more than 1.5 years (median 6.1y, range 1.5-12.8). They 
were on no medication apart from insulin. All control subjects had normal 
HbAi concentrations (Median 6.0%, range 4.2-7.8).
2.1.0 Clinical protocol
GH profiles for estimation of secretion
Exogenous insulin was discontinued before admission for overnight studies: 
ultralente at least 44 hours, lente 36 hours, soluble insulin 8 hours before the 
study night. The subjects were admitted at 1730h and had a small low-fibre 
meal (2/3 of normal carbohydrate intake) before 1800h and then fasted during 
the study. Venous cannulation and methods were as described previously. 
Overnight glucose clamping was carried out from 20.00-08.OOh and the target 
blood glucose entered into the clamp programme was 5.0mmol/L.
All subjects (29 Type 1 diabetes, 34 control) had 12hour overnight G H  profiles 
from 20.00h-08.00h (15-minute integrated sampling). The control subjects were 
admitted on a single night: the diabetic subjects were admitted on two occasions 
and were studied under different conditions. The raw data of 15minute plasma 
GH profiles obtained from diabetic NR, EC and PIR were analysed by the 
Distribution Method (Chapter 6) and then subjected to deconvolution 
analysis.
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2.1.1 Experimental conditions 
Normal insulin regime group (NR)
Fifteen (7M, 8F) adolescents with Type 1 diabetes were maintained on their 
usual insulin regime and had their normal meal and snack pattern with the last 
snack taken before 22.OOh.
Euglycaemic Clamp group (EC)
Twenty-nine (15M, 14F) adolescents with Type 1 diabetes (including 15 subjects 
studied during normal insulin regime night) underwent an overnight 
euglycaemic clamp protocol after exogenous insulin had been discontinued 36h 
before admission.
A variable rate insulin infusion was used to achieve and maintain euglycaemia 
(target blood glucose 5mmol) between 20.00-08.OOh based on 15min bedside 
glucose measurements with rate of insulin infusion being calculated- by a 
microcomputer programme (Matthews 1989, Appendix 5). Blood glucose 
concentrations below 6.0 m m ol/L were achieved by 21.30h. Overnight 
(01.00-08.OOh) mean ±SD plasma glucose was 5.26 ±0.04 mmol/L. The 
principle of clamp programme is provided in Appendix A5.1.
Pirenzepine group (PIR)
Seven of the adolescents who were clamped on the first night underwent a 
second identical overnight euglycaemic clamp but with the addition of two 
50mg oral doses of the anticholinergic drug pirenzepine given at 19.45h and 22- 
23.OOh to suppress their endogenous G H  secretion (Martina 1987, Page 1987a). 
The plasma glucose concentrations were mean ±SD 5.36 ±0.14 mmol/L 
between 01.00-08.00h. Results of deconvolution analysis under the three 
experimental conditions are provided in Chapter 4.
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2.1.2
G H  SIGNAL STUDY
Studies examining the metabolic effects of GH in-vivo are complex, particularly 
as the human model is subject to individual variation. Changing metabolism 
occurs on a daily, hourly or minute basis and interferes with both inter-subject 
and intra-subject study variability. In order to standardise daily routine, I have 
examined subjects overnight both to minimise exercise activities and meal-cued 
events. Sleep is also a normal activity contributing to the daily metabolic 
timetable of Type 1 diabetic subjects and observation overnight should be of 
immense interest.
2.1.3 Study design
The Distribution analysis performed on plasma G H  profiles is an objective 
method of estimating baseline, mean and peak hormone concentrations 
(section 4.0.7) and allows representation of the spectrum of GH levels 
experienced by adolescent diabetics.
G H  is unstable when given as an infusion unless a buffer solution is used. The 
GH infusion rates would also depend on individual clearance of the hormone 
and in order to construct a standard GH profile in all study subjects, various 
adjustments and metabolic parameters need attention. Diabetic subjects also 
require standard metabolic conditions of glucose and adequate insulin 
throughout any study period.
Standardised, reproducible double-blind study conditions should be achieved in 
order to differentiate the GH signal and its effects on metabolites, particularly 
when examining ketogenesis, lipolysis and insulin sensitivity.
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Aims
1) Achieve adequate endogenous GH suppression overnight (12 hours)
2) Standard metabolic conditions of glucose and insulin
3) Prevent hypoglycaemia or exaggerated fall in glucose stimulating counter­
regulation
4) Reproduce a physiological GH profile seen in adolescents with Type 1 
diabetes, separating components of the GH message
5) Achieve standard reproducible control conditions for each study night
6) Investigator and subject to be blinded to the GH infusions given
7) Adequate observation time to examine changes in insulin, glucose, ketones 
and lipolysis
2.1.4 Subject characteristics (GH signal studies)
Eight subjects (HJKLMNPQ) with Type 1 diabetes were initially recruited and 
their individual details are given in Table 2.1c. Subject exclusion and refusal 
(detailed in Appendix 2b).
Metabolic and hormone data were analysed from six subjects who were young 
adults (2 female, 4 male JLMNPQ), median age: 19 years (range 14-26), median 
weight was 66.6kg (range 52-80.75), median surface area 1.78 m^ (range 1.48- 
2.05) and they were non-obese (median BMI 23.6, range 21.9-26.9 kg/m^. 
Median duration of diabetes was 10 years (range 6-18). Each was controlled on 
insulin (median 0.68 U /kg/day, range 0.45-0.95) given 2-4 times daily. Median 
glycosylated haemoglobin (HBAi) level taken nearest the study dates of 8.8% 
(range 6-12.5%; reference range 3.8-6.0%).
All subjects (H-Q) were no other medications apart from insulin. All were in 
good health except for their diabetes and there was no evidence of any long 
term diabetic complications. Based on two nearest H bA i to study dates, mean 
H bA i was 8.9% (range 6-14, reference range 5.6 - 8.2%); group median height 
165cm (range 154.1 to 189cm), the median surface area 1.84 m2 (range 1.4 - 
2.05m^) and the median BMI 21.9 kg/m2 (range 17.3 - 27.9kg/m^).
Subject H* J
.■c
K* L M N P Q
Age years 13 14 17 27.9 16 22 26 19
Sex F F M M F M M M
Weight kg 44 65 66.6 78.6 52 74.4 80.8 58.1
Height "" cm 159.9 162.3 174 167.8 154 169.5 189.0 160
Surface area 1.41 1.68 1.78 1.91 1.48 1.94 2.07 1.6
BMI kg/m^ 17.3 20 22 24.4 21.9 26.9 22.6 23.6
HbAi % 8.9 7 12.5 11.5 8.8 9.7 6.6 9.6
Duration Diabetes 
years 4 7 8 18 6 14 10 15
Insulin Dose 
u/kg/day 1.09 1.16 0.78 0.87 1.08 0.92 0.77 0.65
Table le  Demographic data of all subjects (H-Q) recruited for overnight 
metabolic studies
O f subjects who had GH signal studies, two were excluded* before reporting 
metabolic data, but their GH data was utilised to assess GH half-life (HJKLMP 
60minute pulse; JLMNPQ 12h infusion) (Chapter 2).
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Figure lb  Study design: GH signal
Intermediate acting insulin was stopped thirty-six hours before 
arrival at the hospital. Each patient was studied overnight under 
normoglycaemic conditions by a variable rate insulin clamp. 
Normoglycaemia was achieved by fifteen-minute bedside glucose 
measurements with an iterative computer programme to predict 
insulin requirements.
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2.1.5 Clinical protocol (GH signal study)
Each subject was admitted on 3 separate nights (19.00-08.OOh). Five (fLMPQ) 
out of the 6 subjects participated on all 3 nights; one (N) for pulse GH and 
control. The study was double blind to both operator (BRP) and patient and 
the sequence of these studies was varied at random 2-6 weeks apart. Subjects 
were admitted at 16.30h on the study day and ate before 18.OOh.
The schematic diagram of the study design is shown in Figure 2,1b. 
Exogenous insulin was discontinued at least thirty-six hours before the study. 
A small easily absorbable carbohydrate meal, being two-thirds of daily 
carbohydrate intake, was given before 18.00 hours with a continuous 
intravenous infusion of soluble insulin to limit the blood glucose rise. Subjects 
then fasted overnight during the study 1900-0800h.
Standard conditions
In order to observe the direct metabolic effects of GH, standard conditions 
were maintained: reproducible GFI signal, insulin-varying clamp, somatostatin 
infusion and glucagon infusion. Overnight infusions were administered as 
shown in the inset of schematic diagram in Figure 2.1b.
2.1.6 “Convolution” of G H  signal
From the results in Chapter 4, adolescent subjects with Type 1 diabetes have 
overnight plasma GH represented by 
“C ontinuous G H  Signal”
at OC50 level of 6.14 -8.38 mU/L = average of 7.4 mU/L 
“Pulse G H  signal”
at OC75 and OC95 of 24.99-52.71 mU/L = average is 39 mU/L
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A GH profile to mimic these levels was thus reconstructed. The components of 
the G H  signal, the pulse and continuous GH signal was separately examined
and compared to a control night without GH.
The calculations were based on G H  distribution volume in diabetic subjects 
obtained from bolus GH decay (section 3.0.4 (6.1L, 8.9% body weight) and 
assuming steady state is reached after 5 half-lives.
Calculation
Continuous Infusion dose m U /kg/h
dose of GH = desired steady state plasma level x DV x 1 x 5 /8.9 
= 7.4 x 6.1 X 0.693 x 5 /8.9 = 17.5 m U/kg total dose 
= 1.5 m U /kg/h  over 12 hours
Pulse infusion m U/kg/pulse_____
Total dose GH = desired plasma level x DV x X (half-life decay constant)
= 39 X 6.1 X 0.693 /  8.9 = 18.5 m U /kg total dose.
= 6 m U /k g /p u lse  as 3 pulses
Total dose of 18 m U /kg r-hGH either as solution A or B was provided by
independent operator (Pharmacy, John Radcliffe Hospital).
Growth hormone solution (80mU/ml) was made up as follows: 4U r-hGH 
(Genotropin 4iu, Kabi, Stockholm, Sweden) was diluted in 50ml phosphate 
buffer solution under aseptic conditions.
Operator Blinded to GH signal
The GH/buffer or buffer only was provided to the operator (BRP) in 50ml 
syringe labelled as solution A and solution B.
On all study nights both solution A and B were administered as either
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Solution A: 12h continuous intravenous GH infusion to achieve a raised 
baseline mean level (1.5mU/kg/h given between 20.00-08.00h) (where Solution 
B=Buffer)
Solution A was infused at 0.02 m l/kg/hr (20.00-08.OOh) using Vickers syringe 
pump and the same solution and syringe was used.
or Solution B: Three separate GH infusions given hourly (6m U/kg/h at
22.00-23.OOh, 01.00-02.OOh, 04.00h-05.00h) to reproduce the pattern of 
nocturnal pulses of GH (where Solution A = buffer)
Solution B was infused at 0.08ml/kg/h at 3 separate hourly periods.
This syringe was infused by modified Vickers pump attached in series circuit to 
a multi-function digital timer’-* (setting accuracy; 0.5% of set time; repeat 
accuracy: jf 0.3% of set time) and this was programmed for time setting at 
60min on/120min off to control infusion rate. The clock was set to start at 
20.OOh in "off" phase.
or a control night: where both solution A and B contains buffer’'* solution (i.e. 
no replacement of GH).
The difference in magnitude of GH pulses and continuous signal was 3.4 
mimicking the difference seen in diabetic subjects (Chapter 6) .
A Buffer’'’ solution alone was used for control nights. The code was announced 
after all study nights were completed, but before analysis of data was carried 
out.
’' Appendix information: A2 -  multifunction digital timer
2.1.7 Standard conditions of glucose
Overnight glucose clamp was carried out from 19.OOh to OS.OOh. A 
microcomputer programme using portable bedside Apple lie computer 
(Appendix 5, A5.1 and A5.2) calculated the rate of the insulin infusion. The 
target blood glucose concentration entered into the programme for the clamp 
studies was 5.0mmol/L. During the clamp, the mean insulin infusion rate for
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the attainment of a steady blood glucose concentration was used to calculate 
insulin requirement for the maintenance of euglycaemia.
Insulin: The insulin infusion (0.1 U/ml) was made by adding 5U of soluble 
insulin (Actrapid, Novo, Copenhagen, Denmark) and 2ml of subject's blood, to 
prevent adsorption (Kerchner 1980), to 48ml 0.9% saline. The syringe was 
changed three times during the night and new insulin was primed in the syringe 
before use on each occasion. The insulin was infused using a Treonic IP3 
Syringe pump (Vickers medical, Basingstoke, U.K.). An overnight 
euglycaemic clamp was undertaken in all subjects.
Glucose clamp conditions
Euglycaemia (< 6  mmol/1) was achieved by 22.00h on all study nights and 
lowest blood glucose measured at any time was 4.0 mmol/L. During control 
nights (n -6 , SRIH alone) blood glucose fell below 3.5mmol/L in 5 subjects and 
<3.0 mmol/L in 3 subjects within the first 2 hours. When additional G H  was 
administered with SRIH (n= 10), a blood glucose below 3 m m ol/L was only 
measured during one study night and below 3.5mmol/L in five nights. No 
subject needed correction of low blood glucose. A stable euglycaemic clamp was 
achieved after 3 hours in all subjects. Euglycaemic mean clamp levels achieved 
on study nights (01.00-08.00h) were comparable: 5.5 4:0.5 during continuous 
GH, 5.9 4:0.5 during pulse GH vs. control 5.3 _+0.4 mmol/L. Infusions of 
glucagon and somatostatin were both commenced at 1900h and interactions 
with the insulin clamp are discussed below and expanded in Chapter 5.
2.1.8 Endogenous G H  suppression
Somatostatin: Endogenous G H  was suppressed by somatostatin throughout 
the study period. The Somatostatin infusion (30 pg/ml) was made by adding 
1500mcg of a 3mg vial of somatostatin 1-14 (Stilamin, Serono,S.p.A, Rome, 
Italy) dissolved in 2ml water, to 49ml 0.9% saline and infused at a rate of 50-
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100 m cg/m 2/h between 19.00-08.OOh by a similar Vickers syringe pump. The 
solution was changed after 6 hours.
Endogenous plasma GH levels were effectively suppressed within one hour of 
SRIH infusion on all study nights (1.4j: 0.4 continuous GH, 0.8 4^  0.2 pulse 
GH, 1.14: 0.3 control mU/L) before administration of GH/Buffer.
Glucagon; Because of the prolonged SRIH suppression, glucagon infusion at 1 
ng/kg/m in (Novo-Nordisk, Gentofte, Denmark) was added to the clamp and 
maintained throughout the study period in order to achieve constant hepatic 
glucose production. The glucagon infusion (Imcg/ml) was 0.5mg of Img vial 
of glucagon (Novo Industri, Bagsvaerd, Denmark) in 10ml 0.9% saline 
(50mcg/ml) then adding 1ml of this to 49ml 0,9% saline. The same solution and 
glucagon was used throughout the study and the glucagon was infused through 
a Vickers syringe pump at a rate of Ing/kg/m in between 19.00-08.00h.
2.1.9 Samples
The blood was collected in 15min aliquots in lithium-heparin tubes for later 
G H  assay but the first 2 or 3 drops of blood for each tube were collected in 
fluoride tubes for immediate blood glucose assay. Samples from an individual 
session (involving 3 bolus or GH infusions (60min or steady state) were assayed 
together after completion of their respective study sessions.
Hourly samples were also collected in lithium-heparin tubes for plasma free 
insulin, metabolites and non-esterified free fatty acids (FFA) assays.
Samples for GH, blood glucose, insulin were analysed as described in Appendix 
3d. Samples for GH analysis were spun, separated and stored at -20°C until 
assay. Validation of GH assays between reporters were also clarified (Appendix 
3e).
Convolution of GH plasma profile and the metabolic effects of these profiles is 
the subject of discussion in Chapter 6.
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2.2.0
JUSTIFICA TIO N  O F PRACTICAL PROCEDURES
The complexity of metabolic control, particularly during the non-steady state 
of normal life in subjects with Type 1 diabetes, makes interpretation of 
probable metabolic processes from single observations impossible. In order 
to gain insight into the possible disordered metabolism, prevent the least 
disruption to normal routine and obtain standardised conditions, I have 
studied most of my subjects during the overnight fasted state. The sleeping, 
fasted state also constitutes a regular part of normal life experience and 
facilitates multiple observations of key metabolites (metabolic profile). 
However, this sort of study will in practice generate a very large number of 
samples.
2.2.1 Blood sampling
Continuous integrated blood sampling was performed in all studies unless 
otherwise stated. An indwelling intravenous polyethylene cannula and a 
double lumen catheter were retrogradly inserted under local anaesthetic and 
cannulation is described in Figure A, Appendix 2.
The blood was collected in fifteen minute aliquots into tubes into a fraction 
collector (L.K.B. Fraction Collector, L.K.B. Instruments Ltd., Surrey) for later 
assay but the first two to three drops of blood for each tube was collected in 
tube caps. This blood was assayed at the bedside for glucose using a Yellow 
Springs whole blood analyser (Y.S.I. model, Clandon Scentific Ltd., Aldershot, 
Hants). Details of sampling frequency for GH and metabolites, assay 
procedures and handling of samples are given in Appendix 2.0, 3.0 and 
discussed in respective Chapters.
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2.2.2 Use of insulin-varying clamp
It is impossible to quantify a requirement for the complete normalisation of 
metabolism in Type 1 diabetes since even with the strictest control of blood 
glucose, blood ketone levels and other intermediate metabolites often remain 
persistently elevated above normal. Therefore, the term "insulin requirement" 
is generally interpreted as meaning the quantity of insulin necessary to maintain 
normoglycaemia. Also insulin requirement will vary according to dietary 
intake and degree of physical activity and in order to eliminate these variables, 
basal (i.e. post-prandial) and resting insulin requirements are probably the most 
useful measure.
Current insulin doses are often equated with insulin requirement, but for 
several reasons this is an inaccurate estimate. Even when glycaemic control 
appears good there is a high incidence of unrecognised hypoglycaemia, 
particularly at night (Whincup 1987) confirming that insulin requirement is not 
equal to the insulin dose regimes. The insulin requirement to maintain 
euglycaemia has been calculated by other investigators to be 7-20 m U /kg/h  
using a variety of methods (Clarke 1980). Waldhausl (1982) calculated the basal 
insulin production in healthy man as being 15_+6 m U /kg/h  and such an 
infusion rate markedly improved metabolic control.
A device that measures the blood glucose, and then administers only 
sufficient insulin to maintain normal glycaemia would effectively quantify 
insulin requirements. Such close linked methods of blood glucose control, 
where insulin is given in direct response to a measured concentration of blood 
glucose, have been used therapeutically in brittle diabetics and those undergoing 
surgery and are the basis of a sliding scale of the insulin dose.
I have used an insulin-varying clamp that predicts insulin requirements 
accurately, without giving rise to pulsatile insulin infusions or the need for 
glucose infusions to maintain euglycaemia. Thus the effects on insulin 
requirements during GH administration can be clearly observed. The glucose
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clamp by insulin-varying method used in this Thesis is described fully in 
Appendix 5.
The programme developed by Matthews, 1989, works on the principle 
that it progressively assembles a data array from its own evolving experience "of 
that particular individual and then uses the array to choose the next insulin 
infusion rate, thus making no assumptions and introducing no bias. This 
system has been shown to be sensitive and the insulin infusion rate is equal to 
the insulin requirement for the maintenance of euglycaemia. The computer 
programme developed by Matthews, 1989 allows adjustment of insulin in order 
to maintain euglycaemia (or any other pre-determined glucose concentration). 
Because insulin takes a finite time to act, the adjustment takes place only every 
10-15 minutes; a total time-period of several hours is thus needed for such 
clamping. The programme does not use any fixed algorithm to predict insulin 
requirements, but uses instead a principle of experience rather than 
preconception as the basis of the prediction (Matthews 1989). Observer bias is 
thus eliminated in the results. This technique therefore yields a robust estimate 
of overnight insulin requirement in adolescent diabetics and is able to provide 
additional information concerning the insulin-glucose interactions.
2.2.3 Use of genotropin
Biosynthetic GH (Somatonorm, Pharmacia) was the first available for routine 
prescription in 1985. Somatonorm consists of the same 191 aminoacids present 
in endogenous GH plus an additional methionine that is present as a 
consequence of the biosynthesis (risk of denaturing the molecule if removed). 
Despite this Somatonorm is physiologically indistinguishable from pituitary 
G H  (Milner 1985).
Advances in recombinant DNA technology have allowed the biosynthesis of 
Genotropin that is structurally identical to endogenous GH. Genotropin is 
produced in E.coli modified genetically to produce human GH, which is
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harvested from the bacteria after a period of fermentation. The hormone then 
undergoes a series of purification steps and is freeze-dried. (Fryklund 1987)
This production process (Fryklund 1987) results in an extremely pure hormone 
identical to endogenous GH and with full biological activity.
2.2.4 GH profiles
Until it was recognised that GH secretion was pulsatile early measurements 
which were of single serum G H  levels yielded uninterpretable results. It was 
later felt that since the hormone appeared to be released in an apparently 
random fashion only a mean integrated concentration could be of any value. 
Studies involving GH profiles require frequent and prolonged sampling periods 
and the interpretation of GH pulsatile changes during puberty, when a 
multitude of dynamic endocrine interactions and physiological changes are 
occurring, is often difficult and confusing.
Before the pulsatile pattern of the hormone profile can be examined it must be 
certain that the timing and frequency of blood sampling is adequate to answer 
the questions asked. It should be decided whether continuous or discreet 
sampling is required: continuous integrated sampling is less likely to miss peaks 
or troughs and a pulse will always be included, although its amplitude may be 
slightly underestimated (Matthews 1988). Albertsson-Wikland & Roseberg 
showed that during twenty-four hour GH profiles of four children, integrated 
and discreet sampling produced almost identical profiles and there was no 
obvious blunting or widening of peaks with the integrated sampling technique. 
Sampling should be sufficiently frequent not to miss any pulses and in practice 
should include at least five samples per oscillatory cycle (Matthews 1988). 
However, there is evidence that more intensive (five minute) sampling of GH 
will unmask higher frequency pulses although there was no pulse identification 
at this frequency that was not contiguous with the majority of the major of the 
episodes which were all uncovered at less frequent sampling intervals (Evans 
1987). The same study concluded that in adults fifteen to twenty minutes
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sampling is the lowest frequency that will identify all the major secretory 
episodes. These findings have also been substantiated in studies by Edge 1990 of 
children during puberty.
2.2.5 Endogenous GH
Heterogeneity of peptide hormones in biological fluids is both a general 
phenomenon and a relative one. For endogenous GH, heterogeneity in serum 
arises from 3 sources: in the secreting organ or tissue; in the circulation and 
peripheral tissues; and during handling procedures in the laboratory. The 
pattern of GH heterogeneity will always differ between the calibrant and the 
patient specimens and the heterogeneity will differ between subjects and within 
a subject under differing circumstances. However these conclusions on GH 
heterogeneity are based upon a number of complex physicochemical tools of 
high selectivity, not upon immunoassays. For the most part antibodies are 
blind to these GH variations and heterogeneity of GH proteins is only one of 
several factors contributing to inter-laboratory dispersion of GH immunoassay 
results (Seth 1988a, Seth & Hanning 1988b). These problems have been well 
reviewed by Baumann (1990) and Smith & Norman (1990). From a 
combination of these sources and mechanisms, although GH in serum is highly 
heterogeneous and previous assays of GH may reflect a sum of many different 
components, specific immunoassays which detects 22kD fragment has been 
used in this Thesis.
Protein binding may or may not affect the physiological and clinical 
significance of GH estimates. Since in-vivo clearance is affected by protein 
binding, concentrations in plasma at any one time will not necessarily reflect 
secretion rate; plasma will become selectively enriched with slowly cleared 
fractions. GH has a number of epitopes (antibody-binding domains) which can 
be mapped using mono-epitopes specific monoclonal antibodies. The GH 
epitopes are thought to be still exposed when protein bound and this is the 
main reason why protein binding does not appear to have a major effect on
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immunoassay results. In addition, binding proteins appear not to be able to 
compete with antibodies for available GH (Baumann 1987). While this is of 
interest and possible physiological relevance, there is no evidence that it alters 
the clinical significance or interpretation of GH assay results (Baumann 1990).
2.2.6 Use of somatostatin
Somatostatin, a gut and brain peptide is a powerful inhibitor of in vivo and in 
vitro GH release and inhibits the GH response to all known stimuli (Wass 
1983). In man somatostatin blocks the GH response to exercise, arginine and 
insulin hypoglycaemia. The dose of SRIH required to achieve adequate GH 
suppression has been examined and a dose of 50-100pg/h was utilised in 
previous studies with adequate endogenous GH suppression (Skamene 1984). 
Native somatostatin, a 14-residue peptide, because of its short circulating half- 
life, must be given by continuous intravenous infusion. Somatostatin (Stilamin, 
Serono) is a synthetic tetradecapeptide hormone (SS-14) with several 
physiological actions including inhibitory effects at the level of the 
hypothalamus. It is presented in a freeze-dried sterile powder form and for 
infusion purposes it can be diluted to the required volume with physiological 
saline and protected from light. The continuous intravenous infusion is stable 
for up to 72 hours at room temperature.
2.2.7 Use of glucagon
Subject H  undergoing 12-hour somatostatin without glucagon was excluded 
from analysis, as she became profoundly hypoglycaemic and this may have 
initiated adrenergic responses. In previous studies in which iv bolus of SRIH 
was given alone or short acting insulin was given alone, or with somatostatin, 
SRIH enhanced the hypoglycaemic action of insulin and delayed the 
restitution of blood glucose to normal (Gerich 1976). This influence of SRIH 
was ascribed to hypoglucagonaemia since it could be eliminated by 
replacement doses of glucagon and not GH (Rizza 1979).
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In order to prevent hypoglycaemic-induced counter-regulation, a glucagon 
infusion was maintained during G H  signal studies. The dose of glucagon 
infused at Ing/kg/m in was used in my studies as this dose has been shown to 
achieve plasma levels of around 75-100 peg/ml (Paolisso 1987), similar to the 
physiological basal glucagon levels of 100-150 peg/ml (Kuku 1976).
Basal glucagon seems to be responsible for at least one third of glucose output. 
Basal circulating glucagon concentrations in insulin-dependent diabetics have 
been reported to be normal (Unger 1970) or increased (Gerich 1975b) compared 
to normal subjects, but are always inappropriately high for the degree of 
glycaemia. In diabetes, the glucagon predominance may contribute to the 
increased net hepatic glucose output and elevates blood glucose values (Gerich 
1975b). Increased lipolysis, mainly due to insulin deficiency, elevates fatty acid 
supply to the liver, which responds to the hyperglucagonaemia with increased 
fatty acid oxidation and ketogenesis (McGarry 1979). This concept has also 
been disputed because of the apparent transient effect of experimental 
hyperglucagonaemia on hepatic glucose production (Felig 1976, Sherwin 1976a). 
In the study reported by Paolisso, 1986, somatostatin was used to inhibit 
endogenous pancreatic hormone secretion, glucagon was replaced by 
continuous glucagon infusion and insulin was administered in a pulsatile or 
continuous manner. The doses of insulin did not completely inhibit hepatic 
glucose production and plasma insulin averaged 7 m U /L  during continuous 
infusion and oscillated between 1.5 and 35 mU/1 during pulsatile delivery. 
Glucagon replacement here resulted in peripheral plasma glucagon levels 
averaging 180-200 pg/ml (versus basal values 110-120 pg/ml) and the possibility 
existed that this over-replacement of glucagon may have stimulated hepatic 
glucose production too strongly to be affected by the peripheral plasma insulin 
achieved. Paolisso, 1987 investigated more precisely the role of glucagon in 
modulating the effects of insulin deliveiy. At low glucagon levels (75-130pg/ml) 
the superior pulsatile effect of insulin became manifest after approximately the 
third hour of insulin infusion but this critically depends on circulating glucagon
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levels, being completely abolished if plasma glucagon levels are in the range of 
200 pg/ml (Paolisso 1987). The doses of glucagon used in my studies should 
not antagonise insulin effects on liver carbohydrate metabolism (Paolisso 1987). 
Furthermore, glucagon does not influence lipolysis in normal subjects when 
infusing glucagon at rates between 0.5-1.5 ng/kg/m in (achieving maximum 
levels 110-130 mg/L) (Gravholt 2001). These observations suggest that the 
glucagon infusion chosen for my studies would not influence glucose disposal, 
insulin action or stimulate lipolysis.
In  summary, when achieving standard conditions, adequate G H  
suppression can be achieved with somatostatin infusion bu t counter­
regulation of exaggerated hypoglycaemic effects can be minimised with 
glucagon infusion at low levels (75-130pg/ml), thus enabling accurate 
observations of glucose/insulin changes due to G H  alone.
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Statistical Analyses
Full details of statistical analyses are provided in Appendix 4 and the 
main statistical authorities used are provided in the Bibliography.
Specific statistical analyses used, results and findings are described 
separately in each chapter.
General Principles of statistical analysis used in this Thesis
Standard formulae were used for the calculation of means, standard
deviations (SD) and standard error of the mean (SEM).
Group results of metabolic data are given as mean+ SEM unless otherwise 
stated. Where SD are provided this can be converted to SEM =SD/'v/N, 
where N  is number of subjects in study. Parametric statistics are used to 
describe statistically significant differences eg Student's paired t-test was 
used for comparisons of mean data between subjects' overnight profiles 
and at individual time periods; unpaired t test
Subject demographic data are described as median+ range and non- 
parametric statistics applied eg Mann-Whitney U, Spearman rank 
correlation) were used as appropriate.
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Data Handling
Normalising data (section A4J2)
Blood glucose and insulin infusion data were normally distributed. 
Log-transformation was used to normalise the ketone, lipid and plasma 
free insulin data. Thus, parametric statistical techniques have been applied 
on these log-transformed data.
Missing Data (section A4.4)
This amounted to only 0.3% of the metabolic and hormone data and was 
due to either insufficient sampHng or a laboratory analysis problem.
Plotting and Graphical representation
The results are plotted graphically by computer programmes updated 
through Microsoft Office programmes.
Programmes used for Statistical analysis (section A4.3)
Between 1989-1993, most of the calculations were done on the Oxford 
University IBM computer with some later usage on the Birmingham 
University Honeywell DPS-8/70M  mainframe computer.
The programmes used were OXSTAT ver 4 and 5 and SLIDEWRITE and 
the BMDP Biomedical Computer Programs (University of California, 
Berkley, USA). Post 1993, Microsoft Office programmes performed word- 
processing, data transfer and analysis and Stats view and Minitab 
programmes (including the online help fadlity in Minitab 10.51).
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Statistical analyses applied
(i) Students' ftest
Students' t  test comparing means at each time point may show 
statistically significant differences at specific time points but not show  
whether there was an overall difference between the profiles, although if 
the majority of individual time points were different then the whole 
profile would probably be different Also the biological significance of a 
statistical difference at one or two time points during a 12hour-study night 
is difficult to assess.
Thus a total mean value for a period studied eg overnight can be 
calculated for each patient in a group and these values then compared 
between groups as non-paired t-test
(ii) AIsFOVA, Analysis of Variance (one way and two way)
Analysis of variance (2-way ANOVA) was used to examine changes with 
time and confirm differences between study nights.
Two-way analysis of variance with metabolite concentration classified by 
group and time (Armitage, Blackwell Science,UK). It is possible with this 
method to compare the differences in the variance between two groups 
removing the variance due to the time the samples were taken. Each 
sample value is used in this method rather than a derived mean. The 
significance of the difference between groups was calculated from the 
variance ratio using F-tables.
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In chapter 6, two-way Anova on log-transformed ketone data was used to 
confirm change with time (20.00-08.00h) and when plateau levels were 
reached (p=NS).
Similarly, steady state GH was determined by ANOVA when serial serum 
GH concentrations over a 12hour period showed no significant drift 
(section 3.0.5).
(in) Mann-Whitney test
The Mann-Whitney test was used to compare the GH secretion data 
between puberty groups as this was not normally distributed. The Mann- 
Whitney test is commonly regarded as a test of medians where one 
median is an estimate that of the probability that one variable is less than 
the other (Altman 1991). However, it is a test of both location and shape. 
Given two independent samples it tests whether one variable tends to 
have values higher than the other. However, it is also important to look at 
distributional differences or spread. 1 have therefore provided the range 
of GH secretion for each puberty group. This w ill provide the features that 
are most chnically important The hypothesis that there was no difference 
between puberty groups can be rejected as both median and spread of the 
difference are different between each puberty group.
(iü) Regression and Correlation
Regression functions can be either linear or of higher form. By changing 
the X or y scale non-linear functions are always converted, to linear ones, 
since the mathematical treatment for this is simpler (y=a+bx). This
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relates to the common regression of y to x, where y  is the dependent 
variable and x the independent variable.
The opposite regression, x to y, gives as a rule a regression line 
somewhat differently inclined to that of the regression y to x. The 
measure of the mutual behaviour of these two lines gives the correlation 
coefficient r.
The square of the correlation coefficient is the measure of certainty and 
shows to what extent the independent variable x influences the 
dependent variable. A measure of certainty of 0.5 indicates that 50% of 
the changes in y can be explained as due to changes in x. There is no 
actual proof that the connnection is a causal one and the result should be 
regarded as a pointer to the direction in which further investigation 
would yield direct proof.
(iv) Confidence Intervals
The confidence interval is the range on either side of a sample mean. The 
95% confidence level (a of 0.05) was used. When measuring plasma GH 
at very low levels, the GH suppression level may be influenced by the 
limits of the GH assay (eg sensitivity of assay 0.3 m U /L and intra-assay 
CV at GH concentration of 2.9mU/L is 8.0%). The confidence interval may 
allow a better description of reliable these suppression hmits. The 
confidence interval (d )  may be viewed as the range of possible values for 
the true difference that are statistically likely around the point estimate 
(mean) values obtained in each clamp ie above or below 95% Q  would be 
a probability of seeing a difference of p< 2x0.025 (Gardner & Altman 
1986).
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Specific Mathematical Analyses used
Chapter 3 (section 3.0.1- 6) specific mathematical formulae were used to 
calculate
Monoexponential Decay of r-hGH 
Biexponential Decay Model 
Volume of Distribution 
Steady State Half-Life
The metabolic clearance rate (MCR) of r-hGH 
Chapter 4
Matthews (1991) has described using a method of cumulative 
distribution and probability to provide an objective assessment of GH 
profiles (section 4.0.1).
Probit Transformation
Continuous summation (from left to right) of the area under the normal 
distribution and plotting the areas against a linear abscissa yields a 
sigm oid curve. The values of its ordinates corresponds to the areas of the 
normal distribution. The sigmoid curve may be transformed into a 
straight Hne by means of the probit transformation, whereby the 
frequency percentages (=areas xlOO) are converted into corresponding 
deviations of the normal distribution increased by the addition of 5 and 
these are known as probits. Probits may be obtained without the need for 
calculation from tables (Statistical Tables published by Oliver and Boyd, 
Edinburgh).
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Deconvolution analysis (section 4.0.2).
Several methods of deconvolution have been proposed (detailed in 
Appendix lb). I have used the Deconvolution model proposed by 
Hindmarsh and its advantages are discussed in section 4.0.3.
GH profile data was provided to DRM and mathematical calculations 
made by computer programmes to calculate to GH secretion. The mean 
overnight secretion (and range) by puberty group is described in 
Chapter 4. GH secretion data is described by standard summary 
statistics.
Time Series analysis (section 4.0.4)
Fourier analysis was performed on GH secretory data. The calculations 
were made by Oxford m odelling software. The Fourier transform of the 
GH secretory data demonstrated the dominant pulse periodicity and 
revealed any differences in puberty groups, during euglucaemia and after 
pirenzepine.
Chapters
Clamp analysis are detailed in section 5.0.1.
Calculation of clamp bias, insulin clearance and coefficient of variation 
have been made.
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Chapter 6 
Cross-correlation
Cross-correlation is an iterative technique for establishing whether there 
are statistically coincident recurring waveforms (of any shape) within a 
data array (Matthews 1983). One data array is serially correlated against 
the other with progressive step changes in the tome-relationship between 
the data. The result is dependent both on the relative amplitude of such 
waves or pulses (eg whether large pulses of one array are associated with 
large pulses of the other) and on the phase relationships between the 
arrays (whether one data array is time-lagged with respect to the other. It 
is independent of absolute concentrations of hormone.
Correlation regression analysis was performed to examine the relationship 
between GH parameters (loglO suppression or peak and mean rebound) 
and concurrent, previous hourly and mean plasma free insulin and 
glucose levels for an appropriate time period. Spearman's rank 
correlation was used to measure the degree of association between GH 
parameters and subjects' characteristics.
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CHAPTER 3
DISTURBANCES OF GH CLEARANCE
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3.0.0
IN T R O D U C T IO N
Elevated hormone levels may result from abnormalities in continued GH 
secretion or decreased metabolic clearance. Previous pulse detection 
programmes and time series analysis does not provide adequate information on 
actual secretory events nor account for possible variations in metabolic 
clearance rates. Deconvolution analysis models using an iterative method of 
"curve stripping" would be required to address the particular issue of increased 
GH secretion. Deconvolution analysis requires assumptions or measurement of 
GH disappearance rate and volume of distribution but these parameters have 
not been clarified in Type 1 diabetes. Other factors such as glucose 
concentrations or insulin levels may also affect half-life and volume of 
distribution in subjects with Type 1 diabetes.
In this Chapter the half-life analysis of exogenous G H  (r-hGH), after 
endogenous GH suppression, was determined in young adults with Type 1 
diabetes after bolus GH (GH clearance study); after 60minute and steady state 
infusion of r-hGH (GH signal study). The experimental conditions allowed the 
examination of GH clearance, GH suppression and GH rebound release during 
metabolic conditions of normoglycaemia, hyperglycaemia and 
hyperinsulinaemia.
Control Subjects for bolus and GH pulse infusion are detailed in Appendix 2. 
Group demographic data confirms that subject characteristics of these control 
subjects were similar to bolus GH clearance study (Table 3.2a).
Subjects
Median values
Type 1 Diabetes Control (normal healthy)
Hindmarsh Shah 
1989/90 1999
No 6 (B -G ) 10 19
Age years 2 1 .5 19 2 7
range 14.9-25 17-45 22-36
Sex 3M : 3F lOM 13M : 6F
Weight kg 6 7 .8 68.1
range 54.2-80.9 46-82.5
Height metres 1 .6 9 0 1 .6 9 5
range 1.62-1.74 1.63-1.74
Surface area 1 .7 7 1 .7 9 1.8
range 1.18-1.92 1.53-1.99 1.23-2.4
BMI kg/m^ 22.6 21.2 2 2 .5
range 16-25.9 17-25.4 16-31
Table 2a Summary of demographic data comparing diabetic subjects (B-G) 
with reported controls.
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3.0.1 Specific m athem atical analyses
Data are given as mean _+ SEM. The half-life of GH was calculated from loge 
transform of its plasma concentration. The relationship between time and. the 
transformed data was described by linear regression. Curve fitting was 
performed with the BMDP statistical software package (University of 
California). The plasma GH concentrations at entry (t=0) in each of the 
studies were compared using two-way analysis of variance (ANOVA) on a 
repeated measures design (Snedecor and Cochran, 1980). Two-tailed paired 
student's t-test was used to compare GH half-life under three different clamp 
conditions and also to compare the distribution volume (DV). The statistical 
significance was set at p < 0.05.
The relationships between the GH half-life and plasma GH concentration were 
analysed by regression of an orthogonal, second-degree polynomial, with 
statistical confidence intervals determined from the joint parameter variance. 
Simple linear regression and Pearson's correlation coefficient were used to 
evaluate a priori null hypothesis of no relationship between GH half-life, 
volume of distribution and prevailing glycaemic and insulin levels.
Comparison of group data from control and diabetic subjects were made via 
unpaired two-tailed Student’s t statistics, assuming unequal variances.
3.0.2 M onoexponential decay
A monoexponential equation was used to fit the plasma G H  concentration 
decay curves, with statistical confidence intervals calculated for the individual 
GH half-life estimate after each bolus injection. Half-life (tVz) was calculated 
from the Ln-transformed plasma GH concentrations using a mono-exponential 
model
[GH] = Ao (e- ‘^) + B
Ao is the amplitude of the phase after the distribution of the hormone in 
the sampling compartment and as previously shown the distribution of
Differentiating the GH Signal, BRP 2002  72
the hormone injected is complete after six minutes (Matthews 1985). 
The distribution phase was derived from each individual concentration­
time plot as the point where the observed data deviated from the 
extrapolated decay curve. Therefore the six minutes values were the 
start point taken for the mono exponential analysis.
X is the elimination rate constant and identical to the slope of the linear
regression.
B is basal serum GH concentration just before the r-hGH bolus injection
and therefore approaches zero when endogenous G H  secretion is 
suppressed by SRIH infusion.
The relationship between time and the transformed GH concentrations was 
described by linear regression. As the half-life is the time taken for a 50% 
reduction concentration it can be calculated by dividing Ln2 (0.693) by the 
slope (A.) of the regression line).
3.0.3 Biexponential decay m odel
In order to compare this mono-exponential model with the bi-exponential 
model as described by Faria, (1989), data were fitted into the equation:
[GH] = + C
Ao is the amplitude of the a-phase, corresponding to the rapid distribution
of the hormone in the sampling compartment.
Bo is the amplitude of the b-phase, corresponding to the decay of GH from 
the circulation.
C is the basal plasma GH concentration just before the r-hGH bolus 
injection and therefore approaches zero when endogenous G H  secretion 
is suppressed by SRIH infusion.
Lambda (Xa and A.b) are the elimination rate constant (tl4 =ln2) and identical to 
the slopes of the linear regressions. The mean parameter values were estimated 
by non-linear, weighted, least squares modified Gauss-Newton iterative analysis 
with the subsequent calculation of asymmetric joint confidence limits for the
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precision of fit for all parameters considered simultaneously (Johnson 1983). F 
ratio testing demonstrated that a biexponential decay model was not justifiable 
statistically at p <  0.01 (protected a  for multiple comparisons).
3.0.4 D istribution  V olum e
The distribution volume (DV, litres) was calculated by dividing the total 
amount of GH injected (dose, mU) divided by the peak plasma GH 
concentration achieved at the time t= 0  min. The plasma concentration of GH 
(mU/L) at t= 0  min was calculated from the intercept (A to regression).
D V  = r-hG H  dose injected (100 m U ) divided by A
3.0.5 Steady State half-life
Steady state was determined by ANOVA of the serial serum GH 
concentrations over the 12 hours showing no significant drift. This inference 
was confirmed by linear regression defining a zero slope.
At steady state, the continuous IV GH infusion rate equals the product of the
measured plasma GH concentration (mean over last 6 hours after reaching
steady state levels) and the rate constant of elimination (k) and the distribution
volume (DV) (Schaefer 1996)
G H  infusion dose = [plasma G H  steady statej.k
The half-life at steady state is determined from tVi =L n 2 /k
The metabolic clearance rate (MCR) of r-hGH was also calculated for subjects
who received a constant infusion of GH (HJLMQ). This was calculated by
method of Rosenbaum 1989:
M C R  = infusion rate o f continuous G H
Steady state plasma G H  concentration  
M C R  (L /m in) = k .(D V  diabetic subjects)
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3.0.6 G H  Rebound Half-life
Calculation of the precise half-life of G H  after discontinuation of somatostatin 
(rebound/release of endogenous GH) was difficult when GH remained elevated 
since it is impossible to exclude ongoing GH secretion. The time between the 
start of the rise of GH plasma concentration and the time when the peak 
plasma GH concentration was reached were calculated. In those that had a 
single peak (n=9 clamps), with the assumption that that additional GH 
secretion was negligible, the half-life was estimated. The characteristics of the 
plasma GH rebound is illustrated and discussed further in Chapter 4.
3.0.7
RESULTS
3.0.8 G H  clearance: bolus
Details of clamp conditions are provided in Table 3.2b and metabolites are 
discussed in Chapter 4.
Grow th hormone
Figure 3.2a demonstrates the GH profiles achieved during each clamp 
condition. The G H  rebound and suppression data discussed later.
Mean GH concentrations after suppression of endogenous G H  with SRIH were 
1.5 _+0.4 m U /L (n:17), mean peak levels reached after lOOmU bolus injection 
were 17 m U /L (range 13-21.8 mU/L). The peak levels obtained were similar 
under the three clamp conditions (t90-150mins Table 3.2c).
Half-life: M onoexponential model
The distribution phase was rapid and complete by 6 minutes as has been 
demonstrated in previous studies of normal subjects (Matthews 1985, 
Hindmarsh 1989). The disappearance of exogenous r-hGH described by a
Clamp Conditions 
by study time
Normoglycaemic
N=6
Hyperglycaemic 1 
N=6
Hyperinsuiinaemic
# # 9 0 - 1 5 0 f' ’ ►  ^' '' ' kv . -
Plasma Glucose
Mean (SEM) mmol/L
5.4 ± 0 .1 12.1 ± 0 .3 5.5 ± 0 .2
Plasma Insulin
Mean (SEMf mU/L
48.0 ± 7 .3 34.7 ± 6 .6 92.2 ±  13.8
Time 150-270
Plasma Glucose
Mean (SEM) mmol/L
5.2 ± 0 .0 4 12.07 ± 0 .0 2 5.2 ± 0 .0 6
Plasma Insulin
Mean (SEM) mU/L
29.9 ± 5 .2 28.9 ± 5 .9 69.9 ± 7 .9
Time 90-270
Plasma Glucose
Mean (SEM) mmol/L
5.3 ± 0 .1 12.1 ± 0 .3 5 .3 ± 0 .1
Plasma Insulin
Mean (SEM) mU/L
36.2 ±  6.2 30.9 ± 0 .6 77.5 ± 7 .4
Table 3 2b Clamp conditions achieved for morning studies when GH half- 
life (t90-150), GH suppression (t90-150) and endogenous rebound 
examinations (tl5Ù-270) were performed.
Clamps: NG=normoglycaemic HG=hyperglycaemic HI=hyperinsulinaemic.
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Figure 3 .2  a G H  profiles during G H  clearance study (t0-270mins)
Plasma G H  levels during three clamp conditions assigned in random order
G H  half-life (t90-150mins) After bolus dose of lOOmU G H  at t90mins, the G H  
decay showed no difference between the three clamp conditions.
G H  rebound after withdrawal of somatostatin infusion at t=  150mins shows wide 
individual variation (note wide SEM bars) during all clamps.
There was no relationship between endogenous rebound G H  levels and prevailing 
glucose or insulin levels.
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mono-exponential model was calculated after the distribution phase was 
complete.
Figure 3.2b illustrates the Ln-transformed plasma G H  concentrations 
following a bolus GH injection in two patients under three clamp conditions 
and shows the linear regression line of the phase corresponding in general to 
irreversible metabolic loss of GH from the circulation. Linear regression
analysis of the loge transformed G H  concentrations revealed a mean correlation
coefficient (r-value) of 0.96 (SD 0.03, n = 17). Calculated mono-exponential GH 
disappearance curves after distribution was complete and the mean regression 
line describing the disappearance of the exogenous GH under the three clamp 
conditions was obtained for all subjects. Data on the half-life, volume of 
distribution, intercept (mU/L) under the three clamp conditions are 
summarised in Table 3.2c. Mean half-life during clamp : N G  14.2 (range 10.6- 
21); H G  11.1 (range 9.5-13.1); H I 15.9 (range 10.9-27.7). There was a large 
variation within each patient under the different clamp conditions but the 
differences did not reach statistical significance. There was no trend in the data 
to suggest that either the distribution volume or the half-life was consistently 
altered by the clamp conditions. Therefore the data of the 3 clamp conditions 
were pooled. After suppression of endogenous GH with SRIH and following a 
bolus injection of lOOmU r-hGH
G H  half-life after bolus injection was
mean ±SEM 13.6 ± 1.9 m in (Range 11.9-19.4 min, n:17)
The half-life was significantly prolonged in the diabetic subjects (Student's t test 
p <0.05) compared to the control group of Hindmarsh, 1989 (mean 8.9 min. 
Range 6.3-11.6) (Appendix 2).
Half-life biexponential model
Table 3.2d shows the half-life of GH of the B-phase corresponding in general to 
irreversible loss of G H  from the circulation estimated by bi-exponential
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Figure3.1b Decay characteristics after G H  bolus
Ln transformation of plasma G H  before calculation of monoexponential decay. 
Upper panel: plasma G H  decay over time (minutes) during 3 clamp conditions. 
This subject illustrates variable decay curves.
Lower panel: Manual calculation of G H  decay curve. This subject shows no 
difference in G H  decay during 3 clamp conditions
Subject . B
-'1; c  _ D E F G
Mean
(SEM)
&
Clam p NG
Intercept mU/L 14.2 12.6 23 .2 2 5 .4 12.2 2 1 .2
18.2
(1 .2 )
Distribution volume L 7.0 7 .9 4.3 3 .95 8.2 4 .7
6.0
(0 .8 )
GH half-life min 17.3 21 10.6 12 12.1 12.5
14.3
(1 .6 )
Clam p HG
Intercept mU/L 12 15.4 18.5 2 1 .6 13.5 2 3 .6
17.5
(1 .0 )
Distribution volume L 8.3 6 .5 5.4 4 .6 7 .4 4 .2
6.1
(0 .7 )
GH half-life min 9.8 9.5 11.8 10.7 13.1 11.8
11.1
(0 .5 )
Clam p NG
Intercept mU/L 18.5 11.2 2 0 .8 18.2 15.1 - -
16.7
(0 .8 )
Distribution volume L 5.5 8.9 4 .8 5.5 6 .63 - -
6.3
(0 .7 )
GH half-life min 10.9 2 7 .7 16.1 13.1 11.8
15.9
(3 .1 )
Group mean (SEM )
Intercept mU/L 14.8(0.7) 13.2(0.6)
2 0 .8
(0.7)
2 1 .6
(1.1)
13.6
(0.4)
2 2 .5
(0.6)
17.5
(0 .6 )
Distribution volume L 6 .9(0.8) 7.8(0.7) 4 .8(0.3) 4 .7± 0 4 7 .4(0.4) 4 .5(0.3) 6.1(0 .4 )
GH half-life min 12.7(2.3)
19.4
(5.3)
12.8
(1.7)
11.9
(0.7)
12.3
(0.4)
12.2
(04)
13.7
(1 .3 )
Table3tZC Monoexponential calculation of bolus GH half-life and distribution volume.
Data are given for each subject (B-G): Results following r-hOH lOOmU bolus under 3 
clamp conditions. There was no statistical difference between the three clamp conditions 
and therefore mean o f all clamps are pooled.
Clamps: NG=normoglycaemic, normoinsulinaemic HG= hyperglycaemic, 
normoinsulinaemic HI= normoglycaemic, hyperinsulinaemic
Subject B c D E F G
Mean
(SEM)
Clamp NG
GH half-life min 18.1 19.8 11.2 11.7 12.8 13.1 14.5
Cl 17.3-18.9 19.0-20.6 10.8-11.6 10.9-12.6 12.0-13.6 12.4-13.8 1.47
Clamp HG
GH half-life min 9.6 10.2 11.5 11.5 13.4 11.4 11.3
Cl 9.1-10.1 9.4-11.0 10.9-12.1 10.9-12.1 11.8-15.0 9.2-13.2 0 54
Clamp HI
GH half-life min 11.3 26.6 17.3 14.3 12.3 — 16.3
Cl 10.7-11.9 24.4-28.6 16.5-18.1 13.8-14.9 11.8-12.8 2.74
Subject mean Cl
GH half-life min 13.0 18.9 13.3 12.5 12.8 12.3 14.012.3-13.6 17.6-20.1 12.7-13.9 11.9-13.2 11.8-13 8 10.8-13.2 1.6
Table 3 SdBiexponential equation suggests there was no significant difference from 
monoexponential fit for GH half-life.
Cl contains the 67% joint statistical confidence limits for the precision of fit. 
Clamps: NG =normoglycaemic HG= hyperglycaemic HI= hyperinsulinaemic
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analysis, in which the first component (a-phase) was 3.1 _+0.6 (SD) min. The 
pooled overall mean was 13.9 minutes (median 12.3, Range 9.6-16.7, n:17). The 
bi-exponential analysis did not show a significantly improved fit of the 
disappearance curves allowing for change in degrees in freedom and the 
estimated half-lives were not significantly different (Student's paired t-test: df 
16 ,t-1 .39 ,p  = 0.183).
D istribution Volume (DV)
The meanj^SEM volume of distribution in diabetic patients was 6.1 _+0.4 L 
(range 4.45-7.8, n=17 clamp studies) compared with the mean value in the 
control group of Hindmarsh 1989 (3.54 j±0.32L, n=14) and Shah 1999 (2.67 
jf 0.28L). (DV in diabetic subjects 0.089L/kg vs. control 0.054L/kg),
3.0.9 G H  clearance: 60min pulse infusion
Mean plasma GH concentration after suppression of endogenous GH with 
SRIH was 3 m U /L (SD 2.6); mean peak plasma GH level achieved during 60 
minutes GH pulse infusions was 33 m U /L (SD 6.4).
Half-life monoexponential model
Three 60-minute GH infusions were applied in each patient at 2-hourly 
intervals and the half-life data of the GH infusion study was estimated using the 
monoexponential model equation (Table 3.2e). No significant improvement 
on the squared-sum deviation was gained by the use of more complex 
exponential equations. Excluding 2 out-liers, results are
Pulse Mean GH  
half-life mins
SEM p value
First pulse 272 3.3 NS ( l v2)
Second 26.5 2.8 FJS(2v:0
Third 219 1.6 NS (3 V 1)
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Figure32c Decay Characteristics after 60minute G H  pulse infusion
Plasma GH concentrations m U /L (y axis) were calculated y = Ae'^* for each 
60 minute pulse decay over the following O-lOOmins (x axis). Comparing three 
pulses (1,2,3) for each subject, the mean exponent X was 0.028. There was no 
association of GH half-life with peak plasma GH concentration.
Ln transformation of GH concentrations are also shown (right panel).
DV was calculated by another method as distribution is unpredictable 
during prolonged GH infusion.
H J K L M P
Mean
(SEM)
Total dose injected
6mU/kg per pulse mU 264 390 339.6 471.6 312 484.8 377
PULSE 1
Exponent -0 .0211 -0 .0 1 8 7 -0 .0 0 0 4 -0 .0 3 5 2 -0 .0 2 8 1 -0 .0 3 2 1 -0 .0 2 3 7
Distribution volume L 7 .14 11 .90 * 5.51 6 .3 4 8.6 9 .0 8
GH half-life min 3 2 8 37.1 * 19.69 2 4 .6 6 2 1 .5 8 2 7 .2  (3 .3 )
PULSE 2
Exponent -0 .0 0 9 -0 .0 3 5 7 -0 .0191 -0 .0 2 9 3 -0 .0 2 6 7 -0 .0 2 5 4 -0 .0 2 7 2
Distribution volume L * 5 .7 6 9 .37 8 .49 6 .1 6 10.10 7.31
GH half-life min * 19.4 36 .28* 2 3 .6 5 2 5 .9 6 2 7 .2 8 2 6 .5  (2 .8 )
PULSE 3
Exponent -0 .0 2 4 3 -0 .0 3 3 4 -0 .0 2 3 8 -0 .0 3 2 6 -0 .0 3 1 4 -0 .0 3 2 2 -0 .0 2 9 6
Distribution volume L 5 .3 7 5 .7 7 7 .06 7.15 4 .9 7.45 6 .3 0
GH half-life min 2 8 .5 2 2 0 .7 5 2 9 .1 2 2 1 .2 6 2 2 .0 7 2 1 .5 2 . 2 3 .9 ( 1 .6 )
Group mean SEM
Exponent -0 .0 2 2 7 -0 .0 2 9 3 -0 .0 2 1 5 -0 .0 3 1 5 -0 .0 2 8 7 -0 .0 2 9 9 0 .0 2 7
Distribution volume L 6 .15 7 .0 4 8 .36 7 .92 5 .75 8 .58 7 .3 8
GH half-life min 3 0 .6 6 2 5 .7 5 29  86 2 1 .53 2 4 .2 3 2 3 .4 6 2 5 .9  (2 .6 )
Table 26 GH half-life and distribution volume: Results following r-hCH 6mU/kg 
given as 60minute pulse infusions
The half-life was calculated from [GH] =Aoe‘ ‘^ where Ao is the maximum GH measured 
after distribution and X is the exponent o f  decay. Half-life was calculated from Ln2/X. After 
excluding 2 outliers* there was no statistical difference between the three pulses and 
therefore results are pooled.
As first order kinetics o f distribution does not describe DV during a prolonged GH infusion, 
steady state kinetics was used to calculate DV (infusion  rateA . m ean p lasm a G H  per pulse). This 
shows increased DV for Type 1 diabetic subjects: mean 7.38L (range 5.75-8.58); the 
mechanism o f  clearance is discussed in Chapter 7.
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There was no statistical significant difference between the half-lives of the three 
pulses (paired student's t test: pulse 1 with pulse 2, p <0.7; pulse 2 with pulse 3, 
p = 0.2). The half lives were pooled and the
Mean (SEM) half-life after 60minutes G H  infusion was 25.9 ±2.6min
The calculated half-life after 60 minutes GH pulse was significantly prolonged 
compared to the overall mean value of 13.6 _+4.6min obtained from the bolus 
study (unpaired Student's t test, p < 0.001). Calculated mono-exponential GH 
disappearance curves are shown in Figure 3.2c.
Using Group mean t test at 60min infusion comparing data from control 
(Hindmarsh 1990, meanj+SD half-life was 14.5_+2.9, n= 10 studies) compared to 
60min infusion half-life in diabetic patients, the difference (D) between the 
means was 1.69, Z statistic (distribution along lines) was 6.63 (13 df if >4.21), 
and p <  0.001.
D istribution volume during pulse infusion
The DV during 60minute GH infusion is difficult to predict accurately as this is 
subject to changing receptor and binding protein alterations.
First order decay assumes that total GH distribution has occurred within the 
first 6minutes. However, DV may be altered by continuous infusion 
(prolonged GH exposure). DV was calculated by using steady state analysis 
for metabolic clearance rate (Schaefer 1996):
MGR (L/min) = X.(DV diabetic subjects)
and MGR = infusion rate
steady state plasma level
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For subjects HJKLMP (Tables 2.1c and appendix A 2.2i)
mean r-hGH dose injected = 377 m U  per hour (pulse)
= 6.28 m U  per minute 
therefore calculating mean exponent X for each pulse 
From section 6.0.2iv mean plasma levels during pulses
m ean G H  
m U / L ^
D V
T
...
Pulse 1 29.2 0.0237 9.08
Pulse 2 31.6 0.0272 7.31
Pulse 3 33.7 0.0296 6.30
M ean 31.5 0.027 7.38
The D V  during a prolonged G H  infusion increases to a m ean o f 7.4L. This 
was used for steady state calculation
3.1.0 G H  clearance: 12hour (steady state) infusion
The mean j^SEM G H  level achieved during steady state (equilibrium) infusion 
(22.00h-08.00h) was 9.8 jfO.4 (SD 1.5) m U /L  (section 6.0.2v)
H alf life: Prolonged G H  exposure
Steady state was determined by A N O V A , 120minutes after the start of G H  
infusion (rate of 1.5m U /kg/h). The serial plasma G H  concentrations reached 
equilibrium over the 10 hours (period 22.00h-0800h) confirming no significant 
drift by A N O V A . This inference was confirmed by linear regression defining a 
zero slope of G H  measurements over the last 6 hours of the clamp (Figure 
3.2d).
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Figure 2d Plasma G H  levels during steady state
Continuous 12 hour overnight GH infusion was commenced at 20.00h. This 
achieved steady state by 23.OOh. The data shown here is for the last 6 hours after 
steady state achieved, which is confirmed by the linear regression defining a zero 
slope.
Mean plasma GH averaged 9.8 m U /L . Steady state calculations (see text) 
estimated decay constant and half-life as iVz of 28.5 minutes. The context in 
which GH enters the circulation (duration of GH exposure) critically 
determines half-life.
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Calculation for steady state
At steady state the continuous iv GH infusion rate equals the product of the 
measured serum GH concentration (mean over duration of infusion) and the 
metabolic clearance rate (MCR) (Schaefer 1996) where
M CR (L/min) -  k.(DV diabetic subjects)
or M CR = infusion rate
steady state plasma level
Also at steady state the half-life (mins) iVi == Ln 2/k  
GH infusion rate = 1.5/60 m U/kg/m inute = 0.025
steady state plasma [GH] =9.8 (SD 1.5) m U /L
Median weight in diabetic subjects (JLMNPQ) is 70.5 kg 
Distribution volume during steady state (DV) = 7.4 L
k = 0.025 X 70.5 = 1.763/72.3
9.8 X 7.4 
k = 0.0243
tVi = Ln 2/k  = 0.693/ 0.0243 = 28.5 (SD 4.3) minutes
mean (SEM) G H  half-life after 12h exposure is 28.5 + 1.8min 
range 24.2- 32.8 minutes
These half-life data (steady state >  60min infusion > bolus) were used together 
to describe the relationship of G H  half-life with duration of GH exposure in 
Type 1 diabetic subjects (Figure 3.2e) and compared to control data (Table 
3.2f).
Duration of GH infusion Type 1 Diabetes Control
minutes GH half-life 
minutes
(SEM)
GH half-life 
minutes 
(SEM) 
Hindmarsh Shah 
1989/90 1999
0 13.6 (1.1) 8.9 (0 .3 ) 9.8
15 12.6 (0 .8 5 )
30
-
14.0 (1 .3 )
-
60 25.7 (2.1) 14.5 (0 .9 )
-
180 - 16.3 (0 .9 )
-
Steady state 28.5 (1.8) - 15.1
r-hGH dose administered lOOmU bolus 
6m U/kg/h pulse 
1.5mU/kg/h steady 
state
50m U& 500m U
3m U/kg/h
2-8 m U/kg bolus 
1 -9m U/kg/m in 
240 min
Table 32f GH half-life is critically dependent on duration of exposure
GH half-life data obtained in Type 1 diabetic subjects in Chapter 2 are 
compared with reported controls. All subjects had endogenous GH 
suppression before GH half-life studies. GH dose o f administration varies 
between studies but this does not influence GH half-life.
Differentiating the GH  Signal, BRP 2002  80
M CR was also calculated and compared to reported normal subjects, corrected 
for surface area: For subjects who received r-hGFI during 12hours infusion
MCR = 1.5 (mU/kg/h) X 7Q.5(kg;) X lOOOmL/min.m^
9,8 (mU/L) X 1.59 {m^  X 60 (min)
M CR for Type 1 diabetic subjects = 113.1 m l/m in .
3.1.1 G H  Exposure and Asymptotic Relationship
The G H  half-life in diabetic patients after different duration of exposure is 
prolonged at any time when compared to the non-diabetic group, for instance, 
half-life controls was 15.3 minutes after 60 minutes G H  exposure, diabetic 
subjects 25.7 minutes. The time-mode of G H  exposure critically extends GH 
half-life and this can be described by an asymptotic relationship [y 
=A.Ln(x)-+B] where y = half-life (mins) and x=time of exposure. A similar 
relationship regarding the duration of GH infusion and G H  half-life has been 
established in normal subjects. Figure 3.2e shows this relationship in subjects 
with Type 1 diabetes and in 2 reported studies of normal data (Hindmarsh 1990 
and Shah 1999).
Rebound endogenous G H
The characteristics of the rebound G H  pulse after somatostatin withdrawal 
(tl50-270mins) are detailed in Chapter 4. There was no statistical difference in 
rebound GH between each of the clamps studied, so data was combined to 
estimate the half-life of endogenous G H  following rebound release in 9 
clamps with a single peak.
Figure 3.2f shows the relationship between endogenous G H  half-life and 
peak GH plasma concentrations and exposure time. A significant relationship 
between GH half-life and duration of exposure was demonstrated (r =0.8, 
p < 0.005) whereas no significant relationship between G H  half-life and peak 
plasma GH levels was observed (r= 0.254, p = 0.5).
y=28931Ln()4 + ia97 
R?=0.9004
30-
Type 1 diabetes3
S
E
y =1.5696Li<x)+7.7424 
R? =0.8787
Control
0 100 200 300 400 500 600 700
GH duration of exposure (ninutes)
Figure 3 Relationship of GH exposure and half-life
Mean GH half-lives after bolus, pulse or during steady state infusions 
are plotted. Impact of time mode of GH entry into blood stream on GH 
half-life is described by the ascending hyperbolic curve y=A.ln(x)+B  
where y = half-life and x = time of exposure. This represents the non­
linear relationship between the GH half-life and the mean plasma 
GH concentration in both Type 1 diabetic and control subjects.
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FigureJ2f Increased duration of GH rebound secretion alters 
GH half-life, whereas peak GH amplitude has no influence
Upper panel: Endogenous GH peak levels (mU/L) following the 
GH rebound release after termination o f  SRIF infusion: No 
significant relationship was observed with half-life (r 0.254, 
p=0.5)
Lower panel: Duration o f  exposure o f  endogenous GH on GH 
half-life is strongly related (r 0.8, p<0.005). This illustrates again 
that the clearance o f  GH is dependent on the time mode o f  
exposure.
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3.1.2
SUMMARY and DISCUSSION
In this chapter, the disappearance parameters of G H  have been assessed in 
young adults with Type 1 diabetes and compared to a control group of normal 
volunteers who underwent a similar study protocol. The parameters of G H  
distribution and elimination have been assessed by a) suppressing endogenous 
GH secretion by giving a somatostatin infusion b) administering a physiological 
or moderate amount of GH and c) the elimination curve of the injected GH 
was measured with a sensitive assay. With this approach, a mean elimination 
half-life (tVz) for bolus GH of 13.6 4^1.1(SEM) minutes (Range 11.9-19.4 min, n: 
17) found in diabetic subjects was significantly prolonged compared to that 
observed in normal subjects (8.9 _+0.6, Range 6.3 -11.6 (Hindmarsh 1989) and
9.8 jfO.Smins (Shah 1999). However, an increase in GH half-life with increased 
duration of exposure is also seen in diabetic subjects (Figure 3.2e). The GH 
half-life calculated after iv bolus injection is significantly (50%) shorter than that 
assessed after 60minutes or steady state GH infusion. Thus, as the elimination 
properties of GH are dependent on the duration of exposure, the differences in 
plasma GH concentrations in diabetic subjects must reflect differences in 
pituitary GH secretion rates with normal controls. I have investigated this 
further in the next chapter.
The exact role played by the altered clearance in the G H  disturbances of 
diabetes is unclear. The reasons are that most studies intended to evaluate GH 
clearance and half-life were performed several years ago with techniques such as 
isotopic dilution (Owens 1973) and tools such as purified recombinant human 
G H  (r-hGH), sensitive assays and mathematical models, were not available. 
This ambiguous situation was compounded further as the GH clearance 
parameters in normal subjects was not previously settled: In fact, a wide range 
of GH half-lives had been reported, ranging from 7.5 to 51 minutes (Laron 
1965, Kowarski 1971); using deconvolution techniques, Hartman, (1991)
Author NormalSubjects Doser-hGH GHSuppression
method
GH t% 
Mean 
(SEM) mins
DV
L/kg  ^ MCR
Bolus GH -
G u p ta
1990
25 S R IF 11.4  to  12 .6
3-4
m l/h m 2
H in d m a r s h
1990
10 50 m U
& 5 0 0 m U
S R IF 8 .3  (0 .8 ) 0 .0 5 4
G a r c ia - M a y o r
1993
4 0 0 m U S R IF 1 3 .8 (1 .6 )
L a n g e n d o n k
1999
24 lOOmU S R IF 4 .8  to  6 .6
S h a h
1999
19 2 -8 m U /k g O c treo tid e 9 .8  (0 .5 ) 0 .0 6 3
Infusion GH
H in d m a r s h
1990
10
3 m U /k g  fo r 
IS m in s  
6 0 m in s  
18 0 m in s
S R IF 12 .6  (0 .9 ) 
14 .5  (0 .9 ) 
16 .9  (0 .9 )
L a n z i
1995
7 6 ho u rs S R IF 18 .4  (0 .6 )
0 .0 5 5 1.7
m l/k g . m in
S h a h
1999
19 l-9 m U /k g .m in
2 4 0 m in s
O c treo tid e 15.1 (0 .6 )
Endogenous GH
V e ld h u is
1991
E n d o g en o u s D eco n v o lu tio n 15 .5  (0 .8 )
N ie v e s -R iv e ra
1993
E n d o g en o u s D eco n v o lu tio n 19.8  (0 .5 )
S h a h
1999
19 E n d o g en o u s D e co n v o lu tio n 1 8 .8 (1 .3 )
Table 3*^9 Published reports of GH clearance in normal subjects.
These studies estimated exogenous GH (r-hGH) half-life after endogenous GH 
suppression with somatostatin (SRIF) or octreotide (long acting SRIF). GH half-life 
measurements in normal subjects are shorter than previous reports in 1970-1980s. 
Endogenous GH half-life was estimated from mathematical deconvolution analysis.
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estimated the mean endogenous G H  half-life to be 17.1 minutes. Faria, (1989) 
demonstrated an endogenous G H  half-life of 18 minutes after G H RH  
stimulated GH release when the exposure to GH was in the order of 90 
minutes. Despite textbooks reporting established GH half-life of more than 
20 minutes, with strict assessment of G H  decay characteristics, G H  half-life of 
less than 10 minutes has been confirmed in normal subjects (Table 3.2g).
The possibility that somatostatin could itself alter some parameters of 
GH distribution and clearance has previously been ruled out (Hindmarsh 1989, 
Faria 1989, Chapman 1991). Ongoing GH secretion during a somatostatin 
infusion is a possibility during GH kinetic studies, but Skamene 1984 has 
shown that the somatotropes are very sensitive to SRIH with adequate GH 
suppression even at a dose of 25 pg/h. Furthermore, I did not see not observe 
any other GH peaks in the individual decay curves. In addition when 
exogenous GH is injected, endogenous GH secretion should be even lower as 
G H  inhibits its own secretion.
Some authors consider the half-life for GH as a non-physiological 
parameter. In fact the concept of half-life for a hormone or a drug is firmly 
rooted in our vision of the pharmacokinetics of biological compounds, so it is 
often difficult to realise that such a parameter has no physiological meaning 
because it is just a mathematical measure of the slope. Moreover, it has a 
mathematical meaning only in mono-exponential models and not additive over 
compartments (DiStefano 1982). For such reasons, mathematicians are more 
prone to use the concept of mean residence time (MRT) for a given hormone 
based on the fact that residence time moments are more useful in modelling and 
kinetic analysis of physiological systems (Matis 1985). However, the calculation 
of half-life for G H  in diabetic subjects was required for deconvolution analysis 
to estimate GH secretory rates and therefore used in this thesis.
As a mono-exponential half-life may correspond largely to the 
distribution phase and therefore underestimate the irreversible metabolic 
clearance, bi-exponential fitting was also performed (Table 3.2d). This did not
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show any significant difference from the mono-exponential half-life values 
derived from the analysis of G H  values after the complete distribution phase 
following injections of exogenous GH.
O f greater interest was the duration of GH exposure that prolonged 
G H  half-life measurements in my diabetic subjects (section 3.1.1). This shows 
an asymptotic relationship (Figure 3.2e) and suggests that G H  half-life has a 
variable half-life that is prolonged and critically related with increasing GH 
exposure. G H  half-life is increased at all exposures compared to controls (Table 
3.2f): 60min GH infusion tVi 25.7 _+2.1 (SEM)mins in diabetic patients was 
prolonged compared to the bolus data (unpaired Student's t test, p <  0.001) and 
to the 60-minute exposure values obtained in controls (14.5 Jh2.7 (SD) minutes, 
group mean t-test p <  0.001).
My data for 12hour GH infusion half-life was utilised from subjects attending 
the G H  signal study. Even with this prolonged infusion, a m axim um  G H  
half-life of 28.5 j+1.8 (SEM) minutes was confirmed. The duration of 
detectable serum G H  concentrations usually lasts between 40-100 minutes in 
normal individuals (Hindmarsh 1990) and these authors consider that infusion 
studies to determine GH half-life do not represent the usual in vivo situation, 
particularly as elevated serum GH concentrations for 3 hours or more are non- 
physiological.
Previous studies on exogenous GH half-life disappearance rates from the 
circulation in diabetic patients compared to controls (normal subjects) are 
controversial: Owens (1973) reported a mean half-life of 21.8 minutes not
significantly different from the 19.0 minutes found in normal subjects after the 
’priming dose-constant infusion' technique of unlabelled hG H  on increasing 
subsequent GH infusion rates covering the normal range of 10-100 mU/1 (5-50 
pg/L); in contrast, Boucher found significantly increased half-lives of 
labelled hGH prepared by the Raben technique given as a bolus in diabetic 
patients compared to the half-life in non-diabetic subjects (Boucher 1969). 
Some of these discrepancies may be explained by the use of different assay
Differentiating the G H  Signal, BRP 2002 84
systems to measure G H  (Celniker 1989) and by the method of half-life 
determination of unlabelled or radio-labelled GH using different analytical 
models. In addition, the variable endogenous GH secretion during studies 
where endogenous G H  was not suppressed could account for the variability of 
earlier published reports. A more direct comparison of my data can be obtained 
from the work of Hindmarsh (1989,1990) where endogenous G H  was 
suppressed with somatostatin. O ther authors reporting G H  half-life data after 
somatostatin suppression also confirm the shorter half-life in normal control 
subjects (bolus tVz 4.8-6.6 mins Langendonk 1999).
More recently Shah (1999) has carried out a series of studies including 
bolus and 240minutes GH infusion in normal adult volunteers after 
endogenous GH suppression with Octreotide (long acting SRIH). They also 
found a varying GH half-life that was predominantly related to the time mode 
of hormone entry into the circulation rather than gender or oestradiol 
concentrations. Their findings confirm a changing GH half-life with duration 
of infusion (240mins equilibrium infusion mean (SEM) tVz 15 1 mins > after
bolus injection was 9.8 +_ 0.8mins). O ther authors using a more prolonged GH 
infusion have found a maximum half-life of under 20 minutes (6hours GH 
infusion tVi 18.4: Lanzi 1995). These normal data provide further evidence that 
compared to normal subjects, GH half-life in my diabetic subjects is prolonged 
at all exposures (and Figure 3,2e).
Some authors measured the metabolic clearance rate (MCR) of GH in 
patients with Type 1 diabetes compared to a normal control group: Lipman
(1972) found lower MCR in young, newly diagnosed patients with Type 1 
diabetes after a bolus injection of "T-labelled hGH as a priming dose followed 
by ^^T-labelled hG H  infusion at a constant rate for 90-120 minutes; Sperling
(1973) described significantly reduced MCR of ^^T-labelled hG H  after constant 
infusion maintained for 150 minutes in patients with Type 1 diabetes. In 
contrast, Navalesi (1975) reported a normal MCR in diabetic patients after a 
bolus administration of ^^^I-labelled hGH. Again the contribution of
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endogenous GH secretion while performing clearance studies of G H  has been 
pointed out (Owens 1973, MacGillivray 1970) and could explain the wide 
variation in half-lives reported.
To examine the model for the GH disappearance profiles, Garcia-Mayor, (1993) 
fitted real data of GH clearance from normal and uraemic patients to a multi­
exponential model following Marquart's iterative algorithm. The model was 
estimated by non-linear, weighted, least squares regression and checked using 
the criteria (1) visual inspection of graph plots and an analysis of variance 
between the original data and estimated model (2) the squared correlation 
coefficient (r^ ) was always higher than 0.98. With such a procedure, the best-fit 
model was bi-exponential, with a first phase of distribution and a second phase 
of elimination.
My data was analysed using both mono- and bi-exponential models after 
log-transformation of GH data and the results were not significantly different 
using either model (Table 3.2c,d). Although, ultrasensitive G H  assays have 
recently become available and was not used here, a more sensitive assay would 
not introduce imprecision in the calculation of GH half-life, but may be very 
useful for the mathematical validation of models employed. The mono­
component GH half-life value estimated after a single bolus is not proportionate 
to the peak serum GH concentration. After a single bolus iv injection into a 
somatostatin-suppressed (GH deficient) circulatory pool, an accelerated half-life 
value of initial GH disappearance would be due to rapid diffusion and advection 
of GH molecules (Keenan 1998).
In contrast, the 60minute pulse and continuous GH infusion represent 
more closely the context of GH entry into and removal from the bloodstream. 
The observations in this chapter suggest that GH half-life in diabetic subjects 
did not increase significantly after an exposure of 60minutes in diabetic patients. 
The available clinical literature remains unclear about the presumptive 
regulation of GH half-life and volume of distribution in Type 1 diabetes and 
there may be several explanations for this observation. Although the G H  peak
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levels were higher for GH infusion (60min) than they were in the bolus study, 
it is unlikely that the GH levels in the physiological range would show a 
significant effect on hG H  half-life since in other studies the half-life was not 
altered by the GH amplitude (Faria 1989, Hindmarsh 1990, Shah 1999). 
Furthermore, my data shows that there is no relationship between the plasma 
concentration and the GH half-life, which confirms data described by Owens
(1973) that the metabolic clearance rate of GH is independent of plasma 
concentration. Some authors previously showed that the kinetics of GH 
hormone disposal had a strong positive correlation with body mass index 
(relative obesity) in humans (Schaefer 1996) and various clinical disorders, 
particularly renal or hepatic disease (Haffner 1994, Cuneo 1995). My subjects 
had normal renal and hepatic function and were not obese (Table 2.1a,c and  
3.2a).
Decreased renal GH clearance has also been suggested as a possible 
mechanism for high plasma G H  concentrations in diabetes mellitus but this has 
been rejected by a study showing that the renal clearance of G H  in children 
with diabetes mellitus is increased compared to normal children (Hourd 1991). 
This is not likely to be the explanation for the prolongation of the G H  half-life. 
In addition, a study looking at uraemic patients, showed that G H  clearance is 
not impressively reduced considering the severity of kidney damage in such 
subjects (Garcia-Mayor 1993). This suggests that either the kidney plays a 
minor role in GH clearance compared with the liver and peripheral tissues or 
that that most of the kidney clearance for GH is preserved even when this 
organ is no longer able to accomplish the minimal detoxifying functions 
compatible with life.
Studies of the size variants GH in diabetes mellitus have revealed a 
higher proportion of monomeric GH than in normal men (MacFarlane 1986) 
and Baumann reported that different molecular weight G H  variants as well as 
GH monomers and dimers may have different clearance rates (Baumann 
1985,1986). However, in this work I used recombinant hG H  (r-hGH, 22kDa),
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SO variants cannot be the explanation here. In addition there was no difference 
in the half-life of GH measured by three different assays, one of them the 
Hybritech IRMA, which specifically detects monomeric 22-KDa G H  (Bowsher 
1990, Appendix 3e).
The biological action of GH is thought to be initiated by the binding of 
the hormone to specific receptors in the cell membrane and this appears to 
represent the major way in which hormone is cleared from the circulation. 
Studies using cultured rat adipocytes have demonstrated two pathways for 
intracellular processing of GH which are independently regulated - the non- 
degradative pathway: GH is taken up into the cell and then simply released 
intact back into the extra-cellular space. This process takes about 30 minutes to 
complete (Gorin 1984, Roup as & Herington 1987 a,b). Secondly, there is a 
degradative pathway - GH is taken up into the cell then broken down. This 
process is much slower and is highly susceptible to prior exposure of the cell to 
GH. Both processes occurring together would support the observations of the 
variable GH half-life seen with duration of exposure (asymptotic relationship) 
in both diabetic and control subjects (Figure 3.2e). A similar model has been 
proposed for the internalisation and processing of the insulin receptor (Marshall 
& Olefsky 1983).
As assays for GH-BP are now available, discussions about the causes of 
prolonged half-life in diabetes now focus on protein binding of GH (GH-BP) 
and the receptor changes (Amit 2000). The presence of a physiological, finite 
capacity, but high affinity, GH-binding protein in human plasma would 
logically account for the variable half-life estimates (Veldhuis 1993). Long 
exposure to GH may more extensively saturate the GH binding protein (GH- 
BP) which is known to increase the half-life since protein-bound G H  is cleared 
significantly slower than free hormone (Baumann 1994). It has been shown 
that in experimental animals each burst of GH pulse is followed by a wave of 
receptor turnover and an increase in serum binding protein (GH-BP) which 
occurs 60 minutes after the G H  peak (Amit 2000).
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Hochberg (1994) described the 24 hour profile of plasma GH-BP and its 
correlation to GH pulsatility in normally growing children in early puberty 
and showed that plasma GH-BP levels fluctuated rapidly (GH-BP pulses were 
seen within 30 min) in relation to the pulsatility of plasma G H  levels. It has 
also been shown that the plasma concentration of circulating high affinity 
binding protein (reflecting the relative abundance of the extracellular domain 
of the hepatic GH receptor) is low in insulin-dependent diabetes, with the most 
striking decrease being during puberty (Mercado 1992). This would suggest that 
reduced receptor binding and internalisation diminish GH receptors in Type 1 
diabetes resulting in delayed clearance.
My results also show that short-term alterations in glycaemia and 
insulinaemia do not alter GH clearance parameters of half-life and distribution 
volume (section 3.0.8, Table 3.2c). There are theoretical reasons why the GH 
disappearance rate from the circulation may be altered by the prevailing 
glycaemic and insulinaemic state. Hyperglycaemia promotes glycation of 
circulating proteins such as haemoglobin and plasma proteins and a study has 
reported that the GH half-life of disappearance from the circulation was delayed 
after periods of hyperglycaemia (Mullis 1988). Although the decline of 
unglycated and glycated albumin is identical, fructosamine (ketomine linked 
glucose to all plasma proteins) measured by the fructosamine assay shows a 
delayed disappearance after periods of hyperglycaemia (Mullis 1988) therefore 
non-enzymatic glycation of the G H  and/or other forms of the half-life 
important proteins may result in an increase of GH half-life.
Insulin deficiency could result in a reduction in GH receptors and hence 
clearance by the receptor and it has been shown that in the diabetic rat, binding 
of GH in the liver is reduced and can be restored by insulin (Baxter 1980b). 
Conversely, as hyperinsulinaemia stimulates the GH-receptor expression 
(Baxter 1980b), one could expect a possible decrease in the calculated GH half- 
life compared to normoinsulinaemic conditions. However, short-term 
metabolic changes (hyperglycaemia and/or hyperinsulinaemia) did not result in
Differentiating the GH  Signal, BRP 2002  89
significantly different GH half-life measurements. Thus, in diabetic patients, the 
previous concerns of fluctuating insulin levels resulting in a alteration of GH 
receptors and hence clearance by the receptor; size variants of G H  and clearance 
rates of different molecular weight GH variants and G H  monomers and dimers 
have not been shown to affect the G H  clearance in my studies.
This chapter shows that the mean volume of distribution was also 
increased in the diabetic patients (6.1 L, range 4.7-7.8) compared to the values 
reported in the controls (3.5 L, range 2.02-5.6, group mean test p < 0.0005) 
(Hindmarsh 1989). This represents a volume of distribution of GH in diabetic 
patients of 8.9% body weight (5.3% in normal subjects). O ther hormone 
kinetic studies in Type 1 diabetes report increased volumes of distribution for 
adrenaline (Dejgaard 1989) but unaltered volumes of distributions for GH 
(Navalesi 1975).
The long-standing controversy whether clearance is correlated with 
body surface area (BSA) or with body weight has so far remained unresolved. 
The choice between use of BSA or body weight for calculating distribution 
volume of GH is dependent on assumptions about the nature of GH 
distribution. Plasma volume appears to correlate well with body weight, while 
the extracellular volume (ECV) correlates with BSA (Boer 1984). Refetoff 
(1970) claimed that purified pituitary GH is distributed partially in the ECV. 
As this is contradicted by other studies, using recombinant human GH, in 
which the distribution space was found comparable to the intravascular space 
(Albertsson-Wikland 1989), I have used the parameter of body weight. The 
larger distribution volume in the earlier study (Refetoff 1970) may also have 
been influenced by the detection of GH peptide fragments in RIA, which are 
not measured in 2-site IRMAs. Although previously body fat and sex hormones 
were thought to influence G H  distribution space, recent studies confirm that 
neither affects clearance (Langendonk 1999, Shah 1999).
The mechanism for altered G H  distribution volume found in diabetic 
patients are several. The increased permeability of the basement membranes in
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diabetic subjects is well described and may precede structural changes (Parving 
1975). In addition, elevated levels of endothelin in patients with diabetes as a 
result of endothelium cell damage has been reported (Takahashi 1990). The 
endothelium cell damage is likely to be an additive factor in increasing the 
permeability of the vessels.
These data on half-life and volume of distribution of GH do not provide 
any information concerning distribution of GH in different compartments after 
bolus or prolonged exposure, nor do they tell us anything about renal or 
metabolic clearance or changes in the compartmentalisation of GH during the 
'emptying' phase. The use of massive bolus of GH or a constant infusion 
could induce a disturbance in the normal distribution and 
degradation/clearance of GH. In fact, supraphysiological doses of G H  might 
alter the distribution of GH between compartments and/or saturate the 
internalisation/degradative process of tissue GH receptors (Roupas & 
Herington 1987a), then redirecting GH toward the extracellular space. 
Although the observation of changes in the disappearance rate with prolonged 
exposure requires further investigations, the data presented are very important 
for the purpose of deconvolution analysis of plasma GH profiles to determine 
GH  secretory rates. I have shown that the prolonged GH half-life measured in 
diabetic subjects is a direct function of the duration of G H  exposure (Figure 
3.2e). This suggests that GH pulse secretion in diabetic subjects must also be 
prolonged: either there is a persistent pulse amplitude, increased pulsatility or 
there is a constantly raised basal GH secretion.
To elucidate whether indeed abnormal GH pulse secretion exists in diabetic 
compared to normal adolescents, I have analysed a series of plasma GH profiles 
in the next chapter.
Summary
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In Type 1 diabetes, G H  half-life is increased w hen  com pared to  control 
subjects and varies w ith  duration o f G H  exposure; short-term  alterations 
in  glycaem ia and insulinaem ia do n ot alter G H  clearance param eters o f  
half-life or d istribution vo lum e
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CHAPTER 4
ANALYSIS OF PLASMA GH LEVELS 
DISTRIBUTION AND DECONVOLUTION
Growth hormone disturbances in diabetess, BRP 2002 93
4.0,0
IN T R O D U C TIO N
Several hormones are released into the blood in a pulsatile fashion, that is, in 
short bursts that cause a rapid increase in the circulating concentration. The 
concentration then declines due to excretion, chemical breakdown, and 
redistribution into other compartments. Based on a series of observations of 
the level of the hormone in blood, investigators desire to quantify 
characteristics of these pulses, which are timing, amplitude, and rate of decay. 
Detecting and describing peaks in a series of hormonal data is complex. As GH 
fluctuates episodically (Figure 4.3a), it is difficult to ensure an adequate 
measure of the mean level, enumeration of pulses and peak detection. The 
literature appears to contain a bewildering large array of methods for pulse 
analysis. However, many of these turn out to be variants of the original Santen 
and Bardin's technique (1973). Santen and Bardin showed that a series of 
samples was a better estimate of the mean. The number of samples required 
depends on the accuracy needed, physiological variability of the levels and the 
errors of the measurement process. Most methods of the analysis of growth 
hormone profiles require the ability to identify and characterise the pulses of 
the hormone in a mathematically explicit and statistically defined manner 
(Veldhuis 1988a). Techniques such as pulse counting or peak picking or 
modelling, using a range of computer programmes are many, each having their 
limitations.
In my analysis of GH profiles obtained from children with Type 1 diabetes and 
controls (section 2.0.7-2.1.1) I have used a distribution method, deconvolution 
analysis and time series analysis.
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Figure 3a Spontaneous plasma GH levels.
Examples of GH profiles in control (normal healthy) (upper panel) and 
diabetic adolescent (lower profile).
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4.0.1 M ethod of distribution analysis
A novel and unbiased application to estimate baseline, mean and peak GH 
levels based on probits (probability units) has been described by Matthews, 
1991. This method does not depend on other factors such as assay sensitivity, 
or the number of observations and allows comparison between subject groups 
with particular characteristics.
Matthews (1991) has described using a method of cumulative distribution and 
probability to provide an objective assessment of G H  profiles. The log- 
transformed G H  concentrations (regardless of their temporal attributes) are 
sorted and allocated to class intervals. The number of observations in each 
interval are then determined and expressed as a percentage of the total 
number of samples drawn in the study period. The cumulative distributions 
are transformed into discrete probabilities (linear probits), which are then 
linear and amenable to regression analysis.
The methodology has several advantages
1. the method is unbiased
2. all the data collected in a GH concentration profile can be used
3. a straightforward visual description of the data can be generated
4. the data can be pooled in a similar manner to that devised for 
autocorrelation and Fourier transformation, hence descriptions of 
populations can be made
5. the technique uses standard statistical methods for the construction of 
the frequency distribution and for assessing the significance of 
differences between frequency distributions obtained from different 
groups of patients and requires no special computer programming
Probability analysis gives an estimate of the trough, which can be defined in 
terms of percentage occupancy - the "Observed Concentration" (OC5) which is 
the threshold at or below which the hormone concentrations are estimated to 
be 5% of the time; the mean which can be defined as percentage occupancy at
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50% of the time (OC50); and peak can be defined as being a percentage 
occupancy above 75% (OC75 = ISD) or 95% of the time (OC95=2SD).
The standard deviation of the observations can be calculated from the slope of 
the probit (since 5% to 95% encompasses _+ 2 standard deviations). Analysis of 
data from groups of individuals with a particular condition can be made and the 
difference between the lines can be assessed using 90% confidence intervals of 
the regression lines (Schefler 1962), where it can be demonstrated that if the 
intervals from comparative lines do not overlap they are different with a null 
hypothesis probability of p < 0.025.
4.0.2 D econvolution  analysis
At any given time, plasma GH concentration is a result of GH secretion and 
elimination. Efforts to separate the effects of secretion and metabolic clearance 
have led to the development of deconvolution techniques (Veldhuis 1987). In 
addition the use of deconvolution analysis has made it possible to estimate the 
frequency, amplitude, mass and duration of GH-secretory episodes which give 
rise to GH concentrations in circulating blood in a variety of physiological and 
pathological states. The time course of the effect of physiological variables on 
GH secretion may be determined more precisely by calculating GH secretion 
rates.
Two general categories of deconvolution methods have been devised - either 
methods using a previously calculated hormone half-life or methods to calculate 
both hormone half-life and secretion rates simultaneously assuming a specific 
shape of the underlying secretory event. Thompson, 1972 proposed a method 
to estimate secretion on the basis of integrated serum G H  concentration 
(ICGH) and the metabolic clearance rate. Finkelstein (1972) calculated the 
secretion per peak on the basis of serum GH levels, the G H  half-life (tl6) and 
distribution volume, according to the method described by Heilman (1970) for 
cortisol secretion. Thereafter, various deconvolution techniques were 
developed in which secretion and elimination were separated as two
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components of a GH profile over time (Veldhuis & Johnson 1988a, Oerter 
1986, Veldhuis 1990 and 1992).
Studies comparing previous methods of deconvolution found significantly 
different results in the calculation of GH secretory rates and the differences 
were large as a factor of 3.5 (Kuilboer 1992). This suggests that significantly 
different assumptions were used by the four methods previously described 
(THOM, HEL, DECONV, PULSE detailed in Appendix lb).
These differences were mainly due to the calculation of G H  clearance 
which were 2.2 times higher in TH O M  (from MGR used in THOM , a tVz of
11.8min assuming distribution volume of 7%; PULSE uses biexponential tVi 
expressed as monoexponential of 18.9min (Faria 1989)); area under curve 
(THOM) or area under baseline (HEL) which differed by 1.6 times; the use of 
all data points by THOM  whereas HEL uses part of peaks detectable by 
PULSAR. The assumption inherent to Heilman's equation is that secretion 
takes place only during a rising serum concentration level. In contrast it has 
been shown by Veldhuis (1987) that secretion can also take place during the 
downslope of a serum G H  peak. Veldhuis has used a multiple parameter 
deconvolution method to estimate both GH secretion and clearance rates 
simultaneously and hypothesised an inferential model of GH secretion 
(interaction of multiple pulses of hypothalamic G H RH  stimulating the 
pituitary gland during a period of diminished somatostatin secretion) (Hartman 
1991). Van Cauter (1992) also observed a multiphasic pattern of G H  secretion 
using a different deconvolution algorithm. All differences contribute to the 
imperfect correlation between these methods. Besides the differences among 
studies, there are also up to 4-fold differences in GH MGR and/or tVz using a 
single method of estimation applied to different subjects (Thompson 1972). 
Difference in MGR turn out to be important for causing differences in 
estimated secretion. There is little agreement among the various studies.
In most of these studies endogenous GH secretion was not suppressed, 
which would account for some of the variations observed. In addition, the use
DECONVOLUTION ANALYSIS
LN .  . (GH)
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Figure 4a (part 1) Principles o f D econvolu tion
A segment from a 24 hour G H  profile showing tw o G H  pulses. The serum G H  
concentration measured at point A  would subsequently decline to AA' if no further 
G H  was released from the pituitary gland and this point could be estimated from the 
known half-life of G H. The plot is linear because of the Ln transformation. At 
point B the serum G H  concentration is higher than A which must mean that further 
G H  has entered the circulation between points A  and B. The amount secreted is 
proportional to the distance between the "stripping curves" (the dotted lines). This 
process is then repeated with the next serum G H  concentration and repeated 
throughout the data array. At point C the dashed lines come closer together and 
eventually overlap at D . This indicates that secretion of G H  ceased at point C and 
that the subsequent concentration at D  represents the clearance of the horm one from  
the circulation since the value can be entirely explained by the half-life of G H.
{taken from reference)
KEY Solid line: actual G H  profile. D ashed lines: “stripping curves”
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of supraphysiological G H  doses over a long period of time in the infusion 
studies has been shown to alter the clearance rate leading to a longer half-life 
(Hindmarsh 1989, 1990). There is no consensus between investigators 
concerning differences between sex and age groups. This suggests considerable 
biological variation among healthy subjects. During the last decade investigators 
have examined GH decay after endogenous GH suppression and found a 
shorter GH half-life in normal subjects than previously reported (Table 3.2g).
4.0.3 Deconvolution model by H indm arsh
The deconvolution formula was derived from the methodology of Turner, 
1971. The delivery rate is an iterative deconvolution whereby the estimate of 
the declination of GH (based on fixed or variable half-life) is subtracted from 
the residual measured concentration. The total secretion observed is the 
integral of secretion rate and time. The technique requires prior knowledge of 
the mode of secretion of a hormone (Veldhuis 1988b) or alternatively a measure 
of the half-life and distribution space of that hormone within the circulation 
(Hindmarsh 1990). The principle of the deconvolution model is illustrated in 
Figure 4.4a, which represents part of a 24-hour profile. Two GH pulses are 
depicted. Serum GH concentrations are Ln transformed. The performance of 
this deconvolution model has been verified and reported by Hindmarsh, 1990. 
This deconvolution model attempts to define as accurately as possible the 
circumstances that affect GH clearance characteristics and it has been used in 
this Thesis.
Chapter 3 has confirmed that the G H  half-life in adolescents with Type 1 
diabetes is prolonged compared with normal subjects studied under similar 
conditions. In order to determine whether alterations in G H  secretion also 
exists, the calculation of G H  half-life and distribution volume were applied in 
the Deconvolution analysis of overnight GH profiles obtained from 
adolescents with Type 1 diabetes and puberty-matched control. The changes 
in G H  secretion during euglycaemia and anticholinergic suppression were
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also examined in diabetic subjects. The subjects and study design are described 
fully in Chapter 2 (GH secretion study, section 2.0.7).
4.0.4 Tim e series analysis
Spectral analysis
Spectral analysis is a standard well understood statistical technique for which 
adequate computer software exists. Murdoch (1985) used "spectral analysis" to 
break down a hormone series into a set of frequency (or equivalently periodic) 
components each with their characteristic amplitude. These components 
comprise the periodogram. Dominant and harmonic frequencies may be 
derived, and tests of statistical significance are available. Spectral analysis does 
not take into account the known magnitude of the noise component of the 
assay. It is hard to derive satisfactory summary statistics such as mean 
amplitude or interpeak interval since the periodogram is a set of values 
comparable in number to the original series.
Three minute moving average
Individual data sets are averaged using a 3-min moving average; this reduces the 
size of any fluctuations shorter than 3 min (noise) at the expense of reducing the 
amplitude of any longer oscillations present.
Fourier Analysis
Time-series data consists of signals together with experimental and assay errors 
or "noise." The ability to detect the signal depends on the signal/noise (S/N) 
ratio (Chatfield 1975). Techniques can be used to maximise the S /N  ratio and 
describe the signal.
Fourier Transform (FT) analysis is an unbiased method of examining all the 
oscillatory signal within an array. Any complex waveform can be analysed as 
the sum of a series of sinusoids F(h) calculated from the data:
n
A(h)Z = cos 2 h(xi/xn) f(xi)
i=o
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B(h) = sin 2 h (xi/xn) f(xi) 
and [F (h )]  =A(h) + B(h)
The components have amplitude and frequency attributes. Fourier Transform 
analysis allows the power of each oscillatory function to be calculated and 
displayed as a histogram of power versus frequency. This is termed a power 
spectrum. Fourier transforms can thus produce composite spectra of data 
showing all the dominant and sub-dominant harmonics together with an 
estimate of power and amplitude. The data can be pooled using parametric 
statistics to yield spectra that are composite for the group of data. Fourier 
analysis has been used in this chapter to analyse GH secretory data for 
assessment of pulse periodicity and amplitude.
4.0.5 Statistics
The results are expressed as mean +_ SEM, unless otherwise stated. Statistical 
analysis was carried out using Student's paired and unpaired t-tests. Mann- 
Witney U  test was used to compare between normal and diabetic subjects by 
sex and at each puberty group (Appendix 4c).
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4.0.6
RESULTS
Eighty-five overnight plasma G H  profiles were analysed: 34 from control 
subjects; 15 Normal Regime (NR), 29 euglycaemic clamp (EC) and 7 
pirenzepine (PIR) profile nights from diabetic subjects.
4.0.7 Plasma G H  characteristics
Mean GH concentration, trough and peak estimates from Distribution analysis 
were calculated for NR, EC and PIR. Plasma GH concentrations were log 10- 
transformed for analysis. The log-transformed G H  concentrations (regardless 
of their temporal attributes) were sorted into ascending order and allocated to 
class intervals. The same class intervals were used for the plasma GH 
concentrations for both diabetic and control groups (Table 4.3a). The class 
interval chosen reflect the range of measured hormone but quantiles are not 
critical. As the sensitivity of the GH assay used was 0.3m U/L and this 
accuracy is limited by the assay CV of 8-10%, the lowest class is commenced 
at 0.5mU/L and the range reflected the peak GH (60-100mU/L). As pooled 
data from several individuals was used, the same set of class intervals was used 
throughout. The number of observations in each interval was then determined 
and expressed as a percentage of the total number of samples drawn in the study 
period: 49 samples at 15minute intervals were taken over a 12 hour overnight 
period. This percentage is displayed as a frequency distribution or domain 
profile and then as a cumulative distribution plotted as sigmoid ogives.
The cumulative distributions can also be transformed into discrete probabilities 
(linear pro bits), which are then linear and amenable to regression analysis. The 
significance of any difference between the frequency distribution of various 
groups can be assessed by ordinary parametric statistical methods.
Class Interval
: X:
Plasma GH Concentration -Logio [GH]
1 0.5 -0.3
2 1.0 0
3 2.0 0.3
4 5.0 0.7
5 7.9 0.9
6 10.0 1.0
7 15.8 1.2
8 20.0 1.3
9 30.0 1.5
10 40.0 1.6
11 50.0 1.7
12 60.0 1.8
13 100.0 2.0
Table 3a Class intervals used for distribution analysis of plasma GH reflects 
the range of levels encountered in overnight adolescent GH profiles.
These intervals are not critical but the same intervals were used for diabetic and 
control subjects.
Plasma GH concentrations were log-transformed for analysis as GH 
concentrations are geometrically distributed.
P lasm a G H
mU/L
T yp e 1 D iab etes  
Distribution frequency %
C on tro l 
Distribution frequency %
NR EC PIR
0.5 0 0 0 14
1.0 0 8.2 12.2 16
2.0 14.3 16.3 22.4 16
5.0 14.3 14.3 28.6 10
8.0 8.2 2 16.3 8.2
10.0 4.1 14.3 2 8.2
15.0 14.3 10.2 8.2 8.2
20.0 12.2 10.2 4 8.2
30.0 12.2 8.2 4 3
40.0 8.2 6.1 2 3
50.0 8.2 6.1 0 2
60.0 4.1 4.0 0 3
100.0 0 0 0 0
Table 3b Distribution Frequency Profile of overnight (20-08.00h) plasma 
GH
Ali the observations o f concentration (regardless o f their temporal attribute) were 
sorted into ascending order. The number o f  observations in each interval were 
then determined (“dwell times” or observed concentrations) and expressed as a 
percentage o f  the total number o f  samples drawn in the study period (each 
subject = 49 samples overnight).
The data from all puberty groups was pooled; Number o f  subjects: Controls=39, 
Diabetic NR=15, EC=29, PIR=7, The same set o f  class intervals was used 
throughout and the data displayed as a frequency distribution.
Key: NR=normal insulin regime EC= overnight euglycaemic clamp 
PIR= overnight EC after pirenzepine was administered
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Figure 3b “Domain profiles” of Distribution analysis
Distribution analysis allows comparison of data between groups and is illustrated 
as percentage occupancy time (observed concentration”O C ”) in each dwell 
domain.
The occupancy in normal subjects and pirenzepine treated group is greatest at 
low  G H  concentrations. In contrast, diabetic profiles show occupancy shifted 
toward higher G H  concentrations. .
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D istribution profile
The dwell domains after distribution analysis for each group of subjects are 
shown in Table 4.3b and displayed as “domain profile” in Figure 4.3b.
These data illustrate that G H  concentrations remain low for control subjects 
for a significant part of the overnight profile, compared to diabetic subjects.
Cum ulative frequency profile
The distribution frequency is converted to cumulative frequency (Table 4.3c) 
and this can be displayed as a cumulative "frequency profile” which is 
sigmoid. The data from diabetic subject (NR) and control subject (Figure 
4.3c) and diabetic EC and pirenzepine are shown plotted as cumulative 
frequency distributions (Figure 4.3d).
These data form ogives that demonstrate graphically the differences in 
concentration frequency overnight. Estimation of the O C  parameters can be 
made from such plots.
P robit analysis
The cumulative frequency data can be readily analysed by probits or a 
probability distribution. These data can be plotted on to ‘probability paper’ 
(Chartwell paper Ref. 5571, HW  Peel & Co Ltd, Greenford,UK) or by use 
the pro bit transform tables (Fisher and Yates, 1967) and calculations. The data 
can be used between 1-99% cumulative probability. Table 4.3c illustrates the 
process. The O C parameters can be estimated easily from the cumulative 
distribution. The probit transformation is shown on Tables 4.3c. The 
original probit plots are shown in Figure 4.3d. To estimate trough 
occupancy (OC5), as the minimum dwell time is linear, the [GH] at 5% was 
estimated by linear regression. The performance model is illustrated by 
plasma GH concentrations from the overnight G H  profiles from diabetic 
(NR) and control subjects in Figure 4.3e.
P lasm a G H T yp e 1 D iab etes '
C u m u lative F requency  %
NR EC PI ^
C ontrb!
C um ulative F req u en cy  %
0.5 0 0 0 14
1.0 0 8.2 12.2 30
2.0 14.3 24.5 34.6 46
5.0 28.6 38.8 63.2 56
8.0 3&8 40.8 79.5 64.2
10.0 40.9 55.1 81.5 72.4
15.0 55.2 65.3 89.7 80.2
20.0 67.4 75.5 93.7 88.4
30.0 79.6 83.7 97.7 91.4
40.0 8T8 89.8 99.7 94.4
50.0 96 95.9 96.4
60.0 99.9 99.9 99.4
Table 3c Cum ulative distributions com pare “dwell tim es” between pooled  
data.
Continuous summation (cumulative percentage) is amenable to transformation 
into linear probits and this is amenable to regression analysis.
Transformation calculations are given in the tables below.
Key for transform ation tables
C F  =  C u m u la t iv e  f r e q u e n c y
E P  =  E m p ir ic a l  p r o b i ts  (d e riv e d  fro m  sta tis tica l tab le s , F ish e r &  Y a tes  1953)
P P  =  P ro v is io n a l  P r o b i t  T h is  is o b ta in e d  from  the  re g re ss io n  line  on p ro b a b ili ty  p ap er.
T h is  c a lcu la te s  m ean  v a lu e  an d  A c o -o rd in a te s  
A (w h en  x= 0 , y=  th e  m in im u m  PP )
M ax im u m  P P  is a t m ax im u m  G H  c o n c e n tra tio n
T h e  p o in ts  o f  in te rse c tio n  a t x p ro v id e  the  p ro v is io n a l p ro b its
V a lu es  fo r the  G H  c o n c e n tra tio n s  a re  th en  read  o f f
N =  P ro v is io n a l  P r o b i t  x c u m u la t iv e  f r e q u e n c y  (C F )  r a t io
W P  =  w o r k in g  p r o b i t  is (N  +  m in im u m  P P )  f o r  e a c h  c la ss
W C  =  w e ig h tin g  c o e ff ic ie n ts  is P P  x n u m b e r  o f  s a m p le s
continued...
C F E P P P N W P C F E P P P N W P
m in im u m  PP 3.1 m in im u m  PP 3 .7
0.5 0 3.4 0 3.1 0.5 14 3.9 4.0 0 .56 4 .26
1.0 0 3.5 0 3.1 1.0 30 4.5 4.2 1.26 4 .96
2 .0 14.3 3 .9 3.8 0.53 3.63 2 .0 46 4.9 4.4 2 .02 5.72
5 .0 2 & 6 4.4 4.3 1.22 4 .32 5 .0 56 5.2 5.0 2 .80 6.5
8.0 3&8 4 .6 4.7 1.75 4.83 8.0 64.2 5.4 5.4 3 .47 7 .17
10.0 40.9 4.8 4.8 1.96 5.06 10.0 72.4 5.6 5.4 3.91 7.6
15.0 55.2 5.1 5.2 2 .87 5.97 15.0 80.2 5.8 5.8 4.65 8.35
2 0 .0 67.4 5.5 5.3 3.57 6.67 2 0 .0 88.4 6.2 6.2 5.48 9.18
3 0 .0 79^ 5.8 5.8 4.62 7.72 130.0 91.4 6.4 6.4 5.85 9.55
4 0 .0 8T8 6.2 6.1 5.36 8.46 4 0 .0 94.4 6.6 6.8 6 .42 10.12
50 .0 96 6.7 6.4 6.14 9.24 50 .0 96.4 6.8 7.2 6.94 10.64
6 0 .0 9&9 8.09 6.6 6.59 9.69 6 0 .0 99.4 7.5 7.4 7.35 11.05
m ax im u m  PP 6.65 m ax im u m  PP  7.5  I
Plàfma GH 0
C F [ ep P P N W P C F E P P P N W P
M in im u m  PP 3.3 M in im u m  PP 3.9
0.5 0 3.6 0 3.3 0.5 0 4.2 0 3 .90
1.0 8.2 3.6 3.8 0.31 3.61 1.0 12.2 3.8 4.4 0.53 4 .40
2 .0 24.5 4.3 4.2 1.01 4.31 2 .0 34.6 4.6 4.8 1.63 5.53
5.0 3&8 4.7 4.6 1.78 5.08 5.0 63.2 5.3 5.1 3.21 7.11
8.0 40.8 4.8 5.0 2.04 5.34 8.0 79.5 5.8 5.8 4.58 8.48
10.0 55.1 5.1 5.1 2.81 6.11 10.0 81.5 5.9 5.9 4.78 8.68
15.0 6 5 3 5.4 5.6 3 .66 6 .96 15.0 89.7 6.3 6.4 5.69 9 .59
2 0 .0 75.5 5.7 5.9 4.43 7.73 2 0 .0 93.7 6.5 6.8 6.37 10.27
30 .0 83.7 6.0 6.3 5.23 8.53 30 .0 97.7 7.0 7.2 7.03 10.93
4 0 .0 893 6.3 6.6 5.93 9.23 4 0 .0 99.7 7 .7 7.6 7.52 11.42
5 0 .0 934 6.7 6.9 6.62 9.92 50 .0 8.0
6 0 .0 994 8.1 7.1 7.09 10.39 60 .0 8.5
m ax im u m  PP m ax im u m  PP 8.6
.' aacf ' ..%;v.
V» ” . »• • c  t DabehcNR
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Figure 3c Perform ance: Cum ulative frequency and Probability
Upper panel: The cumulative distribution (sigmoid curve) demonstrate graphically the 
differences in overnight GH concentration frequency between diabetic and control 
subjects. Approximate estimates o f  OC parameters can be made from such plots.
Lower panel: Transformation o f  percentages into probits (probability distribution) 
enables a robust estimates o f  OC parameters by regression analysis o f  all the data.
F igu re 3d P robab ility  p lo ts (or ig in a l data)
L ow er panel: U sing cum ulative distribution analysis Empirical probits (EP) 
are derived from  Fisher and Yates Tables. These values are p lotted  on  C hartw ell 
paper and Provisional Probits (PP) are read off at each log [G H ] value. T he 
m inim um  PP differs in each group.
U p p er Panel: W orking probits are calculated and plotted. U sing  Schaffler’s 
90% confidence intervals o f regression lines, as the com parative probit lines do  
not overlap, they are different w ith  a null hypothesis o f p <  0.0025. The 
standard deviation o f the observations can be calculated from  the slope o f the 
probit (as 5-95% encom passes jf 2SD)
For diabetic subjects (NR) OC50 (SD): 8.91 (2.69) m U /L
O C 75(SD ): 28.61 (3.44) m U /L
These data were used for convolution.
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Figure 3e Comparison of all groups
Pooled data (all puberty groups) can be presented as a frequency distribution  
(upper panel), a cumulative frequency distribution (middle panel) and as a 
probability plot (lower panel). Pirenzepine (PIR) brings G H  levels towards 
control values. Euglycaemia (EC) is similar to normal regime (NR).
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Effect o f puberty
The effect of stature and gender on trough G H  has not previously shown to 
differ (Matthews 1991) but age influences this with a difference between 
young <9years having higher levels compared to older children >9years. 
The control data (plasma G H  values for normal subjects in different stages o f  
puberty) was pooled for analysis as all adolescent subjects were above 9 years. 
Puberty stage and gender do influence mean and peak G H  levels but I have 
not quantified this separately by probit analysis.
D iabetes vs. C ontrol
All G H  profiles irrespective of puberty group was pooled. Diabetic subjects 
on normal regime insulin (NR), euglycaemic clamp (EC) and pirenzepine (PI) 
were compared to control subjects. The G H  concentrations were calculated 
from Probit analysis. Parametric statistics were used to compare mean values. 
The confidence interval of the mean was used to compare values (95% Cl, 
two-tailed a  at p <  0.05). Confidence interval was calculated from mean . 
-f 1 .96 x SD /V N .
Type 1 diabetes
Plasma GH (95%CI) 
m U/L
C ontrol 
-Plasma GH (95%CI) 
m U/L
**'p value
O C 50 8.91 (7.83,9.99) 2.23 (1.09,3.37) p < 0 .0 5
O C 75 28.61 (27.49,29.82) 16.98 (15.89, 18.07) p < 0 .0 5
O C 95 60.26 (59.12,61.40) 25.41 (24.29,26.53) p < 0 .0 5
'^■probability ines for w hole series differ being outside C l with significance of
p <  0.0025
Effect o f euglycaem ia
The effects of euglycaemia can also be compared to normal subjects and 
diabetics on normal insulin regime (Figure 4.3d).
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Diabetic
subjects
Normal regime ±
: ^plasma GH (95^CI) 
i -  mU/L
Euglycaemic clamp 
V  plasma GHi95%Cl)
*p value
OC50 8.91 (7.83,9.99) 5.62 (4.46,6.78) p<0.05
OC75 28.61 (27.49,29.82) 21.37 (20.19,22.55) p<0.05
OC95 60.26 (59.12,61.40) 45.15 (40.34,49.96) p<0.05
This suggests that during euglycaemia clamp GH occupies mean and peak dwell 
times at lower plasma GH than N R night. However, EC subjects still have 
significantly higher GH levels compared to control subjects (probability lines 
outwith 90% confidence). Interestingly, the lines of cumulative probability for 
diabetes diverge at high levels (Figure 4.3d). This reflects the grossly elevated 
peak GH (OC99) in these diabetic subjects (with levels of 70-90mU) double that 
seen in normal subjects (OC99 45 mU/L) during puberty.
The disparity between GH levels between control and diabetic subjects is 
related to different dwell times at all concentrations (Table 4.3c). In diabetic 
subjects the peak GH levels are 3.5 to 7 times the mean GH levels.
As the diabetic subjects have raised GH levels during both normal regime 
(NR) or clamp (EC) conditions, the respective findings for both groups of 
diabetic subjects was used :
Subjects with Type 1 diabetes 
Mean plasma GH (NR and EC groups)
OC50 (mean 95% Cl) 
OC75 (mean 95%CI) 
OC95(mean 95%CI)
7.27 (6.14, 8.38) m U /L  
24.99(23.84, 26.19) m U /L  
52.71 (49.73, 55.68) m U /L
Thus, the aim for reproducing a GH profile during puberty, would consist of 
peak pulse GH level between OC75 and OC95 (i.e. 24.99-52.71 mU/L. The 
difference between peak and mean level should be approximately 3.4 - 7.25 
times in magnitude.
Differentiating the GH Signal, BRP 2002 104
E ffect o f  a n tich o lin erg ic
After pirenzepine administration the diabetic subjects have reduced G H  levels 
w ith  mean (OC50) at similar G H  levels seen in control subjects but w ith  low er  
peak values (Probit Regression lines, F igu re 4.3d,e).
(95% C l, tw o-tailed  a  at p <  0.05).
I& • % pe 1 diabetes .
pJasfefeH{SD)mU/L'-
value
O C 5 0 2.24 (0.87, 3.61) 2.23 (1 .09 ,3 .37) N S
O C 7 5 7.08 (5.66, 8.5) 16.98 (15.89, 18.07) p < 0 .0 5
OC95 15.14 (13.74,16.54) 25.41 (24 .29 ,26 .53) p <  0.05
’^ No significant difference between probability lines as these over ap at 95% Cl
at mean and low er occupancies.
T ro u g h  levels
T he O C 5 level for subjects w ith  T ype 1 diabetes (N R  1.50, E C  0.85) and 
control 0.45 m U /L  also differed significantly. The trough level in diabetic 
subjects was reduced after pirenzepine (PIR 0.7 m U /L ). M atthew s 1991 has 
estim ated O C 5 during puberty as being constant around 0.37-0.68 m U /L  and 
in adult life as falling to  0.03 m U /L .
T ype 1 diabetic subjects in puberty thus have higher m in im um  trough G H  
levels than expected in puberty.
4.0.8 G H  secretion  characteristics
The half-life data for G H  used in the analysis o f the G H  profiles from  the 
normal subjects was that determ ined by H indm arsh, 1989, 1990. T he G H  half- 
life data em ployed in the deconvolution  analysis o f profiles from  diabetic 
subjects were those from  Chapter 3: - Bolus half-life mean 13.6min (range 11.9- 
19.4); 60min exposure was 23.7min (range 19.4-37.1) and steady state (prolonged 
GH exposure) mean 28.3 (range 24.3-33.7) min. The volum e o f distribution used
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was 0.089L/kg in the diabetics (section 3.0.8) and 0.054L/kg in normals 
(Hindmarsh 1989).
Deconvolution analysis of G H  profile data was analysed by the methods of 
Time Series analysis (Hindmarsh 1988b). Noise reduction was carried out by 
use of a three-minute moving average and the data was stationarised to remove 
any underlying long-term trends by linear regression. These stationary data 
arrays thus had no progressive shift in the baseline with time. Fourier 
transforms produced composite spectra of data showing all the dominant and 
sub-dominant harmonics together with an estimate of power and amplitude. 
The data can therefore be pooled using parametric statistics to yield spectra that 
are composite for the groups of data. A power spectrum displays the data as a 
histogram of power and frequency.
G H  Secretory characteristics by Deconvolution
Figure 4.4b provides a schematic example of a deconvolution secretory profile. 
The raw data illustrating plasma profiles, variable half-life and deconvolution 
analysis of GH data comparing diabetic and control subjects by puberty group 
are shown in Appendix 6. The mean GH secretion is summarised in Figures 
4.4c-g.
Diabetic subjects (NR) versus Controls
Mean overnight secretion ranged from 0.56-3.81 m U /m in (median 1.88) in 
diabetic subjects: highest values were seen at puberty stage 4/5 in both boys and 
girls. In control subjects, mean G H  secretion ranged from 0.32-1.92 m U /m in 
(median 0.60): highest values were seen at puberty stage 2/3 in girls and 4/5 in 
boys. GH secretion was increased in diabetic adolescents compared with 
matched controls in all puberty groups and both sexes, p <  0.001 (Figure 4.4c).
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Figure 4a Perform ance o f deconvolution  to estim ate G H  secretion
Upper panel: Schematic representation of a plasma G H  concentration 
profile and the calculated G H  secretion
Lower panel: G H  secretion (m U /h) in an adolescent subject with 
Type 1 diabetes (left) and in a puberty-matched control subject (right).
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Figure 4b Summary mean overnight GH Secretion: diabetes versus 
control
Mean overnight secretion significantly differed (p< 0.001) between 
diabetic and control adolescents when analysed by sex or by puberty stage.
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Figure 4c Periodicity of GH secretion: diabetes versus control
Spectral power of the Fourier transformation of overnight GH 
secretion in diabetic (upper spectrum) and normal adolescents 
(lower spectrum) pooling all puberty groups.
The dominant pulse periodicity {maximum spectral power) is 
shorter at 90minutes in diabetics, compared to 135minutes in normal 
adolescents (p = 0.0256). The amplitude at all periodicities is greater 
in the diabetic group. Error bars show SEM
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Periodicity
Visual scrutiny of the original plasma G H  profiles revealed an average of 3-5 
pulses over a 12-hour overnight period in diabetic subjects.
The Fourier transform of the GH secretory data demonstrated that the 
dominant pulse periodicity for G H  secretion in diabetics was shorter at 90 
minutes, when analysed by sex or puberty stage, compared to that found in 
control (normal subjects) at 135 minutes p== 0.0256 (Figure 4.4d). The 
amplitude of GH pulses at each periodicity was greater in the diabetic group.
Euglycaemia and Pirenzepine -  effect on G H  secretion
Deconvolution analysis in the 29 subjects who had overnight euglycaemic 
clamp showed no significant difference in GH secretory characteristics from the 
15 subjects during normal insulin regime (NR) night (Figure 4.4e,f). The mean 
overnight GH secretion rates were similar (NR 1.82 _+ 0.1 versus EC 2.04 
0.25 mU/min) except in 4 boys at stage 4-5 where there was a noticeable 
increase during euglycaemic clamp from 2.29 0.14 to 3.92 +. 1-05 m U/m in.
The dominant pulse periodicity remained at 90min during euglycaemic clamp. 
Pirenzepine administration (n-7) reduced the mean overnight GH secretion in 
Type 1 diabetes to levels which were comparable with the normal children. 
The mean GH secretion in seven diabetic subjects on EC compared to 
E C 4-pirenzepine was reduced from 1.59jh 0.19 to 0.71+_ 0.08 m U /m in 
p <  0.001. Expressed as a percentage GH secretion was reduced by 9.3 - 82.8% 
(median 63%) compared to respective subjects' clamp night (Figure 4.4g). 
Fourier analysis confirmed that GH pulse amplitude at each pulse periodicity 
was reduced but the dominant periodicity was maintained at 90min.
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Figure 4d GH secretion in Diabetics: Normal insulin regime versus subjects’ 
euglycaemic clamp
This shows that there was no significant difference in GH secretion between 
NR and clamp nights apart from in puberty group 4/5 in boys.
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Figure 4e Pulse periodicity in  diabetic subjects: norm al insulin  regim e  
and euglycaem ic clamp
U pper spectrum: Overnight euglycaemic clamp (EC) did not alter maximum  
G H  pulse periodicity (top line) which remained at 90 minutes, similar to 
subjects’ N R  night
Lower spectrum: Control subjects with maximum pulse periodicity at 
135minutes.
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Figure 4f Secretory rates in diabetic subjects: effect o f pirenzepine  
(anticholinergic) versus euglycaem ic clamp (EC)
Upper panel: Pirenzepine reduced the mean overnight GH secretion in all puberty 
groups compared to subjects’ clamp night Lower panel: spectral power. The 
dominant pulse periodicity was maintained at 90minutes although the amplitude was 
reduced at all periodicities
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4.0.9
SUMMARY A N D  DISCUSSION
The development of objective, statistically based, and reproducible 
computerised algorithms to quantify episodic G H  release is numerous (Urban 
1988). Three basic approaches have been discerned: peak detection, time series 
analysis (frequency spectra) and modelling.
Originally Santen and Bardin defined a secretory pulse as 'an increment from 
nadir to peak of greater than 20%'. Later modifications, by other authors, 
allowed for within-assay noise (non-systematic fluctuation) and defined the 
pulse as an increment of x times the intra-assay coefficient of variation and x 
was between 3 and 5. Even with modifications that there was a high false 
positive rate, which was worst at high sampling frequencies (Royston 1989). 
Urban (1988), in a detailed comparative study of eight computer programs for 
pulse detection found that the Type 1 error rate increased with the integrated 
area under curve (lAC). The methods described previously (Merriam & 
Watcher's PULSAR algorithm, Clifton & Steiner's 'Cycle Detector") all have 
disadvantages. The methods of Van Cauter (1981) and Veldhuis & Johnson
(1986) emerged from the study of Urban, (1988) as having similar performance, 
judging by a concordance of 70-80% between number of peaks detected and as 
having well controlled Type I error rates. The method of Clayton (1987) uses a 
simple iterative method of trial peaks (governed by two parameters-a mean and 
a minimum height peak), its Type I error can be controlled satisfactorily but 
requires further comparative testing. A major problem with peak picking is 
the dependence of the number of pulses found on the sampling interval 
employed. The number continues to rise even at 5min sampling. Thus 
studies which use different sampling regimes are hard to compare. Another 
problem is that the expression of results as means of peak heights, interpeak 
intervals may be misleading if the standard deviations of these quantities are
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large. It is therefore important that the researcher specifies clearly the 
questions he or she is trying to answer and selects sensible summary statistics 
accordingly.
In this chapter overnight plasma G H  profiles have been analysed by an 
objective method to describe characteristics in a simple and robust manner. 
The Distribution Method of analysis allows an objective “best estimate" when 
reconstructing a “physiological” G H  profile. This G H  profile can be 
separated into its components of minimum (OC5), mean (OC50) and peak 
(OC75 or OC95) which describes the “dwell-times” at “observed 
concentrations”. As the distribution data is pooled G H  levels seen in 
diabetic subjects at all stages of puberty, the analysis reflects the G H  levels 
experienced by most adolescent diabetics. Diabetic subjects on their normal 
insulin regime and during euglycaemic clamp have significantly higher GH 
levels to puberty-matched control subjects. Pirenzepine administration to 
diabetic subjects brings GH O C  parameters towards that seen in control 
subjects.
Analysis of trough levels may be particularly important in 
understanding the regulation of GH secretion and action. The metabolic 
significance of the “height” of the baseline of hormone concentrations is likely 
to be related to receptor or post-receptor 'recovery' characteristics since up- 
regulation and down-regulation are time dependent phenomena. I have 
therefore utilised this data to model a continuous and pulse G H  profile in order 
to examine the signal for metabolic disturbances (Chapter 5).
In order to describe GH secretion in adolescent subjects, deconvolution 
analysis of overnight (20.00-08.OOh) of GH profiles was performed. I have used 
the model proposed by Hindmarsh, 1990 (with the measured variable half-life 
and volume of distribution in normal subjects and that measured in diabetic 
subjects (Table 3.2f). This model is preferred to that suggested by Veldhuis,
(1987) and others (Appendix lb) since this model utilises an accurate assessment 
of the circumstances that affect the clearance characteristics in the study
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subjects. I have shown that in diabetic adolescents pituitary GH secretion is 
increased (mean and amplitude of secretion) at all puberty stages and in both 
sexes compared to matched controls. A shorter dominant pulse periodicity of 
secretoiy episodes (90 minutes compared to 135 minutes in normal subjects) 
suggests the frequency of GH  secretory episodes is also increased.
Neither G H  secretory amplitude nor frequency is affected significantly by 
overnight euglycaemic clamp. The anticholinergic drug, pirenzepine appears to 
suppress GH pulse amplitude secretion but has no effect on frequency of GH 
secretion. Cholinergic muscarinic receptor blockade with pirenzepine 
suppresses GH release in normal subjects and in patients with Type 1 diabetes 
and is thought to act via SRIH release. This suggests that the mechanism of 
hypothalamic regulation of G H  release in Type 1 diabetes may be abnormal 
with a persistent existence of reduced somatostatin suppression due to 
cholinergic overdrive.
Some authors have found a marked difference in GH secretion with 
increased levels accentuated in prepubertal subjects, but during puberty in 
boys, there was little difference in G H  secretion compared to normal subjects 
(Nieves-Rivera 1993). My analysis of GH profiles in diabetic adolescents on 
their usual regime NR, suggests that there was increased mean overnight GH 
secretion at all puberty stages compared to normal subjects (p < 0.001) (Figure 
4.4c (median (range) GH secretion: diabetics N R  and EC was 1.88 (0.56- 
3.81), control group was 0.62 (0.32-1.92) mU/min).
In suboptimally controlled adults with Type 1 diabetes there was altered 
pulsatility (Asplinl989). This is confirmed in my adolescent subjects where the 
dominant pulse periodicity was altered (diabetics 90min, control 135min, 
p <  0.0256). Interestingly, this intrinsic 90 min rhythmicity of GH release in 
diabetics is also seen in normal adult subjects during fasting. When comparing a 
control fed day with the first and fifth days of a five day fast, GH secretion 
changes were accompanied by both frequency and amplitude modulation of the 
pulsatile G H  secretion (Ho 1988, Hartman 1992, 1996). Furthermore, as there
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was also an uniformity of a 90minute cycle on both fasted days; this suggests the 
presence of an intrinsic 90-minute ultradian rhythm associated with the release 
of GH in man. A number of behavioural and neuro-muscular functions in 
man have a similar cycle of occurrence these include rapid eye movements sleep 
(Holl 1991), dreaming and tumescence, blood pressure variations.
In contradiction, animal studies in the fed state suggested the presence of 
frequency components of 3-5 hourly pulses of GH which were postulated to be 
meal cued events (Driver 1981). However, during sampling studies carried out 
in the fasting state, these investigators noted an enhancement of pulse frequency 
associated with new frequencies. This three-hour periodicity appears to be a 
harmonic of the more fundamental 90-minute rhythm identified during the 
physiological adaptation to starvation.
It is also possible that I maÿ have under-estimated the number of GH 
secretory episodes: more frequent sampling of Imin intervals (compared to 
20min) may detect twice as many pulses (Holl 1991); and ultrasensitive GH 
assays (sensitivity 0.002 pg/L) (Iranmanesh 1994, Veldhuis 1995) may allow 
better recognition of the neurosecretory pattern of G H  secretion (Winer 1990, 
Reutens 1996, Veldhuis 1996c). However, observations of my G H  data, using 
integrated sampling techniques which would be less likely to miss a pulse, do 
suggest a difference in pulse frequency between the two puberty-matched 
groups (control versus diabetic subjects).
In subjects with Type 1 diabetes, short-term euglycaemia does not 
reduce the parameters of GH secretion. During overnight euglycaemic clamp, 
neither mean GH secretion nor dominant pulse periodicity showed any 
significant difference from subjects' normal insulin regime night (mean +_SEM: 
overnight GH secretory rates EC 1.82 +_0-33 versus N R 1.91 +_0.37 m U/m in, 
p=N S by Student's paired t-test); dominant pulse periodicity 90min. This has 
also been shown in clinical studies where the spontaneous GH release in Type 1 
diabetes patients could not be restored to normal despite maintenance of 
improved control during the periods of either intensified conventional insulin
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treatment or continuous subcutaneous insulin infusion (Vigneri 1976, Arias 
1984, Hermansen 1987),
The shorter pulse periodicity in diabetic subjects suggests either that the 
periods of SRIH withdrawal and/or GHRH secretion may be abnormally 
frequent. It has been reported that G H  release can occur at higher blood 
glucose concentrations in Type 1 diabetes than in normal individuals 
(DeFronzo 1980), suggesting that oscillations of blood glucose, even without 
frank hypoglycaemia, may result in GH secretion. Others have shown that 
fluctuations in blood glucose concentrations during sampling period explained 
some but not all, of the GH secretory episodes (Molnar 1972).
The possible mechanisms for increased G H  secretion must still be explained by 
events at the pituitary or hypothalamic level. The fact that the G H  cannot be 
normalised by good metabolic control (euglycaemia) suggests that the increased 
GH release may be due to a hypothalamic or pituitary dysfunction induced 
either by the diabetes itself or by the treatment of the diabetes.
SRIH plays a major role in GH regulation and previous evidence suggest that 
decreased hypothalamic SRIH secretion in Type 1 diabetes is likely to be 
responsible (Schaper 1992). The mechanisms of metabolic interaction on 
hypothalamic SRIH are unclear.
It has been suggested that glucose may directly suppress somatostatin release at 
the hypothalamus in rats (Lewis 1987) however, in normal man, 
hyperglycaemia suppresses GH secretion, presumably by increasing 
hypothalamic somatostatin secretion (Penalva 1989). This suppressive effect of 
hyperglycaemia appears to be independent of the concomitant increase in 
plasma insulin (Schaper 1990). As hyperglycaemia does not inhibit GH 
secretion in response to various stimuli in Type I diabetes (Press 1984b, Ajlouni 
1975), this suggests a defect in hypothalamic SRIH regulation of G H  secretion: 
a reduced somatostatin (tone) in Type 1 diabetes allowing increased GH 
secretion at higher blood glucose concentrations.
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The high GH concentrations may be a direct result of feedback from low levels 
of IGF-1 in some studies of Type 1 diabetes (Lanes 1985). In some 
hyperglycaemic studies, the serum IGF-1 level was noted to be depressed in 
diabetic subjects in comparison to healthy volunteers (Schaper 1990) suggesting 
that IGF-1 may also be a contributory factor of the effect of glucose on GH 
secretion in Type 1 diabetes. The inhibitory effect of IGF-1 at the 
hypothalamic level is felt to be mediated by both inhibition of GH RH  and 
stimulation of somatostatin (Berelowitz 1981), but other studies have shown 
that IGF-1 acts on a different population of somatotrophes from somatostatin 
(Hoeffler 1987). Since IGF-1 suppresses pituitary response to G H RH  
(Berelowitz 1981) the low IGF-1 levels in diabetes could explain the exaggerated 
responses to this and other stimuli. However, several studies on strictly well- 
controlled diabetic subjects (HbAl < 6.5%) show that an increased GH response 
to GHRH-stimulation still persisted while IGF-1 levels were normalised to that 
comparable to control subjects (Schaper 1990), suggesting that either the 
reduced IGF-1 is not the major cause of increased secretion; or that the changes 
in IGF-1 binding proteins could alter its feed back on G H  secretion (Baxter 
1987, Suikkari 1988); or that there is a disturbance in the short-term 
autoregulation of GH secretion (i.e. GH stimulating hypothalamic 
somatostatin) (Ross 1987); or other metabolic factors are involved.
The mechanism of G H  suppression by anticholinergic agents is also 
speculative but may be related to the tonic inhibitory effect exerted by 
acetylcholine on endogenous SRIH release from the hypothalamus (Richardson 
1980, Goni 1997). Cholinergic blockade thus releases endogenous SRIH that in 
turn inhibits GH release from the anterior pituitary. Results from this chapter 
have confirmed that pirenzepine does suppress GH secretion by reducing 
overall secretion (mean _+SEM GH secretion from 1.57 Ji0.19 to 0.71 _+0.80 
m U/m in, p <  0.001 showing a median (range) reduction of 63% (9.3-82.8%) 
when compared to the subjects' clamp night) with reduction in pulse amplitude 
at all secretory levels to nearer that seen in normal subjects. Curiously
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pirenzepine has no effect on the periodicity of GH pulse secretion which 
remained at 90min (135min in normal subjects) in diabetic subjects during 
either their usual insulin regime(NR) or euglycaemic clamp (EC).
This suggests that the primary abnormality of GH secretion in Type 1 diabetes 
may be caused either by GH RH  alterations or that pirenzepine may cause an 
increase in SRIH tone which may be sufficient to reduce the amplitude of the 
GH secretory episode in response to GH RH  pulses but insufficient to prevent 
response to eveiy GH RH  pulse stimulus,
Pietschmann (1986) and Ismail (1993) confirm that cholinergic muscarinic 
blockade with pirenzepine greatly suppresses GH responses to maximal 
stimulatory dose of GHRH in both normal and diabetic adult subjects but the 
GH response was still significantly higher in diabetic subjects. This is consistent 
with a decreased sensitivity to muscarinic cholinergic receptor blockade (Coiro 
1990). Interestingly, enhancement of cholinergic tone by pyridostigmine 
causes enhanced GH responses to G H RH  in normal subjects (Massara 1986, 
Ross 1987, Penalva 1990), but in contrast did not lead to enhancement of GH 
response in diabetic subjects (Ismail 1993). Diabetic subjects also appeared to 
have a similar level of GH response to GHRH as normal subjects with 
additional pyridostigmine (Ishmail 1993), In addition, experimental diabetes in 
rats is associated with significant alterations in the brain cholinergic system 
(Wahba & Soliman 1988) providing further evidence for the importance of this 
system in diabetes. These data suggest that the level of hypothalamic 
cholinergic tone in diabetic subjects is similar to the enhanced cholinergic tone 
seen in normal subjects pre-treated with pyridostigmine.
There is accumulating physiological evidence that, in addition to the 
opposing actions of G HRH and SRIH on anterior pituitary cells, SRIH can 
also exert a tonic inhibitory influence on hypothalamic G H RH  secretion. 
Evidence in Type 1 diabetic subjects suggests that impaired somatostatin tone 
exists during hyperglycaemia whereas a normal GH response to GH RH  was 
seen (Martina 1997). Furthermore, GH negative feedback on its own secretion
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occurs predominantly through increased hypothalamic somatostatin secretion, 
which is under inhibitory cholinergic control (Ross 1987) so that this 
mechanism of auto-feedback would be deranged in patients with diabetes.
It appears that although modification in hypothalamic neuropeptides, 
GHRH and SRIH, may be altered in Type 1 diabetes, changes in the sensitivity 
of the hypothalamus and pituitary to the feedback effects of GH may also 
occur. Recent work in poorly controlled diabetic rats suggest that the 
expression of both GH RH  and SRIH declines specifically in the anatomical 
areas involved in anterior pituitary control and further alterations of pituitary 
GH receptor mRNA occur with prolongation of diabetes (Busiguina 2000).
Summary
In adolescents with Type 1 diabetes on their normal insulin regime, 
pituitary GH secretion is increased at all puberty stages and in both sexes 
compared to matched controls. During GH secretion, dominant pulse 
periodicity, by Fourier analysis, is shorter at 90min in Type 1 diabetes 
(135min in normal subjects). Euglycaemia does not alter secretory 
characteristics; the anticholinergic pirenzepine reduces the quantity 
secreted but not the frequency of pulses.
It appears therefore, that in diabetic subjects a reduced somatostatin tone is 
present because of cholinergic overactivity. This may persistently exist due 
to alterations in the expression of SRIH or the pituitary GH-receptor that 
is induced by diabetes itself or by the treatment of diabetes with insulin. I 
have examined the influence of insulin and SRIH on GH suppression and 
release in the next chapter.
Differentiating the GH Signal, BRP 2002  115
CHAPTER 5
REGULATION OF GROWTH HORMONE CONTROL
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5.0.0
IN T R O D U C T IO N
Somatostatin (SRIH) is known to inhibit basal and GHRH-stimulated GH 
secretion (Vance 1985) and previous studies defined withdrawal of 
hypothalamic somatostatin as the only involvement with the timing and 
duration of the GH pulse, whereas G H RH  was responsible for the amplitude 
of the pulse. However, conflicting evidence still appears: somatostatin has been 
shown to decrease both the mass and frequency of G H  secretory bursts 
(Calabresi 1996) and GHRH shown also to participate in the generation of GH 
pulses in humans (Jaffe 1993). Thus, the elevated levels of G H  in Type 1 
diabetes could arise because of decreased pituitary sensitivity to SRIH, decreased 
hypothalamic SRIH secretion, or increased pituitary sensitivity to GHRH.
There is still no consensus on the role of glucose and insulin in the 
regulation of G H  secretion in Type 1 diabetes. The increase in G H  frequency 
in the diabetic group suggests that the periods of SRIH withdrawal and/or 
GHRH secretion may be abnormally frequent. It may be that G H RH  pulses 
are occurring with the same frequency in both groups, but that in the presence 
of reduced SRIH 'tone' in Type 1 diabetes allows more of these stimulatory 
pulses to result in pituitary GH secretory episodes. In this chapter, I have 
therefore analysed the effects of glucose and insulin on SRIH suppression of 
GH and on the endogenous GHRH-driven GH rebound secretion after ceasing 
SRIH.
Details of subjects with Type I (insulin-dependent) diabetes mellitus who 
attended for GH clearance study (section 2.0.4, Table 2.1a) and G H  signal 
studies (section 2.1.4) are provided elsewhere. The study protocols are 
summarised in Chapter 2 and Figures 2.1a,b and detailed in section 2.0.5 and 
2.1.5-2.1.9.
Differentiating the GH Signal, BRP 2002  117
5.0.1 Analysis of interactions of somatostatin and insulin
Somatostatin is widely used in experimental metabolic studies to control 
hormone actions. Apart from the well-known suppressive effects, it has been 
suggested that somatostatin per se may alter insulin sensitivity. Previous studies 
suggest that the interaction of SRIH and insulin is time dependent (Adamson 
1982). In the first hour of SRIH administration, this peptide is thought to 
potentiate the effect of insulin (Gerich 1979). Moller (1995) in forearm studies 
in normal volunteers, has shown that when somatostatin (dose of 25pg/h for 1 
hour) is infused either as a systemic venous or local intra-arterial infusion 
during a hyperinsulinaemic euglycaemic clamp, enhanced insulin-stimulated 
glucose uptake occurred but only during local forearm infusion (55% greater 
compared to intra-arterial administration). Moller suggests that this insulin- 
stimulated muscle utilization of glucose could potentially interfere with 
metabolic studies, although the local mechanism remains unidentified. Other 
authors have shown that SRIH counteracts insulin after 2 hours (Lins 1976). 
The mechanism behind this anti-insulin action of SRIH whether it is localised 
to the liver or periphery or attributed to the antagonism of or resistance to the 
action of insulin still remains to be explained. These findings highlight that 
before any observations affecting alterations in insulin, glucose and GH 
dynamics are made, the effects of SRIH and insulin interactions require further 
clarification to ensure this is not a confounding factor.
I have examined the detailed changes and function of the insulin- 
varying clamp during GH signal studies. These subjects had a constant 13 
hour infusion of SRIH (50mcg/mVh). Subject H  had been excluded as she 
had developed profound hypoglycaemia during initial clamp stabilization. 
Therefore a glucagon infusion at Ing/kg/m in was started at 1900h for all 
other subjects attending GH signal studies. Data from the G H  signal study 
(SRIH 4- glucagon ±GH) during a 12hour insulin-varying clamp were initially 
examined for clamp bias or drift and were compared to reported insulin- 
varying clamp data in Type 1 diabetic subjects without SRIH or glucagon
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(Matthews 1990). The first 60minutes of the clamp during G H  clearance study 
(without glucagon or GH administration) were also examined.
G roup 1 G H  signal (control night)
6 diabetic subj ects : SRIH + glucagon
G roup 2 G H  signal (pulse and infusion)
10 diabetic subjects: SRIH+ glucagon + G H
(the total dose of GH was 18 mU/kg).
G roup 3 O vernight clamp (Matthews 1990)
26 diabetic subjects without SRIH 
G roup 4 G H  clearance study t30-90
Clamp analysis
Bias: The bias of the glucose clamp theoretically depends on the insulin
(infusion) clearance between subsequent periods glucose levels (G1 and G2).
For insulin-varying clamp this would be:
Insulin clearance = insulin infused per unit time 
insulin concentration
Bias can be calculated as the difference in glucose (G2-G1) from the mean 
glucose (G1 + G 2/2).
The median coefficient of variation in the last 2 hours of clamp was calculated 
comparing consecutive time periods as 
CV %= SDxlOO/mean glucose
5.0.2 Glucose and insulin on G H  suppression and rebound secretion
The GH clearance study (section 2.0.2-6) allowed analysis of clamp stabilization 
(t30-90min) [SRIH + insulin + glucose]; and SRIH suppression on endogenous 
GH (t90-150min); and endogenous GH rebound (tl50-270min). G H  secretion 
was suppressed by somatostatin infusion starting at 08.30h (t = 30) and 
terminated at t=150minutes. The insulin/glucose clamp was maintained for
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the whole study (t = 270minutes) to generate normoinsulinaemia or 
hyperinsulinaemia (section 2.0.5). Growth hormone, glucose and metabolites 
were measured as described in Chapter 2 and Appendix 3b.
GH suppression and rebound analysis
Results are given as mean +_SEM unless otherwise stated. Blood glucose was 
normally distributed. Linear interpolation with log-transformation normalised 
the GH and plasma free insulin data and therefore parametric statistical tests 
have been used.
Student's paired t-test was used to compare the data profiles from the same 
subject during the three clamp study mornings and unpaired t-test for whole 
group data, p < 0.05 was considered significant.
Correlation regression analysis was performed to examine the relationship 
between GH parameters (loglO suppression or peak and mean rebound) and 
concurrent, previous hourly and mean plasma free insulin and glucose levels for 
an appropriate time period. Spearman's rank correlation was used to measure 
the degree of association between G H  parameters and subjects' characteristics. 
Confidence Intervals were used to describe GH suppression levels during 
different insulin and glucose levels.
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5.0.3
RESULTS
5.0.4 Effect of somatostatin on insulin action
The initial blood glucose before commencing clamp in overnight studies was 
similar between Group 2 and Group 3. The interactions between glucagon and 
SRIH and insulin have been discussed in section 2.2.7 and accepted that at low 
glucagon levels, the superior effect of insulin can be seen (Paolisso 1987). Table 
5.4a and Figure 5.5a displays characteristics of the respective clamp. Plasma 
free insulin concentrations are provided in Table 6.5a and insulin infusion rates 
during overnight clamp are demonstrated schematically in Figure 5.5b.
The maximum declination (dG/dl) was at 15 minutes for all study groups. 
Between 01.00-08.OOh of all clamps the mean blood glucose achieved adequate 
euglycaemia (stable clamp period). Mean insulin infusion rates required for 
euglycaemia during the steady state period (01-0800h) ranged from 
G roup 1 SRIH+ glucagon : 2.4-9.2 m U /kg/h  (median 4.6)
G roup 2 SRIH4-glucagon + GH: 3.5-15.6 m U /kg/h  (median 7.6).
This is significantly lower than those values reported previously by Matthews 
1990 (5.3-23.3, median 14.3 m U /kg/h) without SRIH.
As it has been observed that during the first hour of SRIH administration, the 
peptide potentiates the effect of insulin, the function of clamp with only SRIH 
during the GH clearance study was scrutinized further. During GH clearance 
study SRIH infusion (started at t=30 mins) caused glucose levels to fall 
dramatically within 15-30mins of being commenced (t = 30-60min) causing the 
greatest rate of fall of glucose at 15min (HI clamp), 20mins (NG clamp) and 
30mins for H G  clamp. (The maximum effect of insulin on glucose declination 
occurs normally at 15mins). The change in glucose per unit time (dG/dt) during 
the first 60minutes (t30-90) of the three clamp conditions (NG,HI,HG) when
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Figure 5a Overnight Glucose clamp with and without SRIF: Upper panel : group 1 
SRIF without GH Middle panel : SRIF with GH Lower panel: group 3 Data from 
Matthews et al 29 subjects who did not have SRIF. To achieve target range glucose 
5mmoI/L the clamp must function under tight limits range (dashed lines).
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insulin infusion was maintained at a constant rate to generate either 
normoinsulinaemia or hyperinsulinaemia (section 2.0.5).
Clamp changes during the first 60minutes of commencing SRIH (Figure 5.5c) 
can be described by the relationship
dG /logPI = -0.1467(logGI) +3.326 
where dG is the rate of change of glucose mmol/min 
logPI is the logio plasma insulin 
logGI is the logio glucose infusion rates (ml/kg/min)
Thereafter, glucose increased at around t = 90mins, one hour after SRIH was 
commenced.
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Group
mean
Start of clamp
BG±SD
mmol/L
Lowest BG
concentration
mmol/L
Mean BG 
OlOO-OSOOh
Median 
coefficient in
last 2 hours%
Bias of clamp 
Last /hours 
Last 2hours
G r o u p  1
S R IH 9 . 3 4 . 6 4.2 + 1.6 at 
165m ins
5 . 2 ±  0.4 4.8%
(R 6.9-19% )
+ 0 .27 
+ 0.2
G r o u p  2
S R I H + G H 7 .2 ±  2.2 4 .6 ±  0.9 at 
120m ins
5 .7 : t  0.4 4.9%
(R 2.3-19.6% )
-0.95
-0.59
G r o u p  3
M a tth e w s
1990
9 .8 +  4.2 4.5+_ 0.8 at 
ISO m ins
5 .3 ±  0.2 4 .1%
(R 1.4-12% )
+ 0.26 
+  0.2
Table 5.4a
The clamp characteristics were compared by group: lowest blood glucose, 
maximum rate of fall of glucose within the first 3 hours (2000-23OOh), the 
median coefficient of variation of blood glucose in the latter part of clamp 
(0600-0800h) and the bias of the clamp.
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Figure 5b Insulin infusions are steady after 90minutes of SRIH
Left panel shows overnight insulin infusion rate (mU/kg/h) and glucose 
levels (up-going error bars) for all study nights with SRIF. Note insulin 
infusion rate is constant after 120mins o f staring clamp.
Right panel shows the first 90 minutes o f clamp when SRIF action is 
critical. Dashed lines are glucose levels during study nights.
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Figure 5c Analysis of rate of glucose declination (dGlu/dT) during an SRIF 
infusion starting at t=30mins.
Solid line represents overnight subjects who were given concomitant glucagon 
infusion and dashed lines represent the 3 clamp conditions during GH clearance 
studies without glucagon.
Note that although the rate o f  change in glucose (fall represented by negative 
values) are similar, the maximum decrement occurs earlier and very suddenly 
during SRIF alone (0-20minutes) but a fall is seen at 20-40minutes following SRIF 
when additional glucagon infusion is given.
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Conclusions from clamp observations
SRIH readily suppresses glucagon and GH levels and has been used to obtain 
standard experimental conditions in this Thesis (2.1.8). Severe hypoglycaemia 
( <  2.0 mmol/L) may trigger adrenergic responses and during G H  studies may 
potentially stimulate other metabolites.
When using insulin-varying clamp, the hypoglycaemic effect of insulin was 
potentiated by SRIH alone as I observed that during the first hour after 
commencing SRIH infusion, there is an abrupt fall in glucose (dG fall). This 
can be prevented by glucagon infusion when no significant hypoglycaemia 
occurred in the presence of glucagon (lowest blood glucose in Group 1, 2 and 3 
were similar). The later restitution of blood glucose to normal was not delayed. 
When compared to previously described data in adolescents with Type 1 
diabetes, the nadir of blood glucose was noted to be earlier (before 3 hours) 
during GH infusion although rate of fall in glucose was similar in all groups 
(1.8, 1.3 and 1,8 m m ol/L /hour in Group 1,2 and 3 respectively). This was 
rather surprising particularly as plasma insulin levels were no higher (mean 
plasma insulin SRIH 55.9 vs. SRIH-hGH  55.4 mU/L) and only 3mU/kg of 
GH had been infused. However, the insulin-like activity of GH does occur 
within the first 2 hours and perhaps being demonstrated here. The nadir of 
mean glucose levels was similar in all groups. During the stable part of the 
clamp (0100-0800h) glucose levels were similar and within clamp limits (mean 
glucose levels of 5.2, 5.7 and 5.3 mmol/L in Groups 1, 2 and 3 respectively). 
The clamp stability over the last 7 hours were comparable and within the target 
range in all groups. However, the bias of the clamp in Group 2 (SRIH+ GH) 
was negative suggesting that as mean glucose values drifted up in the last 2 
hours, the difference was lowered.
Very interestingly, mean insulin infusion rates (hence requirements) were far 
lower during SRIH infusion in clamp period 01.00-08.OOh (only 32% during 
SRIH and 53.1% during SRIH + G H  compared to insulin infusion rates used in 
Matthews, 1990). Mean plasma free insulin levels were 17.2 and 21.8 m U /L
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during SRIH alone and SRIH +G H  respectively. This confirms that insulin 
requirements to maintain glucose clamp conditions are much lower during 
SRIH infusion. This could either be because SRIH potentiates insulin action or 
decreases insulin clearance (Rollind 1990). Since the dose of SRIH 
administered was low (50mcg/mVh), it was not likely that circulatory effects of 
the peptide alone could explain these divergent actions.
My observations suggest that the interaction of SRIH and insulin is mainly seen 
during the first hour of SRIH administration, the peptide potentiates the effect 
of insulin that rectifies by bOminutes. After this time, glucose levels are 
maintained effectively with good prediction of insulin requirement by the 
programme used and an appropriate glucose clamp maintained with a constant 
SRIH infusion. This allows the observation of exogenous GH actions on 
changing insulin requirements.
5.0.5 G H  suppression data
The GH profiles obtained under the different clamp conditions are illustrated 
in Figures 3.2a.
Using the same dose of SRIH, suppression of endogenous G H  was achieved 
within bOmins (mean _+sem plasma G H  levels at t90: N G  clamp l.b +.0-5; 
H G  clamp 0.8 _+0.2; H I clamp 2.1 jfO.bmU/1) when the appropriate 
glucose/insulin clamp had been established for 90min and again at time 
t=  150min, plasma GH levels: N G  clamp 1.9 jfO.b; H G  clamp 1.1 4^0.2; HI 
clamp 3.3 1.2mU/l) (Table 5.4b displays individual subjects’ data).
Thus, the plasma GH suppression levels, when using the same dose of SRIH, 
were noted to be higher during the hyperinsulinaemic than during the 
hyperglycaemic or normoglycaemic clamps.
Subject A B C D
if :
E "  ; A
NG clamp - .
Plasma GH mU/L * 3.7 3.9 0.5 3.9 0.5 1.7
Mean t60-90 ±1 ±1 ±0 ±0.5 ±0 ±0.6
Plasma GH mU/L * 1.9 2.8 2.3 3.7 1.3 1.8
Mean tl20-150 ±0.7 +0.6 ±0.4 ±0.5 ±0.9 ±0.3
HG clamp
Plasma GH mU/L * 3.3 1.5 1.1 1.1 0.8 0.5
Mean t60-90 ±1.1 ±0.3 ±0.4 ±0.3 ±0.2 ±0
Plasma GH mU/L > * 0.6 1.1 2.1 2.2 2.2 1.9
Mean 1120-150 ±0.03 ±0.2 ±0.6 ±0.4 ±0.6 ±0.4
HI clamp
Plasma GH mU/L * 2.4 7.4 2.9 9.5 1.4
Mean t60-90 ±0.8 ±2.0 ±0.8 ±3.7 ±0.3
Plasma GH mU/L * 5.0 2.2 3.8 4.5 2.1
Mean 1120-150 ±1.1 ±0.3 ±0.4 ±0.3 ±0.2
Summary
GH Suppression NG HG HI P value
mU/L N=6 N=6 N=5 H IvH G
GH t60-90 2.4 (0.3) 1.4 (0.3) 4.7 (1.5) P=0.014
G H tl20-150 2.3 (0.4) 1.7 (0.3) 3.5 (0.5) P=0.008
Mean (SEM) 2.35 (0.3) 1.55 (0.3) 4.1 (1.0) P=0.002
Table 4b Hyperinsulinaemic clamp antagonises somatostatin suppression 
of endogenous GH
Clamps: NG=Normoglycaemic HG=Hyperglycaemic and 
HI=Hyperinsulinaemic GH suppression in both time periods (t60-90 and tl2 0 -  
150) showed significantly higher plasma GH levels during HI cIamp>NG>HG.
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5.0.6 G H  suppression - effect of glucose and insulin
The effect of glucose and insulin on GH suppression by SRIH was examined 
further by comparing the mean G H  suppression over 30min of the two time 
periods (t60-90 and tl20-150) and the relationship to the mean plasma insulin 
levels and glucose levels achieved over the previous bOminute time period 
respectively (t30-90 and t90-150) for all clamps (Figure 5.5d,e,f). There was 
no relationship identified between G H  suppression and mean blood glucose 
levels or glucose infusion rates (Figure 5.5d).
Mean GH suppression with SRIH during the hyperinsulinaemic clamp over 
both time periods was significantly different when comparing clamp mornings 
(viz. tbO-90 mean+.sem GH suppression: H I clamp 4.7 1.5 vs. N G  clamp 2.4
_+0.5, p = 0.102 vs. H G  clamp 1.4 +^ 0.3 mU/1, p = 0.014; viz. tl20-150: H I 
clamp 3.5 _+0.5 vs. N G  clamp 2.3 +^0.4, p = 0.002 and H G  clamp 1,7 +0.3 
mU/1, p== 0.008 ).
When measuring plasma G H  at low levels, the mean GH suppression level may 
be influenced by the limits of the G H  assay (sensitivity of assay 0.3 m U /L  and 
intra-assay CV at GH concentration of 2.9mU/L is 8.0%). The confidence 
interval may allow a better description of reliable suppression limits.
The confidence interval (Cl) may be viewed as the range of possible values for 
the true difference that are statistically likely around the point estimate (mean) 
values obtained in each clamp i.e. above or below 95% Cl would be a 
probability of seeing a difference of p <  2x0.025 (Gardner & Altman 1986). 
Further analysis of confidence intervals confirmed a true difference in GH 
suppression, which was statistically significant:
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F igu re 5d G H  suppression: effect o f  g lucose
Individual subjects GH suppression level at t60-90min and tl20- 
150min and plasma glucose levels. There was no significant 
relationship between glucose levels and GH suppression with 
somatostatin (r^  = 0.144, P = NS)
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Figure 5e GH suppression: effect of insulin
Individual subjects’ GH suppression at t60-90 and 1120-150 
and relationship to mean plasma insulin (mU/L) (log scale) 
in respective time periods (r‘ = 0.48, p = 0,004)
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Figure 5f Plasma G H  suppression during SR IH  is determ ined by prevailing  
insulin  levels
G H  suppression (x axis) during somatostatin infusion and mean plasma insulin (y
axis, log scale) has a linear relationship y =  0.089x + 1.44
Left panel: Log plasma insulin and plasma G H  (suppression) are plotted for
subjects’ clamp: N G  normoglycaemic, H G  hyperglycaemic, HI
hyperinsulinaemic. Regression line confirms r= 0 .6, p=0.01
Right panel; Relationship o f mean GH suppression o f  each clamp (NG,HG,HI)
during time periods t60-90 and tl20-150  and mean plasma insulin (log scale) in
the previous hour. Note linear correlation between GH suppression and plasma
insulin (r=0.96, p=0.002)
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Mean G H  suppression (95% confidence interval, two-tailed a  at p <  0.05)
at study time = 90min
H I clamp 4.7 (0.9, 6.2) vs. 2.4 (1.1, 3.7) (NG)
1.4 (0.6, 2.2) (HG)
at study tim e= 150min
H I clamp 3.5 (2.2, 4.8) vs. 2.3 (1.3, 3.3) (NG)
1.7 (0.9, 2.5) (HG)
Furthermore, mean G H  suppression independently during both these time 
periods showed a correlation (r=0.96, p = 0.002) with the mean plasma insulin 
level over the previous hour (t30-90 and t90-150 mins) (Fig;ure 5.5e,f) and was 
best described best by the relationship
Log [plasma insulin] = A [G H ] +  B 
For individual subjects' data the correlation between mean G H  hormone 
suppression and mean plasma insulin was still significant (r=0.52, p = 0.016) 
(Figure 5.5f).
5.0.7 G H  rebound release- effect o f glucose and insulin
The endogenous G H  rebound response after stopping SRIH infusion is shown  
in Figure 3.2a for each clamp.
(i) Responders
Exaggerated G H  response (i.e. peak G H  > 5 0  mU/1) was noted in six clamp 
mornings (4 N G , 1 H G , 1 HI), a moderate G H  response (< 5 0  mU/1) noted in 
5 clamp studies (3 H G , 2 HI) and there was no G H  response in 6 clamp studies 
(2 N G , 2 H G , 2 HI) representing all of the study mornings in tw o subjects 
(Table 5.4c,d).
Subject Responders Non-Responders
No 4 (1 2  clamp studies) 2 (6 clamp studies)
Median Age 
years 19.5 21.5
Sex 3 F 1 M 2M -
Median weight 
kg 64.3 76.1
Median height 
cm 1.67 1.72
Median surface area 
m^ 1.72 1.89
Median BMI 
kg/m^ 23.05 25.7
Median HbAi 11.8 10.1
% (range) ( 8 . 8 - 1 5 . 8 ) ( 9 . 7 - 1 0 . 4 )
Duration Diabetes 12.6 12
years (range) (6.1 -  2 0  years ) ( 1 0 - 1 4  y e ars )
Total daily insulin 42.8 70
Dose (u/kg/day) (0 .9 9  u /k g /d ay ) (1 .1 9  u /k g /d a y )
Table 4c Comparative demographic characteristics of non-responders 
with subjects who showed endogenous GH rebound after withdrawal of 
somatostatin suppression.
No clear demographic characteristics could be discerned, but numbers are small.
Subject
B C D* E F* G
AU clamps 
Mean (range)
Responder Nonrespondcr
NG Clamp
GH at start t=0 
mU/L 22.4 43.8 0.5 11.1 0.5 0.8 19.5 0.5
GH peak 
mU/L 76 120 0.7 151 0.8 50 99.3 0.75
mean GH 
mU/L 27.9 49.8 0.6 69.1 0.6 19.0 41.5 0.6
HG Clamp
GH at start t=0 
mU/L 4.2 11.8 7.8 3.0 0.8 2.4 5.4 4.3
GH peak 
mU/L 23.5 40.4 0.9 44.8 1.6 55.6 41.1 1.25
mean GH 
mU/L 9.4 13.2 0.7 2Z2 1.1 18.2 15.8 0.9
HI Clamp
GH at start t=0 
mU/L 6.4 41.6 13.8 7.7 12.9 2.4 14.5 13.4
GH peak 
mU/L 30.7 15 1.7 104 6.4 48 49.9 4.05
mean GH 
mU/L 13.2 9.0 1.2 51.5 2.6 24.6 1.9
S e ru m  IG F -1  NG 
m U /L  HG 
HI
0.59 0.68
0.66
0.97
0.26
0.85
0.34
0.68
0.50
0.36
0.72
0.50
0.46
0.736
(0 .4 -.9 7 )
0.56
(0.26-0.85)
P la sm a  in su lin  NG 
m U /L  HG 
HI
45.87
18.74
38.18
49.38
29.95
169.20
37.77
19.29
36.61
45.05
25.10
118.42
50.22
53.43
180.72
16.14
20.18
39.1
23.5
108.6
43.99
36.4
108.66
Table 4d Parameters influencing endogenous GH rebound secretion after ceasing 
somatostatin suppression , are no different between non-responders* and 
responders.
Note that responders show highest rebound during NG (normoglycaemic) clamp. 
Clamps: HG = hyperglycaemicc HI= hyperinsulinaemic
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There was marked variability of endogenous G H  rebound secretion:
1. Time of G H  pulse increase after SRIH term ination: median time 30min, 
range 10-60min n= 11 clamps)
2. Mean duration between start of endogenous GH release and GH peak 
values (median time 30min, range 10-70min, n== 11 clamps)
3. Peak G H : Peak G H  jFsem levels (n=12 clamps) were highest during N G  
99.3 22.5 (vs. Hyperglycaemic 41.1 _+6.7; Hyperinsulinaemic 51.3 
_+38.9mU/l) but did not reach statistical significance.
However, when examining the differences in clamps for subjects who showed 
rebound G H  secretion, the mean _+sem plasma GH levels over the rebound 
period of study (tl50-270min) reached statistical significance during N G  
normoglycaemic (44.7 Jh9.8 mU/1) vs. their respective H G  (16.9 j+3.6. Students 
paired t test, p < 0.001) and H I clamp (26.3 _+6.8, p <  0.001).
(ii) Non-responders
In two subjects there was no G H  rise (mean GH levels: N G  0.8 _+0.1; H G  1.3 
4^0.4; HI 4.1 ± 2 A  mU/1) on all study mornings (n = 6). There were no 
differences between ‘responders’ and ‘non-responders’ with respect to H bA l, 
duration of diabetes and insulin dose (or other metabolic data) (Table 5.4c).
5.0.8 Metabolites (Table 5.4e)
Although fasting total ketones (pOHB+ACAC) were high on all three study 
mornings (mean_+sem: 0.570 0.148 (NG), 0.758 0.203 (HG), and 0.738
0.339 (HI) mmol/L). Ketones were suppressed quickly after commencing 
glucose/insulin clamp and SRIH infusion. Ketone levels remained constant 
throughout the study periods (Figure 5.5g) although all subjects had 
significantly lower levels during N G  clamp (mean+^sem during study period 
t90-270 POH: N G  0.029 ±0.015 vs. H G  0.043 ±0.009, p <  0.001; H I 0.048
C.60
0.48
ü8a
C.12
C.OC
0 100 200 300
C.60
0.48
0.12
O.OC
300200100
time time
N I N G  NIHG HING
Ü
2
1
Oc 100 200 300
Figure 5g Metabolic data
during 3 clamps
Ketones and NEFA levels 
showed a similar pattern with a 
consistent fall over the study 
period. There was no 
significant difference between 
clamps. These metabolites had 
no association with GH 
rebound or suppression levels.
tim e
Metabolic
Conditions
Normoglycaemic
N=6
Hyperglycaemic
N=6
Hyperinsulinaemic
N=5
Time 90-150
Plasma ketones
POHB 
Acetoacetate 
Mean (SD) mmol/L
0.121 (0.096) 
0.063 (0.002)
0.098 (0.042) 
0.087 (0.012)
0.081 (0.059) 
0.100 (0.016)
NEFA
Mean (SD) mmol/L
0.680 (0.434) 0.395 (0.107) 0.293 (0.099)
Time 150-270
Plasma ketones
pOHB 
Acetoacetate 
Mean (SD) mmol/L
0.014 (0.002) 
0.053 (0.003) 0.032 (0.005) 0.070 (0.003)
0.040 (0.001) 
0.078 (0.002)
NEFA
Mean (SD) mmol/L
0.357 (0.041) 0.273 (0.025) 0.332 (0.046)
Time fasting t=0
Plasma ketones
pOHB 
Acetoacetate 
Mean (SD) mmol/L
0.359 (0.104) 
0.211 (0.045)
0.467 (0.137) 
0.291 (0.066)
0.470 (0.225) 
0.268 (0.1 11)
NEFA
Mean (SD) mmol/L
1.938 (0.534) 1.948 (0.716) 2.053 (0.547)
Table 4e During morning studies (study time 90-270minutes) metabolic data 
showed a consistent fall in ketones and NEFA from initial fasting levels.
There was no significant difference noted between clamps as there was a large 
variation in metabolic data (SD).
Clamps: NG=normoglycaemic HG=hyperglycaemic HI=hyperinsulinaemic
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_+0.006 mmol/1, p <  0.001 and ACAC: N G  0.056 ±0.003 vs. H G  0.076 
±0.006, p <  0.001; H I 0.089 ±0.008 mmol/1, p <  0.001).
Fasting NEFA levels were also high and similar on all study mornings 
(NG 1.94 ±0.53; H G  2.05 ±0.54; H I 1.95 ±0.72 mmol/1), fell by 30min after 
commencing glucose/insulin clamp and were even lower by 90mins. 
Thereafter, levels remained fairly stable (mean±sem N G  0.422 ±0.055 vs. H G  
0.293 ±0.025, p = 0.008; H I 0.332 ±0.033 mmol/1, p=NS) but showing a 
gradual decline over the study period (Fig;ure 5. 5g).
There was no correlation of either ketones or NEFA levels to any of the GH 
parameters (during suppression or rebound).
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5.0.9
SUMMARY AND DISCUSSION
Controversy persists regarding the role of metabolic control in the altered 
neuroregulation of GH in Type 1 diabetes. Although nutrients such as glucose, 
free fatty acids and amino acids have been shown to modulate GH secretion 
(Imaki 1986), it is not clear from current studies whether these metabolites are 
stimulatory or inhibitory to G H  secretion. As the prevailing metabolic 
conditions of glucose and insulin may influence the regulation of GH secretion 
in Type 1 diabetes, I have analysed the effect of different glucose and insulin 
levels (3 clamp conditions) during somatostatin suppression of GH. After a 
period of somatostatin suppression of GH, the endogenous GH rebound 
secretion was also observed during three clamp conditions (NG, H G  and HI).
I have clarified that when using the SRIH with insulin, the potentiation 
of insulin action that commences within 30minutes, has resolved within 
60minutes after commencing SRIH. The stability of the clamp is thereafter 
accurately maintained and experimental observations can be made.
My findings were that trough levels of GH following somatostatin suppression 
were greater during the hyperinsulinaemic clamp than during either of the 
other clamp studies. Overall the mean GH suppression during two time periods 
showed a correlation (r = 0.962, p = 0.002) with the mean plasma insulin level 
over the preceding period. Neither insulin nor glucose affected the endogenous 
GH rebound (GHRH driven) secretion following somatostatin suppression. 
From these observations and the previous chapter, it appears that, in diabetic 
subjects a reduced somatostatin tone is present because of cholinergic 
over activity and this is exacerbated further by excessive insulinaemia which 
directly or indirectly antagonises somatostatin suppression. Insulin has no effect 
on the GHRH driven GH secretion.
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(i) G H  suppression
Jaffe (1993) reports that GHRH, though responsible for the pulse amplitude, it 
is not involved in the non-pulsatile component or pulse frequency. 
Interestingly, evidence using antibodies to GH RH  and SRIH, suggest that the 
G H  pulse is not related either to hypothalamic GH RH  or SRIH but there 
appears to be other factors causing a direct action on pituitary release.
Some studies in Type 1 diabetes report an altered set point for the inhibitory 
effects of glucose, insulin and free fatty acids on GHRH-stimulated G H  
secretion (Schaper 1990) and these changes may be reflecting long term changes 
in hypothalamic/pituitary function.
The results of my analyses in Chapters 4 and 5 showed that glucose 
levels did not influence either spontaneous GH secretion or somatostatin 
suppression. Contradictory evidence regarding the role of glucose exists: 
normalisation of GH secretion has been demonstrated after a period of 
improved diabetic control (Tamborlane 1979) but in other studies, GH 
secretion has remained unchanged (Hermansen 1987) or increased (Edge 1990a). 
Short-term clamp studies have failed to show any reproducible effects of glucose 
concentrations on G H  secretion. In normal man, hyperglycaemia does 
suppress GH secretion, presumably by increasing hypothalamic somatostatin 
secretion (Frohman 1983). This suppressive effect of hyperglycaemia appears 
to be independent of the concomitant increase in plasma insulin (Schaper 1990).
In vitro and in vivo data from animal studies suggest that in chronic 
hyperglycaemia, glucose transport into the brain is depressed (Gjedde 1981). 
GH secretion by 2-deoxy-glucose inducing neuroglycopenia occurs even in the 
presence of elevated levels of plasma glucose levels, indicating that changes in 
intracellular glucose metabolism may be more important in determining the 
effects on GH secretion. Ismail, (1991) also showed that short-term effects of 
ambient glucose concentration in the range 5-15 mmol/1 did not alter GH 
responsiveness to exercise-induced stimulation. Failure of glucose mediated GH
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suppression has also been noted in other studies of subjects with Type 1 
diabetes (Press 1992).
My results in this chapter, suggest that somatostatin suppression of 
endogenous GH is affected by hyperinsulinaemic conditions, either indirectly 
or directly. The somatostatin dose that I used in my studies was not particularly 
high (4.8 pmol/kg/min) and yet that led to adequate GH suppression during 
my studies. Higher infusions up to pharmacological doses of 6mcg/kg/h SRIH 
have been used to suppress endogenous release (Calabresi 1996).
Cohen, (1991) suggested that there was a threshold infusion rate of 
somatostatin for significant suppression of GHRH-induced GH secretion and 
this was higher in subjects with Type 1 diabetes. I am not aware of any 
comparable data indicating that the somatostatin requirement for the 
suppression of physiological GH secretion is greater in subjects with Type 1 
diabetes. Certainly my data would suggest that a modest dose of somatostatin 
effectively suppressed GH suppression. A possible contribution of peripheral 
hypersecretion of SRIH has been hypothesised as a mechanism for 
downregulation of pituitary SRIH binding in diabetic rodents (Olchovsky 
1990). Such an explanation seems unlikely here, as there was no difference in 
peripheral plasma SRIH administration during all study days.
A direct relationship could be described between G H  levels after 
somatostatin suppression and plasma insulin levels in my studies (Figure 5.5f). 
Insulin receptors have been identified in the pituitary and the hypothalamus 
however, experimental data suggests that these cause inhibition rather than 
stimulation of GH secretion (Yamashita and Melmed 1986). O ther studies have 
demonstrated that hyperinsulinaemia is associated with an exaggerated GH 
response to GH-releasing hormone (GHRH) in poorly controlled subjects with 
Type 1 diabetes (Press, 1992) or noted an increase in GH levels during a steady 
state hyperinsulinaemic euglycaemic clamp (Sharp, 1987). This author also 
concluded that increased insulin concentrations appeared to have a stimulatory 
effect on GH release in diabetic subjects with and without retinopathy (Sharp
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1984, 1987). In addition as G H  increased during a low insulin infusion rate 
with a further rise during a higher rate, a dose response effect of GH 
stimulation was seen.
Contrary to this, suppression of GH secretion by insulin has been 
described by some studies of in-vitro pituitary cells and rats (Melmed 1984, 
Yamashita & Melmed 1986). Debate thus continues as to whether insulin may 
have a stimulatoiy or inhibitory effect on pituitary cells.
Data already suggests that basal and GHRH-stimulated G H  release from rat 
anterior pituitary cells in vitro is not to be influenced by varying glucose or 
insulin concentrations (Page 1987b). Furthermore, I found that the rebound 
G H  (endogenous GHRH-driven) response following cessation of somatostatin 
could not be correlated with plasma insulin levels and in fact, the highest 
rebound responses was seen during the euglycaemic study.
I conclude therefore that the mechanism of increased insulin levels is not 
stimulatory in influencing GHRH-driven GH release as previously suggested in 
other reports (Schaper 1990), but insulin appears to act by antagonising 
somatostatin suppression of GH.
An interesting explanation for insulin action has been proposed by 
Isaacs and colleagues who have demonstrated that the effect of insulin on rat 
GH gene expression can either be stimulatory or inhibitory depending on the 
metabolic state of the cell and therefore insulin may be directly capable of GH 
regulation in the rat (Isaacs, 1987). Thus high insulin concentrations could 
produce increased GH levels in Type 1 diabetes.
The somatostatin suppression of GH that is antagonised by increasing 
insulin exposure, could account for the raised non-pulsatile plasma G H  levels 
seen in diabetes. This may appear to be contradictory in diabetes, where GH 
levels are increased and the insulin is generally depleted. However, 
hyperinsulinaemia is a common occurrence when normoglycaemia is attempted 
(Rizza 1980).
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The evidence from in-vitro studies of human pituitary cultures show 
that insulin can cause inhibition on both GHRH-stimulated and basal GH 
release in man (Ceda 1985), it has been suggested that these effects may have 
been mediated by the IGF-1 receptor (Dieguez 1988, Ceda 1987). There are 
many other ways in which insulin can influence GH and hepatic IGF-1 
production.
During hyperinsulinaemia, although glucose utilisation is mainly increased in 
peripheral tissues, predominantly muscles (DeFronzo 1985) changes in 
hypothalamic glucose utilisation after intravenous injection of insulin has been 
described in the rat (Grunstein 1985). Insulin can also affect the hepatic GH 
receptor number (Baxter 1980b) and post-receptor mechanisms essential for 
IGF-1 production including mRNA production (Russel-Jones 1992). It appears 
that although the available evidence indicates that the raised GH levels may 
result from reduced feedback inhibition from IGF-1, a direct effect of the high 
peripheral insulin levels in Type 1 diabetes cannot be excluded.
The IGF-1 via receptors on the pituitary cells is known to exert negative 
feedback on GH release in animal studies (Phillips 1990). Thus, many of the in- 
vitro effects of insulin may have occurred because of cross-reaction through the 
IGF-1 receptor. However, it is unlikely that changes in IGF-1 are an 
important mediator of the inhibition of somatostatin effects on G H  suppression 
that I observed, as short-term administration of high levels of insulin will have 
no discernible effect on IGF-1 concentration, although would reduce levels of 
the insulin-dependent IGF binding protein (IGFBPl) (Holly 1988). This IGF 
binding protein is thought to be inhibitory in most IGF bio assay systems 
(Taylor 1990) and thus one could predict that a reduction of levels during 
hyperinsulinaemia would increase rather than reduce IGF bioactivity. Thus, it 
is most likely that insulin itself, may have regulatory effects on GH release. 
This may be particularly important when considering the differences in GH 
regulation in diabetic compared with normal subjects.
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(ii) GH rebound secretion
The complete lack of any G H  rebound effect after the cessation of the 
somatostatin infusion in two of the subjects studied was unexpected. I would 
infer that during a somatostatin infusion, endogenous somatostatin would be 
suppressed and on withdrawal of the infusion, the GH rebound should reflect 
G H RH  tone and the amount of the G H  stored in the pituitary. Somatostatin 
inhibits the effect of GH RH  on GH release (Fukata 1985) but it does not 
inhibit the stimulation of GH gene transcription caused by G H RH  (Barinaga 
1985) so that pituitary stores are likely to increase during a continuous 
somatostatin infusion.
Intravenous administration of GH RH  to humans causes a dose-related release 
of GH from the pituitary although greater inter-individual variation is seen 
(Evans 1985b). Growth hormone release is detectable within five minutes, 
maximal at thirty to sixty minutes and returns to baseline by 120 to 180 
minutes. Studies have shown no major differences in GH responses to G H RH  
between male and female responses in normal subjects (Gelato 1986) or a 
difference between GH responses in neonates, children and young adults. 
Several groups (Giampietro 1987, Schaper 1992 Guistina 1993) report an 
exaggerated GH response to growth-hormone releasing hormone (GHRH) in 
Type 1 diabetes.
I was unable to identify any significant demographic differences between the 
two subjects who did not show a rebound response following withdrawal of 
somatostatin and those subjects who did have a rebound response. The mean 
plasma GH rebound (tiso-zzo min) response in those two subjects who had no 
rebound response during all 3 clamp studies were similar in all clamp 
conditions (mean ±sem  GH 1.1 ±0.1 mU/1, n -6 ). These subjects were not 
GH deficient as judged by their IGF-1 levels and one subject had a measured 
G H  level of 24.2 mU/1 at the start of the clamp study HING. Unfortunately I 
have no data concerning their G H  pulsatility during the previous night and it is 
possible that they had depleted stores of GH and the study duration of the
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Study (4.5 hours) was insufficient to replenish these. Alternatively, for some 
reason, these two subjects may have remained refractory to G H RH  stimulation 
over the period of rebound observation.
The study protocol devised also included an injection of endogenous 
GH between the two periods of somatostatin suppression. This G H  bolus was 
given in order to determine the half-life of GH under prevailing conditions of 
glucose and insulin. Schaper (1990) reported impaired auto-feedback by which 
GH inhibits its own secretion in Type 1 diabetes. I did therefore consider the 
possibility that the GH bolus may have been affecting subsequent rebound 
response to GH following somatostatin withdrawal. However, similar peak 
GH levels were obtained during all of the clamp studies and no differences were 
seen in the two subjects who failed to subsequently show rebound GH 
response. Thus I have no reason to believe that short-leu feedback from the 
bolus could have affected my results.
Consideration that elevated fasting glucose needs to be normalised in most 
patients before the start of the normoglycaemic (5mmol/l) clamp and that the 
stimulus to the higher G H  rebound could be caused by the falling blood glucose 
even within the euglycaemic range (DeFronzo 1980). In my study the mean 
glucose fall (tO-90) was higher during normoglycaemic clamp studies (NG 43%, 
H I 39.5% vs. H G  7.5%) but although there was corresponding higher mean and 
peak rebound GH during normoglycaemic clamps, this did not reach statistical 
significance.
Glucose administration has a biphasic effect on GH secretion in man. 
The acute inhibitory effect of glucose on plasma GH levels appears to be due to 
an alteration in hypothalamic activity, since both oral and intravenous glucose 
inhibit basal and GHRH-stimulated GH release (Johnston 1985, Masuda 1985). 
The mechanisms involved in the delayed rise in GH have been investigated 
recently who have shown that oral glucose markedly increases G H  responses to 
GHRH when administered 3.5h prior to GHRH (Valcavi 1990) but cause 
suppression if glucose is administered 1 hour prior to GH RH  (Masuda 1985).
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It appears likely that the late rise in G H  secretion induced by oral glucose 
occurs via a non-GHRH-dependent mechanism and possibly as a consequence 
of reduced release of somatostatin from the hypothalamus. Similar amounts of 
10% glucose were administered during the clamp mornings and although, a 
delay in GH rebound could account for the negative response noted in 2 
subjects, it is surprising that during all hyperglycaemic clamps this effect was 
not seen.
Acetylcholinesterase inhibitors (pyridostigmine) are hypothesised to 
decrease hypothalamic somatostatin tone. A study by Giustina (1990) showed 
that in normal subjects pyridostigmine with or without iv G H RH  caused a 
significant increase in GH levels and acted in a synergistic fashion. However in 
diabetic subjects the GH response to GHRH was variable, some (10/18) 
showed an exaggerated GH response after GHRH and a lower GH response 
after pyridostigmine than normal subjects while others (8/18) showed similar 
response to normal subjects. Duration of diabetes, basal GH levels were higher 
along with a slightly higher H bA l in the first group.
In a further study, G H RH  stimulated GH production in six diabetic subjects 
showed that maximal levels were achieved at 15-30 mins and peak G H  levels 
reached were similar (36 ±16.9 pg/L (72 ±33.8 mU/L) and 38.7 ±18.9 pg/L 
(77.4 ±37.8 mU/L) during hyperglycaemia (15.3 ±0.2 mmol/1) and 
normoglycaemia (6.8 ±0.1 mmol/L) (Miller 1992) but insulin levels were not 
reported in this study. In my study, similar peak levels were reached (mean 
±sem  GH 99.3 ±22.5 (NING); 41.1 ±6.7 (NIHG); 49.9 ±38.9 (HING); 
mean all clamps 63.9 ±17.9 m U/L, n==17) and after a median time of 30min 
(range 10-70min) after the start of the GH pulse.
Studies in normal man show that short-term elevations of insulin to 
supraphysiological levels (200mU/l) while euglycaemia is maintained, do not 
influence either basal or GHRH-stimulated GH secretion (Schaper 1992). The 
potentiation of the response to GH-releasing hormone by insulin would 
indicate loss of an inhibitory effect on the pituitary either directly or mediated
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by a reduction in somatostatin levels. My data would support the hypothesis 
that it would appear that insulin is directly inhibiting the suppressive effects of 
somatostatin at the level of the pituitary. The mechanisms underlining these 
observations are likely to be complex.
Short-term hyperglycaemic clamp in my study confirmed that high ambient 
glucose concentrations had no effect on the ability of somatostatin to suppress 
the pituitary release of GH.
I did not see increased GH rebound levels (GHRH driven) during 
hyperinsulinaemic conditions. There is also possibility that hyperinsulinaemia 
in the studies reported by Press (1992) may be having an effect on endogenous 
somatostatin production by the hypothalamus. Thus I would conclude from 
these observations that the effects of insulin on GH secretion are mediated via 
antagonism of somatostatin effects on the pituitary rather than an effect on 
GHRH.
In conclusion, this data provides evidence tha t hyperinsulinaemia, directly 
or indirectly, may inhibit suppressive effects of somatostatin at the level of 
the pituitary, whereas it has no effect on the G H R H  driven G H  response 
seen following the withdrawal of the somatostatin infusion.
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CHAPTER 6
CONVOLUTION AND DIFFERENTIATING THE GH
SIGNAL
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6.0.0
IN T R O D U C T IO N
In this section I report overnight studies in young adults with Type 1 (Insulin- 
Dependent) Diabetes Mellitus where the effects of continuous or pulsatile GH 
administration (the GH signal) on ketogenesis, lipolysis, and insulin sensitivity 
were compared with a control night during which endogenous GH secretion 
was suppressed with somatostatin. The data following in this section are given 
for 6 subjects 0LMNP and Q). Nocturnal GH plasma levels found in insulin- 
dependent diabetes mellitus were reproduced in study subjects. The estimate of 
G H  dose used was calculated from deconvolution estimate and volume of 
distribution with the aim of mimicking diabetic physiological plasma levels in 
study subjects. Study design, practical procedures and standard conditions are 
described fully in Chapter 2 (section 2.1.2-2.1.9).
(i) Cross correlation
Cross-correlation (Chatfield 1975) was used to examine the phase relationships 
between oscillations in the G H  data and insulin requirements. This involves 
time series data (GH pulses) being correlated with insulin infusion rates, which 
are then moved to the right of the GH pulses by minute intervals and 
correlated again. Data in phase have a positive r value at zero lag. If there are 
regular cycles the serial values of r will fall until they reach a nadir when the 
data are 180° out of phase. The first positive peak represents the period of any 
regularly recurring cycle. Data can be pooled using Fisher's 2  transformation 
and the significance can be determined from the r-value. The correlation 
coefficients are calculated and the phase relationships between oscillations in 
both data sets can be found by examining the maximum positive correlation.
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(ii) Insulin clearance
Metabolic clearance rate for plasma insulin (MRC-I) (mL/kg/min) was 
determined for the period of euglycaemic clamp during steady state for each 
study night as a ratio of insulin infusion rate to plasma free insulin (Castillo 
1994). Using the formula
Metabolic Clearance Rate of Insulin = insulin infusion rate x 1000 
mL/kg/min plasma insulin
(iii) Statistics
Results are given as mean_+ SEM unless otherwise stated. Blood glucose and 
insulin infusion data were normally distributed. Log-transformation normalised 
the ketone, lipid and plasma free insulin data and therefore parametric statistical 
techniques have been used on these log-transformed data. Student's paired t- 
test was used for comparisons of mean data between profiles and at individual 
time periods. Analysis of variance (2-way ANOVA) was used to examine 
changes with time and confirm differences between study nights.
Differentiating the GH Signal, BRP 2002 141
6.0.1
RESULTS
6.0.2 Convolution of G H
(i) G H  plasma profile
Comparison of adolescent G H  profiles in diabetic and control subjects are 
illustrated in Figure 4.3a. Appendix 6 illustrates further G H  plasma profiles 
seen in diabetic adolescents by puberty stage.
(ii) Mean G H  between study nights
G H  dose administered ranged between 78-121 m U /h on continuous infusion 
GH; 312-484 mU/pulse on pulse night and mean G H  (20.00-08.OOh) levels 
achieved were similar at ^.7±_ 0.4 and 9.8+. 1.5 m U /L respectively.
(iii) Separation of G H  signal: Pulse versus Continuous Infusion
Characteristics of the GH pulse profile when administered either as a 
continuously raised baseline (12 hour infusion) or as three pulses are shown in 
Figure 6.6a.
(iv) G H  PULSES
During pulse GH administration plasma levels rose by 30min and reached peak 
plasma levels by 60min after the start of GH infusion. After cessation of GH 
infusion, the pulse was sustained for 30min (time taken to reach half-peak 
levels) and had reached suppression levels by 60min. Pulse characteristics 
achieved in all study patients (n 5) were similar and there was no difference 
between the first, second and third pulses given. The range for peak-pulse was 
26.5-36.9 mU/L. This was within the predicted model requirement.
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Figure 6a R econvoluted G H  profiles: all subjects
Endogenous G H  was suppressed with somatostatin. G H  replacement was infused as pulses 
(6m U /kg/h) (upper panel) or continuous infusion (1.5m U /kg/h) (middle panel). Mean 
overnight plasma G H  levels were similar at 9.7 _+0.4 and 9.8 _+1.5 m U /L  although the 
signal differed. Pulse signal: There was no difference in characteristics between first, 
second or third pulse (see text). C ontinuous signal: G H  levels maintained between 8.6- 
10.8 m U /L , although oscillations were noted. A N O V A  confirmed no significant drift and 
linear regression defined a zero slope.
C ontrol n ight (lower panel) when there was no G H  signal: endogenous, G H  remained 
suppressed at mean j^SEM 1.1 _+0.1 m U /L  throughout the study period 20.00-08.OOh
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Mean (SEM) plasma GH . ''
Pulse I Pulse 2 ^f  .'ft:
Peak level 29.2 ±2.7 VS. 31.6 ± 2 .6  vs. 33.7 ± 3 .2 m U /L (p = N S ),
inter-peak 2.3 ±0.2 vs. 2.5 ±0.5 vs. 1.8 ±0.5 m U /L .
(v) G H  12h C O N T IN U O U S  IN F U S IO N
Administration of continuous G H  infusion showed a rise in plasma G H  
levels by 30min and had reached mean plateau peak levels (+_ 1 SD) by 
120min after start of G H  infusion. Thereafter, steady G H  levels were 
maintained between 8.6 - 10.8 m U /L  although oscillations in plasma levels 
were noted. These oscillations were not related to either the administration 
of G H  nor the practical equipment as the “Buffer pulses” occurred after 
oscillations were first seen. The SEM in the infusion G H  profile do not alter 
in magnitude with the oscillations, suggesting that this observation is a 
physiological change which occurs as r-hGH is metabolised after entering the 
blood. The continuous level was acceptable within the predicted model.
(vi) C O N T R O L  Mean G H  levels on control night remained adequately 
suppressed at 1.1 0.1 m U /L .
The characteristics of the pulse signal and the continuous signal were adequately 
separated and both compared to a control night when endogenous G H  was 
suppressed. The maximum m ea n S E M  G H  levels achieved on study nights 
were: 32.8 _+2.2 (peak level during G H  pulses); 9.8 0.8 (continuous GH) and
1.1 _+0.3 m U /L  (control level). However, mean G H  plasma level achieved 
overnight (20.00-80.OOh) was similar ^.7±_ 0.4 and 9.8+_ 1.5 m U /L  during pulse 
and continuous G H  study nights respectively.
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Figure 6b GH signal: glucose clamp
Pooled overnight (20.00-08.OOh) blood glucose concentrations (mean jf SEM) from  
all subjects during study nights using variable rate insulin clamp. Euglycaemic 
conditions were achieved (range between dashed lines). Right panel shows the 
fasting glucose levels were higher on G H  nights (P = pulse G H  6.5 +.0.4,
C = continuous G H  6.4 0.4, R = control reference (no GH) 5.4 jf 0.5 m m ol/L ).
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6.0.3 Glucose clamp
Comparable normoglycaemic conditions were achieved on all three nights 
(20.00-08.OOh) with meanj^SEM glucose levels of 5.8 +_0.1 (pulse GH); 5.5 jfO.l 
(continuous GH); 5.3 jfO.l (control) mmol/1.
Early morning blood glucose levels were noted to rise between 05.00-08.OOh 
despite increases in insulin infusion rates during GH study nights (pulse GH 
6.24^ 0.4 vs. control 5.55_+ 0.3 mmol/L, p = 0.001; continuous G H  5.9jf 0.3 vs. 
control, p = 0.002). This was reflected in a significantly higher fasting glucose 
levels (pulse GH 6.5_+ 0.4 vs. control 5.4_+ 0.5 mmol/L, p <  0.001; continuous 
GH 6.4j+ 0.4 vs. control, p <  0.001).
6.0.4 Insulin changes
Mean insulin requirement between 01.00-08.OOh was highest with pulse GH: 
0 . 1 7 0.03 m U /kg/m in vs. control 0.09_+ 0.01 (p< 0.001) with only slight 
increase during continuous GH: O.lOj^ 0.01 vs. control (p=NS). This 
represented a mean increase of insulin infusion requirement of 88.8% during a 
pulse GH night (Table 6.5a).
Plasma free insulin levels (01.00-08.OOh) were correspondingly higher on the 
pulse GH night: 26.53+ 3.01 m U /L vs. control 17.16+_ 0.42 (p=0.01); pulse vs. 
continuous GH 17.88+^ 1.55 (p=0.01). During a pulse G H  night despite a 
88% increase in insulin infused, mean blood glucose was higher by 12.7% in the 
same time period compared to control night.
(i) Insulin sensitivity and insulin clearance and G H
Plasma free insulin concentrations during steady state euglycaemia were used as 
an index of insulin sensitivity. This suggests that only pulses of growth 
hormone mediate the decrease in insulin sensitivity (mean rise of insulin 
requirement by 88.8% compared to control and continuous G H  infusion).
Time Period Insulin requirement ; Insulm Clearance
mU/kg/min - 
Pulse  ^(%utfol Pulse %Contmuous . Contra!
*22.0(M)1.00h 0 .1 2 2+0.054 0 .1 4 3+0.040 0 .0 8 7+0.024 - - -
0 1 .0 0 -0 4 .0 0 h 0 .1971 0.111 0 .0 7 0 7.1 4 .8 4 .2
±0.092 ±0.022 ±0.009 +2.1 + 1.1 +0.1
0 4 .0 0 -0 8 .0 0 h 0 .1 5 7 0 .1 1 9 0 .102 6 .2 7.4 5.8
±0.069 ±0.015 ±0.022 ±2 .1 + 0 .5 + 0 .4
mean
*01.00-08.00h 0 .1 7 3±0.081 0 .1 1 5±0.022 0 .0 8 6±0.022 6 .5+ 1.5 5 .6+ 0 .8 5.1+ 0 .2
% insulin change* 29.5% - 24.3% -1.2%
Table 5a Insulin requirements increase only on pulse GH night without 
signifîcant alteration in insulin clearance.
The Metabolic Clearance rate o f  insulin (MCR-I) was calculated from the 
insulin infusion rate divided by the plasma insulin.
These data suggest that alteration o f  insulin sensitivity occurs on pulse GH 
night.
Study night Insulin infusion rate 
mean (SEM) '
mU/kg/min
Plasma Insulin 
mean(SD) ^
^  Glucdse^ 
mean (SEM)
mmol/L _
Clock time 01-08h 01-08h 01-08h
Pulse
J 0.113 7.72 7.08
L 0.113 31.95 6.06
M 0.285 28.97 5.52
N 0.228 52.93 5.49
P 0.139 11.11 5.35
Q 0.157 11.71 4.92
Mean 0.173 24.10 5.74
+0.081 +12.7 +0.3
Continuous '
J 0.1247 11.7 5.19
L 0.0983 37.15 __  5.59
M 0.1271 17.78 5.92
N - - -
P 0.0752 9.79 5.29
Q 0.2129 13.14 5.31Mean 0.115 17.9 5.46
±0.022 ±6.7 ±0.2
Control
J 0.0214 8.62 5.01
L 0.0654 22.49 5.30
M 0.0847 14.39 4.98
N 0.1235 39.09 5.01
P 0.1656 10.83 5.35
0 0.0570 7.59 5.12
Mean 0.086 17.16 5.13 ...
+0.022 +7.2 +0.1 >
Table 5b GH puise signal compared to control, significantly 
increases insulin requirements (p<0.001) and plasma insulin 
levels (p=0.002) during overnight euglycaemic clamp.
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Figure 6c GH signal: insulin requirements (infusion rate)
The overnight oscillations o f insulin infusion requirem ents (solid line and error bars) 
and the plasma concentration o f G H  (solid line) indicate a oscillating pattern.
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Figure 6d G H  signal: Cross-correlation
The relationship between GH concentration and insulin infusion rate shown here as 
a correlogram. A maximum significant positive association is seen at 135minute lag 
time (r = 0.21, p <  0.001), indicating that on average maximum insulin infusion rates 
were required 135minutes after a GH pulse.
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When examining overnight insulin clearance during time periods 2000-2400, 
0100-0500 and 0500-08OOh, the mean clearance was similar (Table 6.5a). Insulin 
sensitivity and clearance were not related to either individual peak G H  levels 
nor mean plasma GH (p=NS). Thus, overnight (01-08OOh) insulin clearance 
showed no significant difference between study nights. To establish whether 
there was a dawn rise in insulin requirement consecutive 4 hour time periods 
were compared between 23.00 and 0.800h. A rise in insulin requirement was 
observed only when comparing the time period 23.00h-01.00h versus mean 
overnight insulin requirements (Ol.OO-OB.OOh) (Table 6.5a and 6,5b).
(ii) Insulin requirem ent and G H  pulsatility
During the pulse GH night, there was a visible oscillatory change in insulin 
requirements (Figure 6.6c). There appeared to be a rise in insulin requirement 
with a phase lag of approximately 2 hours following a G H  pulse, which was 
maximal at 3 hours and had fallen again by 4 hours. Cross-correlation was 
used to confirm the time-relationship between GH and insulin oscillations. •
(iii) Relationship between G H  oscillations and Insulin
Cross-correlation between insulin infusion rates and GH pulses showed a 
maximal significant positive association (r = 0.21, p <  0.001) at 135min (Figure 
6.6d) indicating that the insulin infusion data are displaying a time-related 
oscillatory pattern where an increase in insulin requirement lags 135min after 
GH pulse concentration.
6.0.5 Metabolite changes
Metabolic data were analysed after obtaining stable clamp conditions during the 
period 01.00-08.OOh. The pattern of |3-OHbutyrate and acetoacetate 
concentrations is shown in Figure 6.6e. After an initial fall from 19.00h levels, 
plasma ketones rose steadily from approximately 21.OOh (continuous G H  night) 
and 23.OOh (pulse GH night) until peak levels were reached between 01.00-
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Figure 6 .66  G H  signal: Metabolic data
Results of mean overnight metabolic data (ketones, lactate and NEFA). Left panel shows 
the results from pulse GH signal; the right panel shows results after continuous GH 
administration. ,
Up-going error bars (SD) on data from GH night and down-going from control night. 
Abscissa = clock time, Ordinate concentrations of acetoacetate, pO H  butyrate, lactate and 
free fatty acids respectively.
Study night * pOHButyrate ^  
Mean (SEM) mmol/L
V. Acetoacetate 
Mean (SEM)  ^
Î mmol/£
_ Lactate 
Mean (SEIVQ^  mmol/L
;;
Clock time h 01-08 S E M ç ^ 01-08 SEM 01-08 SEM  ^ ^
Pulse
J 0.365 0.031 0.284 0.082 0.711 0.024
L 0.357 0.042 0.263 0.023 0.616 0.050
M 0.038 0.009 0.046 0.004 1.149 0.182
N 0.011 0.002 0.041 0.002 1.617 0.148
P 0.190 0.041 0.065 0.013 0.670 0.035
Q 0.295 0.078 0.240 0.025 0.874 0.082
Mean (SEM) 0.209 0.014 » 0.156 0.010 0.939 0.035
Continuous
J 0.468 0.048 0.290 0.032 0.651 0.030
L 0.130 0.031 0.118 0.016 0.955 0.054
M 0.245 0.028 0.129 0.010 0.664 0.055
N - - - -
P 0.082 0.004 0.056 0.006 1.282 0.127
Q 0.528 0.050 0.331 0.038 1.221 0.156
Mean (SEM) 0.289 0.014 0.185 0.017 0.955 0.038
Control Reference
J 0.241 0.043 0.148 0.055 0.608 0.020
L 0.051 0.013 0.073 0.009 0.670 0.059
M 0.034 0.009 0.063 0.012 0.750 0.048
N 0.007 0.001 0.047 0.002 0.916 0.085
P 0.012 0.004 0.066 0.008 1.018 0.092
Q 0.138 0.054 0.148 0.061 0.706 0.055
Mean (SEM) 0.084 0.008 0.091 0.010 0.778 0.024
Table6.5cMean overnight metabolites are increased by both a continuous and pulse GH signal
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02.00h. The level of ketones was sustained at this high level until OS.OOh. The 
rise in 3-OHbutyrate was most exaggerated during continuous GH infusion 
night and was different to control night at all time periods. These changes 
reached significance between 05.OOh and OS.OOh resulting in high fasting levels. 
Mean (SEM) overnight (Ol.OO-OB.OOh) 3p-OHbutyrate levels (Table 6.5c) were 
significantly increased on both G H  nights (continuous GH 0.2898 j+O.OM vs. 
control 0.0840 0.008 mmol/L, p <  0.001; pulse GH 0.209 _+0.014 vs. control,
p < 0.001) and fasting (OS.OOh) levels were increased: continuous G H  0.3116 
0.090 vs. control 0.1057 _+0.055 mmol/L, p<0.05; pulse G H  0.2130 _+0.084 
vs. control, p=NS.
Plasma acetoacetate concentrations followed a similar pattern with significant 
but less pronounced changes during GH administration (Table 6.5c). (Mean 
(SEM) 01.00-08.00h: Both continuous GH (0.1848 ;f0.017) and pulse GH 
(0.1562 +.^.010) were significantly greater than control (0.0908+. 0.010 
mmol/L, p <  0.001). Fasting: continuous GH 0.206 0.053 vs. control 0.1042
j+0.034 mmol/L (p<0.05), pulse GH 0.1678 _+0.057 vs. control (p<0.02^^). 
Two-way Anova on log-transformed data confirmed that ketone levels changed 
with time between (20.00-08.OOh) on all study nights (F 5 .95,p<0.001) but had 
reached plateau levels between 01-08.OOh (F 0.7862, p=NS) and that the mean 
ketone levels were significantly different between the three study nights (F 
83.56, p <  0.001) being most pronounced between continuous G H  and control 
(F 111.73, p <  0.001). High variation of ketone data was noted between subjects 
on pulse GH nights (Figure 6.6e),
The mean fasting total ketone levels were elevated Control 0.2099; Continuous 
GH 0.5176; Pulse G H  0.3808 mmol/L
Lactate levels fell initially (from 20.00h level) and did not vary over time during 
the later period (01-08.OOh F 1.13, p=NS) but there was a small but significant 
difference between both pulse GH (F 5.9, p <0.05) and continuous G H  (F 3,87, 
p<0.05) and control night detected by ANOVA, Mean plasma lactate levels 
were only slightly raised with GH administration: Mean level (01-08.OOh) on
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continuous GH 0.955 4:0.038 and pulse GH night 0.939 jk0.035 vs. control 
0.778 0.024 mmol/L (p=0.045) (Figure 6.6e).
6.0.6 NEFA changes
Overnight (01.00-08.OOh) mean levels of free fatty acids (NEFA) were increased 
slightly and reached significance during continuous G H  1-09 0.07 versus
0.61 J :  0.05 mmol/L control (p=0.001); but were less marked during pulse GH 
0.94J : 0.04 versus control (p=0.042). Fasting levels however were not 
significantly different: continuous GH 1.04j+ 0.16, pulse GH 0.834: 0.13, 
control 0.64J : 0.13 mmol/L) as there was a large variation between subjects. 
Anova confirmed that NEFA levels did not change with time between Ol.OO- 
OB.OOh (F 0.50) but there was a definite difference in mean plasma levels which 
were higher during continuous G H  administration compared with both 
control (F 27.08, p <  0.005) and pulse GH (F 19.15, p < 0.005) over this time 
period. (Figure 6.6e).
6.0.7 O ther hormones
2 patients had hourly cortisol and 4 patients had 2 hourly IGF-1 levels 
measured (details provided in Appendix 6). Glucagon levels were not assayed 
as previous work has shown adequate plasma concentrations at the infusion rate 
given of Ing/kg/m in. Cortisol levels showed a similar profile between nights in 
the 2 subjects with a morning rise. Levels of IGF-1 measured showed no 
significant change overnight/ N o significant difference in the mean or 08.00h 
levels of IGF-1 measured by radioimmunoassay were observed when the three 
study nights were compared although, pulse GH nights appeared to cause a rise 
in IGF-1 in keeping with other reports.
1However, I did not however carry out measurements of IGF binding proteins, as BP3 binding protein is 
thought to be inhibitory in most IGF bioassay systems (Taylor 1990) and IGFBP-1 responds acutely to 
insulin levels.
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6.0.8
SUMMARY A N D  DISCUSSION
Six young adults with Type 1 diabetes were studied on three occasions 
overnight. On each night somatostatin and glucagon were infused 
continuously and r-hGH (total dose 18mU/kg) was given in phosphate buffer 
as either: 3 discrete hourly pulses (6mU/kg/h, 120 mins apart) or a 12h infusion 
(1.5mU/kg/h) or buffer solution only as control night. The study thus achieved 
peak pulse level which were 3.35 times the continuous GH and reflected the 
similar alteration seen in diabetic subjects (section 6.0.2 and 4.0.7, page 103). 
The pulse signal causing these metabolic effects was thus differentiated and 
contrasting metabolic effects were seen.
(i) Differentiating the G H  signal
GH is known to have both insulin-like and insulin-antagonistic properties 
(Davidson 1987). In vitro, insulin-like activity occurs soon after the tissue is 
exposed to GH and includes increased glucose utilisation and related pathways 
and anti-lipolysis. There is controversy surrounding an insulin-like effect of 
GH in intact animals and humans as several investigators have been unable to 
demonstrate one (Batchelor 1976, Metcalfe 1981). The lack of the 
hypoglycaemic effect in vivo has been ascribed to the simultaneous rise of 
portal vein insulin and glucagon, which neutralise each other (Okuda 2001). 
However, other researchers have found a transient hypoglycaemic effect of GH 
that was mild and transient lasting only approximately one hour (Goodman 
1981). In vitro studies have also assessed the role of G H  on insulin action. 
Tissue effects of GH are much more easily seen if the tissue has not been 
previously exposed to GH (Hart 1984). In liver glucose conversion to glycogen 
was increased transiently by GH during the first hour of incubation but not 
after 1.5 hours (Honeyman 1980). Furthermore, exposure of the tissue to GH
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only during the first fifteen minutes of incubation rendered it refractory to the 
hormone during the fourth hour (Goodman 1981). Inspite of the insulin-like 
effects of GH demonstrated under various experimental conditions, it is 
doubtful whether these play any physiological role. I did not observe any 
insulin-like effects of GH during overnight GH infusions when using an 
insulin-varying clamp.
Exposure of tissue to GH in vitro certainly causes insulin-antagonistic 
effects. Interestingly, when human fibroblasts were cultured with extremely 
high concentrations of GH, glucose uptake was suppressed during the first 
four hours of incubation but returned to normal by 20 hours (Takeda 1984). 
In normal subjects, Sheu (1990) determined that hepatic glucose production 
could be regulated (suppressed to approximately 50% of the original value) by 
varying the rate of exogenous glucose infusion during glucose clamp studies in 
the absence or presence of glucagon (5.2 pmol/mVmin) during SRIH infusion. 
Orskov (1989) showed that physiological increments of circulating GH (30 
mU/L) during both 6 and 14 m m ol/L glucose clamp impaired glucose- 
induced glucose uptake and increased endogenous glucose production. This 
effect was more pronounced during somatostatin infusion (large doses of 250 
and 750 micrograms per hour) without G H  (44% glucose uptake with G H  
versus 97% without GH). Increased glucose output and hyperglycaemia still 
occurred with hypoinsulinaemia and normoglucagonaemia. The same plasma 
levels increased glucose production 2-3 fold during insulin deficiency.
The mechanism for this effect is still unclear. Reductions in insulin receptor 
numbers at the tissues could affect insulin action; there is evidence that factors 
causing abnormalities in the post-receptor mechanisms could cause both 
reduced insulin sensitivity and reductions in insulin receptor numbers and 
hence insulin mediated clearance (Unger 1998); GH could be acting directly 
through its own receptor interfering with insulin signalling at a post receptor 
level (Muller 2001). G H  could also act indirectly through mobilisation of 
NEFAs from adipose tissue (Hettiarachchi 1996).
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(ii) The Dawn Phenomenon
The term "dawn phenomenon" has been limited to indicate specifically the 
increase in insulin requirements (or development of hyperglycaemia if the need 
for insulin is not met) in the absence of declining insulin delivery, as well as in 
the absence of nocturnal hypoglycaemia (Bolli 1988). Such a definition implies 
that the dawn phenomenon can only be accurately assessed as the cause of 
fasting hyperglycaemia in diabetic subjects in whom insulin deficiency is 
prevented. During previous studies, the plasma insulin concentrations usually 
fell overnight after the evening injection of depot insulin (Francis 1983). Many 
of the earlier studies of the dawn phenomenon in adults thus involved technical 
problems with loss of available insulin and waning of insulin delivery (Brennan 
1985, Harris 1986, Campbell 1986).
The practical contribution of insulin deficiency to the dawn phenomenon could 
not easily be separated during such clinical observations. In addition, the 
heterogeneity of the study population, varying study conditions used and the 
different definitions applied to the dawn phenomenon added further confusion. 
Many reports suggest that virtually all (80-100%) Type 1 diabetic patients 
exhibit a dawn phenomenon (Perriello 1991, Perriello 1988, Campbell 1986, De 
Feo 1986, Edge 1990b, Beaufrere 1988). By measuring the 2400-0700 increase in 
plasma glucose concentrations during overnight insulin delivery at a fixed rate, 
the initial Biostater studies show that the dawn phenomenon accounted for 
quite a large increase in plasma glucose concentrations i.e. 5-7mmol/l 
(Campbell 1985b). However, in studies in which the artefact of insulin waning 
was prevented, plasma glucose concentrations increased by only 1.5-2mol/l in 
the period from 2400-0700 (Perriello 1988, 1990). Thus it is likely that the 
specific contribution of the dawn phenomenon to fasting hyperglycaemia is 
quite modest. Atiea (1992) suggests that even an increase of 1 mmol/1 or more 
of plasma glucose was clinically significant during the early morning. Results 
from this chapter show that even when using a variable insulin clamp and
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providing optimum insulin with higher insulin rates during pulse G H  nights, 
fasting glucose concentrations were higher than control on both G H  nights 
(pulse GH 6.54: 0.4 versus control 5.4j: 0.5 mmol/L, p <  0.001; continuous 
GH 6.4 j :  0.4 versus control, p <  0.001). Thus, a fasting glucose level does not 
adequately reflect the alterations in overnight insulin resistance or actual insulin 
requirement.
However, the extent to which the dawn phenomenon contributes to 
early morning glycaemia remains controversial, partly because comparison of 
overnight time-periods differs between studies. Insulin sensitivity has been 
found to be greater in the 2400-0200 period, compared with the 0600-0800 
period, both at the level of the liver, as well as the peripheral, insulin-dependent 
tissues in conditions of euglycaemia (Perriello 1990) contrasting the 
observations of Widmer, (1988) who found no apparent change in insulin 
sensitivity between the 0100-0200 and 0700-0800 periods in a group of Type 1 
diabetic patients.
In my studies when comparing mean insulin requirements during time periods 
01-04.OOh and 05-08.OOh, there was no consistent mean or individual change 
between study nights (Table 6.5a). However, when comparing mean insulin 
requirement change between 22-01.OOh and 01-08.OOh, a clear incremental 
change in insulin requirements occurred on a pulse GH night (29.5% increase 
vs. control -1.2%).
Various non-hormonal and hormonal factors have been implicated for the 
decreased insulin sensitivity at dawn period (05-0800h) compared with the 
early night hours but most reports now focus on the parameters of the G H  
pulse. It has been suggested that reductions in insulin sensitivity at dawn are 
attributable to the effects of GH on peripheral glucose metabolism (Amiel 
1991). Prolonged hyperglycaemia appears to produce regular 100-min plasma 
insulin oscillations that entrains cyclic changes in peripheral glucose uptake, 
while hepatic glucose efflux was inhibited (Bowden 1980). More recent studies
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however show that presence of insulin secretion rhythmicity is independent of 
glucose variations (Bizot-Espiard 1998).
My results suggest that the nocturnal insulin requirements are triggered only by 
GH pulse signal. Although the total dose of r-hGH delivered was identical, 
continuous GH had no significant effect on changing insulin requirements 
(Table 6.5a) nor were free insulin levels any higher from control night during 
euglycaemic clamp (mean(SD) insulin 01-08h: continuous 17.9(6.7) m U /L  vs. 
17.16(7.2) control, Table 6.5b). This suggests that either raised GH pulse 
amplitude and/or GH pulsatility (pulse frequency) causes insulin resistance. 
Perriello in a study of subjects with Type 1 insulin-dependent diabetes mellitus 
came to similar conclusions although they compared the effects of basal versus 
basal and pulse GH administration (Perriello 1990). Removal of G H  pulses 
resulted in complete abolition of the increased rate of hepatic glucose 
production at dawn. Replacement of nocturnal spikes of G H  faithfully 
reproduced the increase in hepatic glucose production at dawn, supporting my 
findings of an increased insulin requirement to maintain euglycaemia occurring 
only during a GH pulse night.
My observations were that the GH pulse signal caused oscillating insulin 
requirements (Figure 6.6c). Oscillatory messages are common in physiology. 
Studies have shown well described oscillations in the insulin/glucose 
homeostatic mechanism with periods ranging from seconds to hours depending 
in part on their sampling intervals and duration of the study. Insulin release is a 
complex oscillatory process with rapid pulses superimposed on slower circhoral 
oscillations, but the exact negative feedback loop linking glucose and insulin 
secretion remains unclear. In the basal state, the plasma concentrations of 
insulin and C-peptide oscillate about a mean value in monkeys and man with a 
periodicity of 10-13min (Lang 1979). Oscillations with periods of greater than 
one hour have been described in the fasting and glucose-stimulated dog 
(Vanhelder 1980). Stimulatory effects of sleep on insulin secretion are achieved 
by an enhancement of the oscillation amplitude that could be partly mediated
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by GH. These different groups of oscillation periods probably reflect separate 
homeostatic mechanisms with different time courses. Their physiological 
importance and metabolic consequences are of emerging interest.
To examine if a temporal relationship existed between the GH pulses 
and the oscillating insulin requirements seen in my overnight studies, cross­
correlation analysis was carried out. In my studies maximum insulin 
requirements lagged behind peak GH levels by 135min (Figure 6.6d) but the 
change was evident by 120min and lasted 240min. Similarly, Moller (1992a) in 
a study of GH pulse on forearm substrate fluxes in humans showed a change in 
glucose uptake from lOmin which was sustained for 240min and maximal at 
120min. Levels of G H  achieved (21fxg/L=42mu/L) were slightly higher than 
those in my study (31.5 mU/L). However, this author could not support a 
primary role for surges of GH (up to 22 +2 pg/L, 444:4mU/L) in the 
pathogenesis of the dawn phenomenon (Moller 1992b). Their diabetic subjects 
were studied in the post absorptive state after an iv bolus of G H  with 
isotopically measured glucose turnover and forearm glucose uptake and other 
factors require consideration.
Fowelin and colleagues (1991, 1995) also showed that whereas lower 
GH infusion rates provoked a rise in insulin requirements which were maximal 
between 3 and 4 hours similar to my observations, higher G H  infusion rates 
induced changes which lasted up to 6-7 hours. Maximal effects were seen with 
plasma levels of 50 mU/L. Levels far in excess of these are often seen in 
adolescents with Type 1 diabetes. Thus as insulin efficacy is determined by 
amplitude, GH effects must also result from a modulation of the oscillation 
amplitude (Song 2000).
Matthews (1983a) showed that pulsatile insulin has greater 
hypoglycaemic effect in normal humans than continuously administered 
hormone and suggested that this effect might result from a greater insulin 
receptor binding. Komjati, 1986 observed a greater efficacy of pulsatile versus 
continuous insulin delivery in restraining glucose production from the isolated
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perifused liver and Bratusch-Marrain (1986a) showed that in insulin-dependent 
diabetics that pulsatile insulin delivery of a dose less than 40% has an equipotent 
effect on reducing hepatic glucose production as continuous administration.
In contrast, studies reported by Verdin, 1984, using the euglycaemic-clamp 
technique combined with 3-[3H]glucose turnover methodology, pulsatile 
insulin (resulting in peripheral plasma insulin levels oscillating between 10-45 
mU/1) and continuous insulin administration (mean plasma insulin levels of 29 
mU/1) exerted similar metabolic effects. In vitro studies have shown that after 
insulin receptor binding and internalisation into cells, insulin and the enzymatic 
processes involved in its degradation, can also influence the generation of 
insulin action (Seta 1997).
Matthews, 1990 has used cross correlation to demonstrate that the nadir of 
blood glucose occurs on average 45 minutes after an increase in insulin rate 
and that the maximal effect on rate-of-change of glucose occurs after 15 
minutes. The 45minute nadir is in accord with the human feed-back loop 
kinetics of the pancreatic-liver interactions, the 'hepa-beta' loop that oscillates 
with a period of 40-80 minutes ((Matthews 1983b). The physiology of insulin 
secretion in normal man, which shows pulsatility with a period of 13 minutes 
(Lang 1979) and the rapid oscillations of insulin secretion seem to be an 
inherent feature of the cellular mechanisms of insulin secretion since they 
persist in the isolated perifused pancreas and in perifused islets. In my 
studies, the 135min oscillation in insulin requirement induced by G H  pulses 
would be a signal appropriate to the harmonics of both the physiological 
insulin and glucose oscillations previously seen.
In Type 1 diabetic subjects, as increased GH pulses are prominent both 
during the day and after the onset of sleep, the endogenous GH pulses would 
continuously induce a refractory state of its insulin-like effects throughout the 
day and night. Therefore, studies describing the 'dawn phenomenon' as 
“diminished insulin sensitivity” (or increased insulin requirements) at specific
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time periods (120-240mins) after a G H  pulse may be a more appropriate 
standard convention for subjects in research studies.
Theoretically, the need for insulin could be attributable to an increase in 
plasma insulin clearance or a decrease in insulin sensitivity or even a 
combination of both. Some investigators have suggested that an increase in 
the metabolic clearance of insulin in the early morning, rather than a decrease 
in insulin sensitivity, is the primary cause of the dawn phenomenon 
(Arslanian 1992).
Insulin clearance rates in patients with Type 1 diabetes are reported as 
decreased (Hachiya 1987) or increased (Waldhausl 1985) or unchanged 
(Navalesi 1978) when compared with healthy control subjects.
When I examined the metabolic clearance rate for insulin in my subjects (Table 
6.5a), there was no significant difference between control and continuous GH 
nights (mean 5.1 and 5.6 m L/kg/m in respectively) and only slightly increased 
during pulse GH at 6.5 m U /kg/m in. Thus the changes in insulin 
requirements that I observed during pulse GH administration must primarily 
reflect a decrease in insulin sensitivity.
It is interesting to note that the overnight changes in insulin sensitivity 
seen during my overnight studies are short lived. In the studies of Perriello 
(1990), the difference in insulin action in the interval of 2400-0200, compared 
with 0600-0800, tended to disappear during the second hour of the clamp 
experiments. Under SRIH and euglycaemic clamp conditions in healthy 
volunteers, the presence of higher plasma insulin levels (80 _+6 vs. 39 4^ 5 
mU/L) caused the expected stimulation of both glucose oxidation and non- 
oxidative glucose uptake (Ferrannini 1989). Perriello (1990) showed that insulin 
sensitivity decreased at dawn compared to the early night hours attributed to 
mainly 30% increase in the rate of hepatic glucose production and 25% decrease 
in rate of glucose utilisation, there being no changes in plasma insulin clearance. 
In fact, the studies of Widmer, were performed in hyperglycaemic conditions 
(plasma glucose 7mmol/l) and it is well known that hyperglycaemic conditions
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can compensate for impaired insulin action by a mass-action effect (Gottesman 
1984). Thus, the increased insulin requirements at dawn must be solely 
attributable to a decrease in insulin sensitivity at this time of day (Bolli 1988).
More interestingly, a clear temporal relationship between the GH 
administered at 180-minute periodicity and the change in insulin requirement 
was noted in my studies. There was no relationship identified between other 
metabolic parameters and insulin requirements. During my studies in Chapter 
6, the pulse GH caused a rise in IGF-1 levels in the 4 subjects analysed, however 
in these respective subjects, IGF-1 levels did not change during 12 hour 
continuous GH infusion. Although IGF-I levels were higher on a pulse night, 
insulin requirements were higher too and ketones and free fatty acids were 
stimulated. As the time response of IGF-1 required is long, IGF-I could not 
have contributed directly to the metabolic changes that I observed following 
GH pulses. To support this further, a study using the hyperinsulinaemic 
euglycaemic clamp, insulin produced short-term increases in IGF-1 levels in the 
absence of a GH response (Grant, 1989). Therefore insulin changes purely may 
have accounted for the rise in IGF-1 levels seen on pulse G H  night when 
insulin infusion rates were higher than on either continuous G H  or control 
nights.
Although in normal subjects, the nocturnal rise of G H  did not appear 
to affect carbohydrate tolerance the following morning (Nielsen 1998), my 
observations in Type 1 diabetic subjects suggest that a decrease in insulin 
sensitivity is induced by nocturnal surges of GH secretion. The evidence 
from my studies suggests that the GH pulse signal is directly responsible for 
inducing insulin resistance. My studies confirm that G H  pulses (achieving 
peak plasma GH of 26.5-36.9 mU/L) provoke a rise in insulin requirements 
that are maximal 3 to 4 hours later. O ther authors have shown that G H  also 
has an amplitude mediated effect on insulin resistance in subjects with Type 1 
diabetes (Fowelin 1995) which induce changes lasting up to 6-7 hours. 
Furthermore, when examining GH secretion, adolescent subjects with Type 1
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diabetes have a shorter GH pulse periodicity than matched controls (Chapter 4) 
suggesting an increased number of G H  pulses.
Given that the number and amplitude of GH pulses overnight vary in 
many young people with diabetes, I would postulate that a greater pulse 
frequency would lead to a gradual incremental rise of insulin resistance 
throughout the night with maximal effects in the early morning. The effect of 
overnight acquisition of insulin resistance, by a combination of G H  pulse 
amplitude and frequency, is the summation seen in the dawn hours. The 
differential effects of GH peak and pulsatility would partly explain the variable 
observation of the dawn phenomenon in Type 1 diabetes.
The Pulse G H  Signal (amplitude and frequency) induces an oscillatory 
rise in insulin requirem ents causing acquisition of overnight insulin 
resistance.
(iii) Metabolites
In healthy normal subjects made insulin deficient by somatostatin infusion, 
when GH was administered blood glucose became grossly elevated along with 
plasma free fatty acid, ketones and glycerol levels (Metcalfe 1981). Similarly, 
when diabetic subjects, who had euglycaemia maintained with insulin infusion, 
were changed over to somatostatin and GH infusions, after only six hours, the 
GH concentrations became elevated and plasma ketone increased impressively 
while blood glucose remained unchanged (Gerich 1976).
(iv) Ketones
Whereas insulin sensitivity was related solely to pulse G H  administration, the 
effects on pOHB and acetoacetate were evident on both GH nights but were 
more marked on continuous GH nights (section 6.0.5; Figure 6.6e, Table 6.5c). 
Two-way Anova on log-transformed data confirmed that ketone levels changed 
with time between (20.00-08.OOh) on all study nights (F 5.95,p< 0.001) but had
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reached plateau levels between 01-08.OOh (F 0.7862, p=NS). The mean ketone 
levels were significantly different between the three study nights (F 83.56, 
p <  0.001) being most pronounced between continuous GH and control (F 
111.73, p <  0.001). High variation of ketone data was noted between subjects 
on pulse GH nights.
In previous studies Edge, 1993 noted that the overnight rise in pOHbutyrate in 
diabetics during an euglycaemic clamp correlated greater with basal rather than 
with pulse GH. However, Jorgensen, observed no differences between 
pOHbutyrate after pulsatile or continuous delivery of G H  to GH deficient 
subjects but insulin and glucagon levels were not controlled in their studies 
(Jorgensen 1990).
Normally, if sufficient insulin is available, much of the ketogenic 
activity of GH is suppressed (Gerich 1976). However, in my studies despite 
using a variable-insulin clamp that allowed optimum delivery of insulin to 
maintain euglycaemia throughout the night, GH signalled a rise in ketone 
levels, which remained elevated. As would be expected from the sensitivity of 
lipolysis to insulin, total ketone concentration initially fell rapidly (1900h) and 
sooner than the glucose concentration. However, following GH 
administration plasma ketones rose steadily from approximately 21.OOh (1 hour 
after continuous GH was commenced) and around 23.OOh (1 hour after first 
pulse GH given) until peak levels were reached between 01.00-02.OOh (3-4 hours 
after commencing GH). The level of ketones were sustained at this high level 
until 08.OOh (Figure 6.6e) and the mean fasting (08.OOh) total ketone levels 
were elevated (Control 209.9; Continuous GH 517,6; Pulse G H  380.8 
pmol/L). The fasting ketones were particularly marked during continuous GH 
administration and of similar magnitude to that reported in other studies (500 
pmol/1) in diabetic subjects.
However, the overnight pattern reported in previous studies is a rise of 
ketones around midnight followed by a fall around 04.30h (Wildenhoff 1972, 
Edge 1993). I noted no reversal even on pulse nights, although ketone levels
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were measured hourly. Furthermore, during studies in forearm substrate when 
a GH bolus is administered, an increase in pOHB occurs maximal at 2h and 
reversed by 4h (Moller 1990). In addition, a 70% increase in serum NEFA is 
seen after 180min and a 400% increase in 3-OH butyrate after 240mins (Moller 
1992a). The pattern I observed was a consistent rise of ketones following GH 
administration and persistence of elevated levels after 01.OOh to the high fasting 
levels seen at 08.OOh. This appears to be directly triggered by G H  alone in 
contrast to control study night.
Part of the explanation for the higher ketone levels noted on continuous 
GH nights may simply be due to the comparatively higher insulin levels 
measured on pulse GH nights. Sherwin (1976b) identified a 42% reduction of 
metabolic clearance rate of ketone bodies in diabetic subjects compared to 
control that may also contribute to hyperketonaemia. This reduced clearance 
reflects the progressive saturation of muscular uptake that occurs with 
increasing ketonemia. The hormonal and metabolic environment appears to 
play only a minor role in this process.
During progressive fasting in normal subjects, the production rate and 
concentrations of ketones rise during the early phase of fasting and reach a 
plateau after 5 days (when GH is maximal). The mechanism appears to be that 
as extraction of ketone bodies by muscle becomes limited during ongoing 
fasting, ketone are preferentially taken up by the brain to serve as a substrate 
replacing glucose. A negative feedback mechanism exists whereby ketone 
bodies restrain their own production rate through their antilipolytic and 
insulinotrophic effects (Moller 1990). Thus, ketones are homeostatically 
maintained only slightly above the maximal metabolic disposal rate, and the 
difference corresponds to the urinary excretion (Balasse 1989).
When Type 1 diabetic subjects are compared with fasting control subjects, some 
authors report that the ketone body kinetics are comparable and the maximal 
removal capacity is identical in the two situations (Fery 1985, Balasse 1989). 
However, when evaluating ketone body utilization in the muscle of fasted and
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steptozotocin diabetic rats, there was a markedly lower muscle enzyme activity 
of 3-oxoacid CoA transferase which prevented ketone body uptake in diabetic 
rats (Okuda 1991) compared to fasted rats. The presence of raised ketone levels 
during either situation inhibited both glucose utilization and decreased the 
phosphofructokinase activity in muscles (Okuda 1991) encouraging oxidation 
of ketones as an energy source rather than glucose. This provides a mechanism 
for ketoacidosis. Hyperglycaemia, through substrate competition at the acetyl- 
coenzyme A level, could also theoretically decrease the disposal rate for ketone 
bodies. However, even during hyperglycaemic clamp conditions in subjects 
with Type 1 diabetes, no inhibitory role for hyperglycaemia in the disposal of 
ketones was identified (Moller 1990). These data therefore suggest that an 
excessive production of ketone bodies is the cause of persisting uncontrolled 
hyperketonaemia. A production even slightly above that in prolonged fasting 
is sufficient to cause a progressive build-up in concentration because of reduced 
ketone body uptake by muscle (reduced 3-oxoCoAT and saturation-limited). 
The oxidation of ketone bodies inhibits phosphofructokinase activity and 
glucose utilization in muscle. The mechanism of increased ketones seen in my 
studies therefore appears to be that G H  is directly responsible for the initial 
excessive production of ketones. When clearance of elevated ketones is limited 
by saturated muscle extraction, this leads to a progressive build-up manifesting 
in sustained and elevated levels throughout the night.
Recent concern is the role that ketones may have on the brain. When 
measuring brain |30HB and lactate in fasted adults, plasma and brain pOHB 
correlated well (r=0.86) (Pan 2000). This implies that the influx of ketone 
bodies into the brain is largely determined by the amount of ketones present in 
the blood (Hasselbalch 1995) which is of great concern when ketones rise above 
normal in Type 1 diabetes. Furthermore, recent work in mouse brain suggests 
that ketones may directly affect the blood-brain barrier impermeability as they 
have shown that pOHB can increase vascular permeability factor in endothelial 
cells and acetoacetate increases the production of the potent vasoconstrictor,
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endothelial-1 (Isales 1999). These effects have been noted clinically in paired 
control experiments m normal volunteers where infusions of pOHB and lactate 
increased the threshold for initiating hypoglycaemia and reduced the magnitude 
of autonomic and neuroglycopenic symptoms, poor counter-regulatory 
hormone responses and cognitive dysfunction (Veneman 1994). Elevated 
ketones may be responsible for the defective counter-regulation causing 
prolonged nocturnal hypoglycaemic episodes reported in children with diabetes 
(Matyka 1999).
(v) Lactate
Lactate is an indicator of cellular energy metabolism. Normally an increase in 
lactate results from ketones displacing lactate oxidation without altering glucose 
phosphorylation and glycolysis, but I observed a fall of lactate: Concentrations 
fell during the night on all three occasions but were slightly higher on pulse 
G H  night. During normal activity in Type 1 diabetes blood lactate levels are 
usually below 2mmol/l (Alberti 1975).
Oscillatory organisation between insulin, insulin sensitivity, glucose and 
lactate were examined in 24-hour profile from healthy volunteers (Feneberg 
1999). Lactate fluctuations exhibited pulsatile fluctuations at an average of 73- 
95minutes during the day and night, and showed temporal and pattern 
synchrony with insulin pulses (periodicity of 75-97minutes) and this was 
inversely correlated to insulin sensitivity. I could not detect any oscillation 
with lactate levels, apart from a mild elevation towards the early morning on 
a pulse G H  night when there was changing insulin sensitivity.
Blood lactate may rise in response to decreased hepatic uptake for 
gluconeogenesis or increased production. Following insulin, hepatic uptake 
does not change but gluconeogenic precursors are diverted into glycogen. As 
optimal insulin replacement was provided and euglycaemia maintained, this 
might account for the lower levels of lactate measured.
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(vi) NEFA
Lipolysis is very sensitive to low concentrations of insulin and it was surprising 
to record during my overnight euglycaemic clamp studies, when optimum 
insulin was supplied, that both ketones and NEFA rose in response to GH 
(Figure 6.6e).
A recent study by Avogaro 1992 looking at the effects of low (20 pU /m l and 35 
pU/ml) and high (70 pU/ml) plasma insulin concentrations on ketone and 
lipolytic responses when stimulated by adrenaline in Type I diabetic patients, 
showed increased ketogenic response and normal NEFA response at low 
insulin levels but high insulin levels were able to suppress ketogenic responses. 
My overnight studies showed moderate levels of plasma insulin levels during 
euglycaemic clamp (pulse GH night: 26.53+ 3.01 m U /L  vs. control 17.16j+ 
0.42 (p=0.01) and continuous G H  17.88+^ m U /L (p=0.01) yet a rise in 
free fatty acids were seen on both G H  nights.
During my studies, mean (ASEM) plasma free fatty acids were increased 
primarily during continuous GH (1.09 _+0.07 mmol/L) compared to both 
control (0.61 +.0.05, p = 0.001) and pulse GH (0.94 jf 0.04, p = 0.003) suggesting 
that a raised continuous level of GH is the primaiy message that stimulates 
lipolysis.
Previously, authors have considered that a direct lipolytic effect of GH 
is not seen in human fat cells in-vitro (Goodman 1970). In contrast, other 
workers have shown that a G H  pulse of 200microgram (=400mU) can induce 
peak interstitial glycerol levels locally in adipose tissue after 135min (femoral 
adipose) and 165min (abdominal adipose) which is not reflected in plasma 
glycerol (or NEFA) level changes (Gravholt 1999). This also confirms the 
direct action of GH pulse on lipolysis.
Along with these observations, in vitro studies of the actions of GH in adipose 
cells initially produced conflicting results of a lipolytic effect (Richelsen 1997, 
Carrel 2000). Further studies in cultured 3T3-adipocyte cell line, which 
provides an appropriate model for the study of short and long-term effects of
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GH, indicate that GH has a dual effect on adipocytes depending on the 
duration of exposure. Acute exposure increased glucose uptake and utilisation 
by 3T3 adipocytes, whereas an extended incubation of 24-48 hours induced a 
suppression of glucose metabolism (Schwartz 1985). O ther studies indicate that 
GH modulates the lipolytic actions of other stimuli and has a modest direct 
lipolytic activity (Berneis 1996, Goodman 1991). In contrast in one study, a 
short incubation with GH produced a transient antilipolytic effect (Dietz 1991), 
The mechanisms underlying the dual effect of GH are presently unknown. 
Experiments in rats suggest that NEFAs reduce hepatic insulin uptake and 
insulin degradation (Svedberg 1990). In humans NEFAs have been shown to 
alter hepatic insulin clearance and have been implicated in the reduced insulin 
sensitivity associated with Type 2 diabetes (Boden 1997). More recently, 
NEFAs also have been thought to regulate hepatic glucose metabolism and 
mediating the actions of insulin on the liver (Cherrington 1998, Piatti 1999). 
Lipid-induced insulin resistance has been investigated in normal subjects using 
euglycaemic and hyperinsulinaemic clamp, with or without heparin-induced 
lipolysis after infusing triglyceride emulsion compared to control. Peripheral 
insulin resistance was observed in the presence of a combined increase in total 
lipid and NEFA oxidation, but not during an isolated increase in NEFA 
oxidation whereas hepatic insulin resistance could be induced even by a 
moderate increase in NEFA availability (Laville 1995).
Studies on forearm glucose uptake shows that the activity of the glucose-fatty 
acid cycle is stimulated at physiological plasma NEFA levels at both 
hyperglycaemic and euglycaemic blood glucose concentrations but NEFA 
activity causes a decrease in peripheral insulin sensitivity only during 
euglycaemia (Walker 1991). Although NEFA levels were higher than control 
on both pulse and continuous GH study nights, insulin requirements only 
changed on pulse GH night.
During my studies glucagon was infused on both study nights. 
Chambrier, (1990) in their study of the interactions of glucagon and free fatty
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acids with insulin on glucose production and utilisation in normal subjects 
infused with somatostatin, showed that the maintenance of glucagon level Had 
only small and inconsistent effects on glucose utilisation but induced a shift to 
the right of the dose response curve to insulin of endogenous glucose 
production (ED50: SRIH +insulin 10.9 mU/1; SRIH+ insulin + glucagon 15.2 
mU/1). Addition of intralipid infusion resulted in almost total suppression of 
the insulin-induced increase of glucose utilisation whether glucagon was 
substituted or not. In the absence of glucagon, intralipid infusion antagonised 
the action of insulin on endogenous glucose production, however this effect was 
no longer apparent when glucagon was replaced. This may explain my studies 
as I did not observe an association between NEFA levels and insulin 
requirements on either GH nights.
Irrespective of mechanisms, the elevated NEFA levels may lead to a decreased 
glucose utilisation during moderate hyperinsulinaemia and thought to mediate 
the insulin resistance in Type 2 diabetes (Bergman 2000a).
In 1965 Randle demonstrated that fatty acids compete with glucose for substrate 
oxidation in isolated rat heart muscle and rat diaphragm muscle. This model 
predicted an increase in muscle glucose-6-phosphate and mechanisms that 
suggested a limitation of glycolysis (Randle 1998). More recent studies using 
euglycaemic, hyperinsulinaemic conditions with either high or low levels of 
plasma fatty acids, showed that by increasing plasma fatty acid concentration 
for 5 hours, this caused a reduction of approximately 50% in insulin-stimulated 
rates of muscle glycogen synthesis and whole body glucose oxidation compared 
to normal control subjects and found a fall in intramuscular glucose-6- 
phosphate (Roden 1996)
This suggests that increases in plasma fatty acid concentrations initially induce 
insulin resistance by inhibiting glucose transport or phosphorylation activity 
and that reduction in muscle glycogen synthesis and glucose oxidation follows 
(Dresner 1999).
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The complex GH rhythms of diabetes mimic those of fasting where a sustained 
rise in free fatty acids is also seen with the change in G H  pattern (Ho 1988). 
Some recent work in animals show that the influence of dietary intake level 
alters protein (leucine) and paimitate/NEFA flux rates to a GH bolus. Animals 
fed on the lowest intake (0.8 of maintenance energy requirement given hourly) 
showed an immediate response to GH (within 3 hours of administration) with 
increased plasma NEFA. However, appropriately fed (1.2-2.65 x maintenance 
energy requirement) showed a markedly reduced response that was not 
apparent for 22-24 hours (Dawson 1998).
As lipid metabolism is differentially responsive to G H  and nutritional status, 
the endocrine adaptation in diabetes parallels the physiological state of 
“starvation” inducing exaggerated NEFA responses to G H  pulses.
Overnight GH either administered as a continuously elevated GH (8.6- 
10.8mU/L) or discrete 60minute pulses of GH (26.5-36.9 mU/L) will 
initiate ketogenesis and lipolysis that contributes to the metabolic 
deterioration in subjects with Type 1 diabetes. Pulses of GH independent 
of other mediators induce peripheral insulin resistance.
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CHAPTER 7
INTEGRAL MESSAGES: FINAL CONCLUSIONS
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INTEGRAL MESSAGES: FINAL CONCLUSIONS
Previous theories related metabolic problems in adolescents with Type 1 
diabetes simply to hyperglycaemia. A number of altered metabolic states such 
as insulin resistance, increased ketones and fatty acids and elevated GH are now 
implicated.
During puberty G H  pulses are often exaggerated (peak amplitude, mean 
and trough) in Type 1 diabetes compared to control subjects. I have shown that 
a combination of decreased GH clearance and increased G H  secretion exists in 
adolescents with Type 1 diabetes. Part of the neurosecretory alteration causing 
increased GH secretion appears to be that an increased cholinergic tone is 
present causing increased peak GH responses to G H RH  stimulation. O f 
greater interest is the cause of the raised trough GH level, which is determined 
by alterations in SRIH tone. I have proposed the hypothesis that 
hyperinsulinaemia may antagonise somatostatin suppression of GH, 
contributing to the higher mean and trough GH levels seen.
Disorganised or elevated serum GH concentration profiles with 
alterations in trough concentrations are characteristic of the physiological 
adaptation in fasting or starvation (Ho 1992, Hartman 1996). Elevated GH 
levels are seen in other pathological models of nutritional deficiency, such as 
anorexia (Laughlin 1996, Stoving 1999). As oscillatory organisation is an 
universal mode of signal transduction representing major functional process in 
biological rhythms, there should be a rational basis for this type of GH 
secretory profile. Therefore when searching for the reason and cause of the GH 
pattern alteration in Type 1 diabetic subjects, the evidence may be found within 
the model of fasting.
Starvation-induced enhancement of GH production rate in normal 
healthy adults is seen after two days of fasting and is related to an increased GH
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burst frequency, increased GH amplitude and shorter periodicity (fasted 
subjects 88 j+4.2 versus fed subjects 143 J^14 minutes) (Hartman 1992, 
Bergendahl 1999). I noted a similar alteration in G H  periodicity when 
examining spontaneous GH secretion in adolescent subjects with Type 1 
diabetes compared with controls (normal puberty-matched).
Exploration of the signals for cell metabolism suggests the pattern of 
pulsatile release of a hormone may code important signals for their target 
organs (Pan 1997). Pulses of insulin are certainly more efficacious in altering 
glucose flux. I have shown that the GH pulse signal is solely responsible for the 
recruitment of insulin resistance overnight and postulated that overnight insulin 
would rise incrementally either with a changing GH pulse amplitude or altered 
GH pulse frequency. The 90-minute GH periodicity of secretion found in my 
diabetic subjects in Chapter 4 and seen during starvation would be an 
appropriate harmonic for the oscillatory release of insulin from intact beta cells 
of the islets, when these are present and responsive in the functioning pancreas.
My studies from Chapter 6 confirm that even during euglycaemia and 
adequate insulin supply (during clamp conditions), the decreased insulin 
sensitivity seen in adolescents with diabetes are caused directly by the pulses of 
GH. From my studies the GH pulses given overnight at 180-minute cycles, 
induced a pulsatility of insulin resistance that occurred with a lag phase of 
135minutes. As insulin requirements oscillated during these glucose-damp 
studies, were insulin requirements to remain stable, a rise and fall of blood 
glucose in an oscillatory fashion would be observed.
In-vitro studies suggest that spontaneous fluctuations of intracellular energy 
metabolism also occur with oscillatory changes of glucose. Recent work has 
shown that in vivo oscillations in glucose at significantly high doses of 6 
m g/kg/m in for 10 minutes caused synchronised pulsatile insulin release in 
normal subjects. Glucose flux may be an important regulator of pulsatile 
insulin secretion in normal subjects. Thus, intermittent G H  pulses, evokes 
oscillations in glucose (or insulin requirement) of 135minutes, which would
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stimulate recurrent insulin secretory signals at the phase-harmonic of 45mins, as 
that reported for insulin action. It appears that during starvation pulses of GH 
at 90minute periodicity occur to induce alterations in glucose and insulin flux 
for energy utilisation. In Type 1 diabetes this manifests as insulin resistance and 
rising glucose levels in the face of depleted or inappropriate timing of insulin 
replacement.
The optimum duration of the pulsatile signal and the optimal interval 
between successive pulses vary as a function of the rates of receptor 
desensitisation or resensitisation and of the maximal ligand level during 
stimulation (Goldbeter 2000). G H  has a changing half-life critically dependent 
on duration of exposure following an asymptotic relationship. I have shown 
that in adolescents with Type 1 diabetes this half-life is prolonged compared to 
controls at all exposures, and reaches a maximum half-life of 28.5minutes above 
60minutes GH exposure. Neither short-term hyperglycaemia, normoglycaemia 
nor hyperinsulinaemia affect these GH decay characteristics.
Studies in the rat have established that the pattern of GH administration is a 
significant determinant of GH receptor status. Maher (1988) reported that 
hepatic receptors of hypophysectomised rats were upregulated when the 
hormone was administered as a continuous infusion but not as multiple 
subcutaneous injections. Furthermore, these investigators have reported similar 
changes in serum GHBP activity in rats from the same study, that is an increase 
in GHBP activity occurred only with continuous administration (Maher 1992). 
These animal data raise the question as to whether GHBP levels in man might 
also be modulated by the pattern of delivery.
There is a major difference regarding the origin of GHBP in rat and 
man. In the rodent, GHBP and the GH receptor have been shown to be 
separate products of two distinct messenger RNA’s derived from a single gene 
encoding the GH receptor (Baumbach 1989, Smith 1989b). However GHBP 
mRNA but not GH receptor mRNA was increased by continuous G H  
infusion suggesting that the effects of continuously elevated GH on GH
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receptor and GHBP gene expression have differential effects at transcriptional 
and translational level (Maiter 1992). In fact the rat’s insulin is directly 
involved in the GH receptor expression (Chen 1997). A separate transcript for 
GHBP has not been reported in humans and therefore this protein is likely to 
be derived from proteolytic cleavage of the GH receptor (Baumann 1988). 
Consequently GHBP levels in man reflects a parallel change in G H  receptor 
status. More recent work has allowed the determination of GHBP in plasma, 
which is reported with a half-life of 30mins and suggests that the GHBP is the 
critical limiting ligand for G H  clearance. This is consistent with the maximum 
half-life of G H  measured in my diabetic subjects in Chapter 3. Thus, the GH 
clearance mechanism is fully saturated and maximised in diabetic subjects.
Although muscle could be a potential tissue for G H  clearance as the 
presence of GH receptor mRNA in skeletal muscle is established, most 
investigators have been unsuccessful in demonstrating any specific binding of 
G H  to skeletal muscle or to myoblasts in culture. It has been equally difficult 
to show direct actions of G H  on cultured muscle cells; GH stimulates 
expression of IGF-I genes in skeletal muscle, although there are a number of 
cases in which skeletal muscle IGF-I expression is elevated in the absence of 
GH. The actions of G H  on muscle may thus be predominantly IGF-1 
mediated. The only positive report concludes that the early insulin-like 
effects of GH can result from direct interactions between G H  and isolated 
muscle cells (Florini 1996).
During starvation, a possible mechanism might be that the growth- 
promoting actions of GH are reduced as fuel must be diverted towards 
nutritional energy need. The continuously raised G H  level may upregulate 
GHBP (hence desensitises GH receptors) resulting in a relative G H  resistance. 
The mechanism in Type 1 diabetes could parallel starvation and as such, this 
G H  receptor resistance, delays clearance compounding the high GH levels 
already present. The elevated G H  in diabetic subjects may be due to hepatic 
resistance to GH induced by the presence of continuous G H  and saturated
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GHBP. Reduced IGF-1 generation together with increased hepatic production 
of IGF-1-binding protein-1 (IGFBP-1) leads to reduced levels of circulating IGF- 
1 and further stimulation of GH production. Increases in G H  secretion and 
serum IGFBP-1 may compound the problem of imperfect insulin replacement 
both by inhibiting insulin action and by reducing available insulin-like activity. 
Thus, the signal of a continuously raised baseline GH downregulates its own 
receptors causing GH resistance, further stimulating GH release and worsening 
insulin resistance.
The continuous signal diverts GH action towards ‘nutrition 
conservation’ as during starvation. My observations suggest that a raised G H  
of 8.6-10.8 m U /L provides a continuous GH signal to enhance ketones, both 
from hepatic induction and stimulation of lipolysis. The picture of insulin 
resistance is made more complex by these metabolites. Patti et al (1999) have 
shown that nutrients (fatty acids or amino acids) inhibit early post-receptor 
steps in insulin action both in vitro and in several in vivo models. These data 
suggest that nutrients directly modulate insulin signalling, perhaps via 
common pathways with GH, and contribute to cellular insulin resistance 
experienced by diabetic subjects.
Marked hyperketonaemia was seen on both GH nights compared to 
control study night. Although in healthy subjects hyperketonaemia has been 
shown to have no effect on basal glucose production or the suppression of 
hepatic glucose production following hyperinsulinaemic euglycaemic clamp 
(Bratusch-Marrain 1986b), experiments in the rat show that after prolonged 
ketone exposure there is a depression of insulin-stimulated glucose oxidation 
which lasts for 4 days (Skutches 1990). This implies that the prolonged insulin 
resistance seen in fasting and Type 1 diabetes could also be attributed to the 
metabolic influence of ketones. In a further study, elevation in ketone levels in 
dogs was shown to directly affect glucose and free fatty acid metabolism 
independent of changes in insulin and glucagon levels or when sympathetic 
activity was blocked by a  and p blockade (Shaw 1984). However, work in the
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rat pancreas has shown that perfusion with only supraphysiological 
concentrations of pOHB and acetoacetate (10 mmol/L) produced increases of 
insulin release of any significance during normoglycaemia, but lower 
physiological levels of ketones (0.1-lmmol/L) did not stimulate insulin release. 
This suggests that in diabetic subjects that the ketones levels observed in my 
studies would not alter insulin requirement. Furthermore, as ketones at both 
levels do have a direct inhibitory effect on glucagon secretion from perifused rat 
pancreas (Ikeda 1987), the role of ketones is mainly through their action on 
depressing glucagon. I thus conclude that in my subjects with Type 1 diabetes, 
raised ketones, although are important in contributing to impaired response of 
glucagon to hypoglycaemia, is unlikely to influence insulin-resistance seen in 
my studies.
Non-esterified fatty acids (NEFA) act as an important signal as well as a 
metabolic substrate. Numerous data now suggest that non-esterified fatty acids 
(NEFA) can act without any metabolic modification as second messengers or 
modulators of the complex signalling network, and include amplification, 
inhibition or signal redirection affecting molecular, tissue and organ situations 
(Nunez 1997). For example, it has been considered that the primary route by 
which insulin maintains control over glucose production is indirect and is 
mediated by the regulation of non-esterified fatty acid release from the 
adipocyte (Bergman 2000b). The glucose-stimulated insulin secretion is ablated 
in fasted rats when an antilipolytic agent, nicotinic acid, is administered 
concurrently but unaffected in fed rats suggesting a powerful interaction 
between glucose and fatty acids (Stein 1996).
My observations confirm that the insulin requirements changed only on 
pulse GH study night but an increase in NEFA was seen on both GH nights, 
with a higher measured NEFA level on continuous GH night. My conclusion 
is that insulin resistance seen overnight was therefore unlikely to be related to 
changes in NEFA. I propose this was elicited directly by GH. Furthermore,
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the phase-lag of insulin resistance oscillated with the G H  pulse while the 
pattern of NEFA changes was unrelated to this insulin resistance.
In support of my findings, a recent report suggests that free fatty acids 
also oscillate frequently 6-8.5mins but this was independent of any insulin 
oscillations and more likely to be central nervous system controlled (Getty
2000). In contrast to my findings, studies in healthy adults during euglycaemic 
hyperinsulinaemic clamp show that GH mediates the reduction of insulin effect 
on the liver, but G H  action on glucose and lipid oxidation is indirectly mediated 
by its lipolytic activity (Piatti 1999).
NEFA can regulate glucose utilisation in muscle and are important 
signals to the liver and intact beta cells. To evaluate whether stimulation of 
lipolysis affects the induction of insulin resistance by GH, studies using 
Acipimox, a nicotinic acid analog that inhibits lipolysis, show that when basal 
rates of lipid oxidation were suppressed, basal glucose oxidation rates were 
lower with GH alone compared with GH+acipimox. This suggests that the 
insulin antagonistic actions of GH are causally linked to the activation of 
lipolysis (Nielsen 2001). However, Nielsen (2001) also noted that G H  may 
induce some residual insulin-resistance through a non-NEFA-dependent 
mechanism.
Other studies in the rat have shown that GH infusion did not alter free fatty 
acids or insulin levels but in contrast, decreased insulin-stimulated glucose 
uptake by 32%, glycolysis by 27% and glycogen synthesis by 40% (Kim 1999). 
The suppression of glycogen synthesis implies that metabolic impairment 
precedes and causes development of peripheral insulin resistance, independent 
of either free fatty acids or insulin. These findings and my observations suggest 
that GH has a direct cellular and molecular mechanism eliciting the insulin- 
antagonistic effects of GH which are independent of both plasma free fatty 
acids and insulin, but the role of fatty acids takes effect in certain metabolic 
circumstances.
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In vivo administration of G H  induces lipid oxidation and enhances 
lipolysis but it is unclear whether GH directly promotes this or increased 
NEFA levels drive it. Interesting work by Leung (1997) using an in-vitro 
bioassay for assessing beta-oxidation of fatty acids in mitochondria, found that 
GH directly stimulated fatty acid oxidation, whereas large doses of IGF-I (up to 
250 nmol/L) had no effect. Further evidence is emerging about the direct 
lipolytic effect. The 20K hG H  might show higher lipolytic activity than 22K 
hG H  in adipose tissue, particularly as 22K hGH produces a large amount of 
GHBP (Asada 2000). Analysis on inhibition and phosphorylation of signalling 
molecules suggested that GH-induced lipolysis stimulation is dependent on gene 
expression and mediated through a pathway which, when activated, continues 
for 48 hours (Asada 2000). These data suggest that GH activates lipolysis and 
NEFA release, but continuously raised NEFA levels may be promoted by a 
different mechanism.
The effects of insulin on serum lipids as a substrate are complex. Insulin 
normally inhibits adipose tissue lipolysis and decreases free fatty acid into the 
plasma. Schade and Eaton (1977) showed that glucose production and lipolysis 
were suppressed at a dose of insulin of only one-tenth that needed to stimulate 
glucose uptake. There is however, stimulatory effects of insulin on hepatic 
lipogenesis and estérification of free fatty acids to form triglycerides. The 
metabolic processes are thus intricately influenced by different concentrations 
of insulin. Independently G H  triggers both lipolysis, releasing free fatty acids, 
and encourages insulin resistance. Conversely, free fatty acids tend to exert 
their effects by modulating hormones, particularly insulin, and also ketones, 
but by a different mechanism (Fery 1996).
The neuroregulation of G H  secretion and the state of the adipose tissue 
reserves are also closely related. The mediators of GH regulation exerted by the 
adipose tissue are not clearly understood, but both free fatty acids and 
adipocyte-produced hormone leptin have been identified (Pombo 1999, Astorga 
1999). Experiments conducted to determine the effect of free fatty acids and
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glucose treatment on GH and LH secretion in the pig suggested that the 
number of GH pulses were only increased by free fatty acids infusion. This 
indicates that free fatty acids is likely to be a more effective modulator of GH 
secretion than acute hyperglycaemia and may account for the change in GH 
pulsatility during nutritional conservation.
A rise in free fatty acids normally blocks GH secretion. This action is rapid, 
dose-related and exerted at the pituitary level with no evident hypothalamic 
participation. The adipocyte produced hormone leptin has no direct action on 
the pituitary and its action at the hypothalamus is mediated by neuropeptide Y 
which is the final step in reducing somatostatin tone, which in turn would 
cause elevated trough levels of GH. Thus free fatty acids normally exert an 
inhibitory feedback action on GH secretion in physiological conditions. 
However, evaluation of the starvation model suggests that even in the presence 
of enhanced lipolysis, high plasma GH levels still exist with enhanced 
pulsatility. The high GH levels trigger lipolysis and further NEFA release. The 
mechanism of GH control therefore does not appear to be influenced by an 
inhibitory feedback from NEFA levels during starvation or in diabetes. This 
suggests that either that the pituitary is unresponsive to increases in NEFA or 
pituitary antagonism by another factor exists or that the set point for response 
is altered.
When trying to resolve this matter, we can look to other studies to provide 
various pieces of evidence. In subjects with anorexia nervosa, authors have 
shown that the somatotroph sensitivity to the inhibitory feedback action of 
NEFA is still preserved (Gianotti 2000). I conclude therefore that despite the 
markedly raised NEFA levels seen in Type 1 diabetic subjects, NEFA levels are 
not able to influence GH regulation, with neither a role in G H  stimulation or 
in promoting GH suppression. An alternative factor has a superior influence on 
GH causing direct pituitary antagonism (pituitary resistance to SRIH) or 
preventing SRIH action on G H  suppression.
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Discussions in chapters 4 and 5 arising from my observations suggest that in 
diabetic subjects a reduced somatostatin tone is present because of cholinergic 
overactivity. This may persistently exist due to alterations in the expression of 
SRIH or G HRH mRNA or the pituitary GH-receptor in specific areas in the 
anterior pituitary as demonstrated in both poorly-controlled or well-controlled 
diabetic rats (Busiguina 2000).
In contrast with humans, metabolic perturbations such as food deprivation and 
diabetes mellitus normally lead to G H  suppression in the rat, partly due to 
increased somatostatin tone. A significant reduction (50-80%) in SRIH receptor 
concentrations occurs in the hypothalamus and anterior pituitary gland within 
5-7 days of induction of diabetes in the rat (Pesce 1994, Berelowitz 1995). 
Hypothalamic and pituitary SRIH receptor levels remain lowered in these 
diabetic rats despite chronic insulin replacement that restored plasma GH levels 
(Pesce 1994). Altered pituitary somatostatin receptor expression in food 
deprivation and diabetes could develop as a result of chronic exposure to 
increased plasma somatostatin causing desensitization of SRIH receptor binding 
(Berelowitz 1995, Bruno 1994). These animal observations indicate that 
pituitary sensitivity to somatostatin may be altered in Type 1 diabetic patients.
The treatment of diabetes with inappropriately high insulin doses may 
also affect somatostatin sensitivity. Hyperinsulinaemia may arise inadvertently 
when trying to overcome insulin resistance in the diabetic patient. I have 
shown that hyperinsulinaemia is correlated with decreased G H  suppression in 
the presence of a constant somatostatin infusion. Insulin is known to be 
stimulatory to GH production either directly or indirectly. A mechanism can 
be postulated that links long term changes in SRIH receptors with chronically 
raised insulin levels. Additive to this is the absence of normal GH negative 
feedback. GH is known to regulate its own synthesis and release by altering 
expression of key hypothalamic neuropeptides and by modulating the 
sensitivity of the pituitary to hypothalamic input by regulating pituitary 
receptor synthesis. In animal models (the GH receptor/GHBP gene-disrupted
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mouse) when IGF-1 levels are low and the circulating G H  levels are high 
because of lack of negative feedback, both hypothalamic and pituitary 
expression is altered to favour stimulation of GH synthesis and release (Peng
2001). In particular, both hypothalamic and pituitary G H RH  was elevated 
whereas SRIH levels were reduced.
Thus, a complex combination of anatomical and physiological alterations 
within the pituitary, hypothalamus and receptors take effect early in diabetes, 
and left uncorrected, become irreversible and hence unresponsive to normal 
metabolic influences, leading to hypersecretory G H  state. Normalisation of 
glucose has no influence on improving this GH hypersecretion. Raised NEFA 
does not suppress G H  release. Replacement of insulin in the face of persistently 
raised GH levels leads to the additive role of hyperinsulinaemia. Insulin 
antagonises SRIF action and may be stimulatory to GH with further 
exacerbation of plasma GH levels and a deteriorating metabolic state.
The combination of raised GH levels, insulin resistance, 
hyperinsulinaemia and metabolic alterations with elevation of ketones and 
NEFA may all influence longer term problems in diabetic subjects. Raised GH 
levels may be involved in the development of proliferative retinopathy either 
directly (through its effects on arterial medial cell growth) or indirectly by its 
production of IGF-1 which has potent mitogenic effect (Pfeiffer 1995). The 
significance of the G H /IG F system in the development of diabetic kidney 
disease is also emerging (Flyvbjerg 1997, Baud 1999) requiring to identify new 
targets for a therapeutic approach in glomerular disease. Acute ketosis is also 
associated with a disturbance of endothelial function that is independent of 
hyperglycaemia (Avogaro 1999). Recent studies have suggested that ketones 
may increase lipid peroxidation (fain 1999) and this elevated cellular lipid 
peroxidation may play a role in the development of cellular dysfunction and 
other complications of diabetes. Furthermore, insulin resistance and poor 
metabolic regulation consequent to G H  hypersecretion are believed to also 
accelerate the development of diabetic angiopathy (Orskov 1996).
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Although GH has long been known as a regulator of body growth and 
metabolism, its mechanism of action at the cellular level has been elusive. 
Various signalling molecules, proteins and hormones work together to elicit its 
diverse effects (Carter-Su 1996, Thomas 1998). This Thesis confirms that the 
qualitative alterations in the G H  pulse signal and the subsequent metabolic 
alterations seen in the diabetic state are parallel to the alterations seen during 
human starvation. Metabolic decompensation is thought to contribute to 
ongoing radical and oxidative stress with the increased risk of complications 
(West 2000). These combined effects may be deleterious to the insulin- 
dependent diabetic patient, in whom increased G H  may precipitate and 
maintain acute metabolic derangement and play a role in long tern 
consequences.
Observations in this Thesis postulate the mechanism for the metabolic 
deterioration seen in adolescents with Type 1 diabetes. Raised GH pulse 
amplitude and increased G H  pulse frequency encourages insulin resistance. As 
a consequence hyperglycaemia, ketosis and lipolysis ensue, each independently 
fuelling metabolic alteration. Hyperglycaemia and insulin resistance also 
encourages the use of large doses of exogenous insulin in an attempt to 
overcome these problems, leading to a hyperinsulinaemic state. Consequent to 
this, hyperinsulinaemia antagonises somatostatin suppression of GH, directly 
or indirectly and this combined with the alterations in somatostatin receptors 
and cholinergic imbalance, leads to chronically reduced SRIH tone in diabetes. 
This interaction provides a vicious cycle of insulin-induced insulin resistance, 
via the promotion of persistently elevated levels of GH.
Unravelling the complex interactions of hormones and metabolites will allow 
the clarification of the spectrum of distinct metabolic sequelae. The partnership 
of investigative and therapeutic strategies aims to diminish metabolic 
complications until a cure is found.
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APPENDIX 1.0 
METHODS OF ESTIMATING ENDOGENOUS GROWTH 
HORMONE SECRETION
The pattern of pulsatile release of the hormones may be important as a signal 
for their target organ. The formulation of algebraically explicit biophysical 
models of G H  secretion and clearance has made possible a complete 
quantitative description of GH secretory and clearance dynamics. Such 
analytical tools allow investigators to enumerate with statistically bounded 
confidence limits the number, amplitude, duration, and temporal locations of 
all significant underlying secretory bursts and simultaneously calculate the half- 
life of endogenous GH disappearance from all GH concentrations and their 
variances considered together. In conjunction with contemporary refinements 
in GH assay techniques, such novel approaches to dissecting the temporal 
structure of GH secretion and clearance in vivo should result in significantly 
enhanced understanding of GH dynamics in health and disease (Veldhuis 
1988a).
Deconvolution Analysis
I provide the principles of these methods in this appendix should you wish to 
compare other methods to the model I have chosen to use in my studies in 
Chapter 3.
A 1.1 Method of Thompson (THOM)
This method estimates the total amount of secretion over a period of time 
without considering the secretory pattern. The theoretical background has 
been described by Tait since 1963 (Tait 1998) and assumes that metabolic 
clearance is constant and independent of plasma hormone concentration. For 
GH, these criteria are assumed to be met (MacGillivray 1970, Taylor 1969, 
Jorgensen 1989).
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The equation is as follows:
Secretion (mU) = MCR (l/min).time {min).ICGH (mU/1)
The term [ICGH.time] is identical to the area under the plasma concentration 
curve (AUG), which can be calculated with the trapezoidal rule. As G H  
clearance has been shown to correlate well with body surface area 
(MacGillivray 1970) MCR can be expressed in litres/day.m2. An MCR of GH 
of 179 litres/day.m2 has been chosen for some studies based on a weighted 
mean of 5 studies (Taylor 1969, MacGillivray 1970, Thompson 1979, Baumann 
1979). Most of these studies were performed in adults, but in children similar 
values have been found (MacGillivray 1970). BSA can be calculated according 
to Dubois & Dubois although more recent estimates to improve accuracy have 
been suggested (fones 1985).
A1.2 Method of Heilman (HEL) using the Pulsar algorithm
Pulsar - The Pulsar program developed by Merriam & Wachter (1982) was used 
to detect serum GH concentration peaks. The program identifies peaks by 
combining criteria of height and duration after subtracting a calculated trend.
To account for the assay SD, which is known to be concentration dependent, 
the individual SD for each sample is calculated using the equation SD = ax  ^ + 
bx + c in which a,b and c are the constants in the regression equation of the 
assay control series. After subtracting the trend from the data, the residuals are 
divided by their SD leading to a series of signal-to-noise ratios. These ratios are 
tested using different cut-off criteria for peaks of different duration. Threshold 
values (G values) which keep the false-positive error rate on signal-free noise 
below 5% (Merriam 1982) are chosen. A smoothing time is set, the splitting cut­
off parameters and weight assigned to peaks. The number of peaks estimated 
by PULSAR compared to those found by visual inspection shows an excellent 
correlation for higher peaks, but small peaks detected visually do not meet 
criteria of PULSAR (Kuilboer 1992).
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HEL
With this method, the amount of secretion necessary to establish a peak 
concentration is calculated per peak, taking into account the ongoing 
elimination during the secretory episode. Significant peaks and baseline are 
estimated using the Pulsar program.
Clearance is assumed to be dependent on body weight and defined as
M GR = (ln2/t-^).V
in which V is the distribution volume. The distribution volume is calculated as 
7% of the body weight (Finkelstein 1972, Refetoff 1970). T% of 23.5 min is the 
mean reported from 3 studies (Refetoff 1970) .
The secretion per peak is represented by equation
S = V.rCi -(G o)+ (Co+ Cl) 
2.(ti-to/T]
where Co is the baseline G H  concentration at time t = 0, the beginning of the 
secretory episode. Ci is the peak G H  level, achieved during this secretory 
episode at time ti T = tVi
ln2
The GH secreted per peak is the amount necessary to obtain the peak serum 
concentration (Ci-Co).V added to the amount eliminated during this period. 
The latter is MCR.AUC or (ln2/tVi).V.(tl-to).(Co +C1). The total 24-hour 
secretion is the sum of all peak secretions, assuming no basal release.
A1.3 Deconvolution model of Veldhuis, Carlson and Johnson 
(DECONV) A 24-hour GH profile is the result of secretion of GH by the 
pituitary gland and concurrent elimination processes in the body.
The concomitant effects of these two processes can be described by a 
convolution integral. The reverse, going back from the result to the 
contributing process, is called deconvolution. In its simplest form, convolution 
is described by the following equation:
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C(t) = S(t)E(t-z)dz where C(t) is the concentration GH at time t, S(t) is the 
secretion function at time (t), and E(t-z) is the elimination function, which 
describes the metabolic removal that took place over the time interval (t-z). 
Veldhuis (1988a, 1992) assumes that G H  secretion from the pituitary gland takes 
place as a discrete finite series of molecular bursts of G H  release, each of which 
comprises a Gaussian-shaped pulse of G H  secretion with non-zero amplitude. 
Such a pulse is completely described by its location in time, amplitude and half­
duration. To describe the elimination processes, a first-order decay function is 
used. One of the parameters, tVz, is estimated individually, which is an 
important feature of this model. All the unknown parameters such as tVz, HD, 
the amplitudes of the pulses and the positions of the pulses are estimated by an 
iterative non-linear least-squares parameter estimation algorithm. During this 
process, the dose-dependent standard errors associated with each sample mean 
are used in the inverse weighting function. Total hormone secretion per day is 
calculated as the sum of the masses of hormone secreted (in m U /m l distribution 
volume) across all the identified secretory bursts. The mass of hormone 
released per burst equals the square root of 2pi times the product of the 
amplitude of the peak and its SD (SD of the secretory pulse, which equals 
HD/2.354).
A1.4 Deconvolution Model of Johnson, Lassiter and Veldhuis (PULSE)
The difference between this model and that of Hindmarsh, 1990, is the 
independence of the shape of the secretory pulse and the need to supply a fixed 
tVz for the hormone of interest. For the GH elimination process, a twophasic 
model is used with a 1st component tVz of 3.5min, a 2nd of 21 min and the 
relative contribution of the slow component to total elimination of 0.63, based 
on the observations by Faria (1989). The combined criteria of a significant rate 
of change of secretion (1st derivative) and a nonzero peak secretory rate identify 
significant hormone secretory peaks. Statistical confidence intervals for these 
two measures (sample secretory rates and their 1st derivatives) can be 
propagated by non-linear methods (Veldhuis 1990,1992).
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A PPEN D IX  2.0 
PRO CED U RES 1: M ETH O D S and EXCLUSIONS
A2.1 Practical procedures
The ethical approval is discussed in Chapter 2 and information sheet provided 
(Information: Al).
(i) Cannulation and blood sampling
The double lumen catheter was inserted into a main vein at the wrist of the left 
arm and the second cannula into the antecubital vein of the right arm (Figure 
A). Continuous integrated blood samples were taken by Watson Marlowe 
lOlU peristaltic pump (Figure B, Watson Marlowe Ltd. Marlborough, 
Buckinghamshire). The forearm bearing this cannula was maintained in a 
heated box throughout the morning study or overnight to arterialize venous 
blood (McGuire 1976).
The blood was prevented from clotting by the use of a double lumen 
cannula. This was made from a standard venflon (21 gauze, Viggo AB 
Helsinborg, Sweden) with the valve removed (using a number 7 stainless steel 
screw). The insert was constructed by using epoxy resin glue and fixing fine 
bore portex tubing (Portex Ltd. Highes Kent, UK) through a metal needle 
shaft, itself inserted through a luer cap. The equipment was gas sterilised with 
ethylene oxide. Heparin 6250 units per ml was infused through the outer 
lumen of the double cannula at 100 of the rate of blood withdrawal giving a 
final concentration of heparin in the blood of 62 units per ml. The 
countercurrent heparin infusion to the inner tube of the blood withdrawing 
needle was achieved using a hydraulic reduction system. The peristaltic pump 
had a separate pipe for distilled water, which was pumped up at the same rate as 
that of the withdrawal of blood: this distilled water was directed into a 100ml 
capacity glass syringe. The barrel of the 100ml syringe was connected back to 
back to the valve of a 1ml syringe containing the heparin. The ratio of the two
H eparin  flow
V enflon T runcated  19G needle
Blood flow
Luer cap
Heparin flow
Blood flow
Figure A The double-lumen blood-sampling needle
This consists of a 21G venflon (Viggo,UK) with a Portex tube central 
lumen fixed to a luer-lock cap using epoxy-resin glue. The inset shows 
how blood is heparinised within 2mm of the tip of the cannula.
Blood flow
from Venflon
Primer
mniiiTni n n n n r r n n n i
Heparin to sidearm Direction of rotation
" from Venflon 
Water
Wa t s o n  Ma r l o w P ump
Figure B The continuous blood withdrawal system.
Blood from the patient is taken through a rotary pump to a fraction 
collector. The first two drops of blood pass into a removable cap 
on the collecting tubes and is used for glucose analysis. Water is 
pumped simultaneously with the blood (lower inset) to a hydraulic 
system consisting of a 100ml glass syringe ‘back to back’ with a 
disposable 1ml syringe containing heparin. Thus retrograde heparin 
can be infused at 1/100 of the rate of withdrawal using a hydraulic 
ram system.
I n v e s t i g a t o r s  :
Dr, D.B. Dungor, Consultant Paediatrician.Dr. B.R. Pal, Research fellow. Department of Paediatrics, John Radcllffe Hospital. Oxford 64711, ext, 7799
Dear Dr.
We have been studying growth hormone production in young people with insulin dependent diabetes mellitus.
We have shown that adolescents with diabetes have higher levels of growth hormone in the blood compared to normal adolescents. We know that the higher level of Growth Hormone may contribute to problems in glucose control and interfere with the action of insulin as well as having a role in the development of other later complications of diabetes such as eye disease.
We are smarting a study to look at the effects that growth hormone has oi metabolism and your patient hasagreed to join in the study.
The study involves three admissions to one of the children's wards (4B if possible), each overnight. Your patient would arrive around 4,30 pn and have their evening meal in hospital with short acting insulia. On all occasions a cannula would be placedinto two arm veins. A drip containing somatostatin infusion to suppress endogenous growth hormone production overnight would then be started through one of the cannulae. During the night exogeneous grDwth hormone/saline would be given through the same cannula at intervals while the patient is asleep. S m a l lvolumes of blood would then be taken continuously from the other cannula to measure levels of growth hormone and glucose every 15 rains and insulin, glucose and other metabolites and growth factors .in the blood hourly overnight.The study would end at 8.00 am the next day and your patient would be given breakfast with his/her usual insulin and would be able to go tc school or work as usual.Your patient will require some minor changes in his/her insulin dose for a day or so beforehand, which will be explained in writing to them. During all the studies, we would give insulin/glucose to try to keep his/her blood glucose levels absolutely stable throughout the night.
None of the substances we would be using has any side- effects in the doses used, and apart from a day or so before the study nights, we would not be changing the usual insulin treatment. We hope that the results will help our understanding of the way that growth hormone levels affects control in diabetes, and may eventually help with some treatment options.
If you would like any further information, or if you do not think your patient should be included in' this study, please do not hesitate to contact Dr. Dunger or Dr. Pal at this hospital.
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syringes allows 1ml heparin to be infused for each 100 mis of distilled water 
pump.
Sampling intervals are given in the respective Chapters. 15minute blood glucose 
measurements at the bedside were required to maintain adequate clamp 
conditions. 15minute GH levels were needed to obtain overnight G H  pulse 
profile data but more frequent sampling for bolus half-life data reported in 
section 2.0.5. The facilities of a digital timer (Information: A2) was used to 
administer GH for GH signal studies.
A2.2 Comparative subject groups for half-life assessment
The subjects attending for GH clearance study (section 2.0.4) allowed 
calculation of bolus GH clearance. These results were compared to other G H  
clearance data.
(i) Subjects for half-life GH data after prolonged infusion
GH data was obtained from subjects attending for the GH signal study. A 
subset of subjects attending for 60minute pulse infusion (HJKLMP), median 
age 16.5years (range 13-27.9) median weight was 65,8kg (range 44-80.8), the 
median duration of the disease was 7.5 years (range 4 to IBy); daily insulin 
dosage was 54 units (30-74), 0.8 u/kg per day (range 0.6-1.1).
A different subset attending for the GH continuous infusion study (JLMNPQ) 
allowed estimation of steady-state GH (equilibrium), their age 20.5 years (range 
14 to 27.9y), median weight 70.5 kg (52-80.8) median duration of diabetes was 
9.2 years (range 6.6-18) and daily insulin dosage was 0.9 u/kg per day (range 
0.65 - 1.08).
The results of prolonged G H  infusion and effect on half-life are discussed in 
Chapter 3.
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(ii) Historical Control data
H indm arsh et al 1989, 1990 (Somatostatin suppression) (extracted from 
original manuscript)
Six male subjects (median age 19 years, range 17-45) who had been previously 
studied by Hindmarsh, (1989) was used as control group for bolus GH. Details 
of 10 normal subjects (age 18-23years) who had undertaken a study for 
assessment of half-life with different G H  exposures (15,30,60 and ISOminutes) 
by (Hindmarsh 1990) are provided in Table 2.1b. One of the control subjects 
was GH deficient after cranial irradiation; the remainders were normal healthy 
adult volunteers. These data have been previously reported and the authors 
used the similar protocol for half-life studies.
Bolus: Following an overnight fast, an indwelling intravenous cannula was 
inserted in the right forearm for the somatostatin infusion and for the 
administration of the bolus injection of exogenous GH. A second cannula was 
placed in the left forearm to obtain the blood samples. An infusion of 
somatostatin 1-14 (50pg/mVh) was commenced at 09.00h and samples for 
estimation of seiiim GH concentration were taken at 15minute intervals for 
one hour. At lO.OOh an intravenous bolus of biosynthetic human GH was 
administered in a dose of either 50 or 500 mU. Blood was drawn at 1 minute 
intervals for 30mins, at 5minute intervals for the following 30minutes and at 
lOminute intervals for a final 30minutes. Samples were spun separated and 
stored at - 2 0 G prior to measurement.
Shah et al 1999 (Octreotide suppression) (Taken from manuscript)
Recent GH data from Shah (1999) was utilised to define the serum GH 
concentration-decay curves for GH half-life data in healthy adult subjects 
(controls). Nineteen adult volunteers (13male, 6female) in good health with 
normal renal, metabolic and endocrine function (Table 2.1b). Bolus (6 male and 
6 female) and GH infusion (7 male and 6 female) studies were performed and 
these data have been recently reported to assess the effects of sex steroid 
hormone milieu, gender or menstrual cycle.
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Bolus’. Subjects were pre-treated with octreotide (Ipg/kg) infused continuously 
iv over 1 hour beginning at OZ.OOh (fasting), 1 hour before G H  injection and 
repeated every 5 hours during study period (Schaefer 1996). One hour after 
octreotide, each subject received each of three randomly ordered doses (1,2 or 
4pg/kg) of human recombinant GH by iv over one minute and consecutive 
injections were carried out 4 hours apart. Before the bolus G H  injection and 
thereafter, blood was samples every 5minutes for 30minutes and then every 
30minutes for 3 hours to define the serum G H  concentration-curves.
Continuous infusion: GH infusions were preceded by iv octreotide suppression 
(as described in bolus study) and studies were carried out after overnight fast. 
After the bolus GH administration, constant infusions of GH were commenced 
for 240 minutes at rates of 0.5, 1.5 and 4.5pg/kg.min. Each infusion dose was 
stopped for 120minutes before starting the next infusion dose. Blood was 
sampled every lOminutes for 4 hours during the infusions.
The control groups (Hindmarsh, Shah) used different GH assays to that used in 
this Thesis. These were compared: A high correlation coefficient between the 
three immunoradiometric assays (NETRIA, Hybritech, Nichols) was 
established (NETRIA-Nichols: r 0.97, p <  0.001; NETRIA-Hybritech r=0.98, 
p <  0.0001). The GH half-life by mono-exponential analysis obtained by 
NETRIA, Hybritech and Nichols kit were not significantly different: 13.6, 13.7 
and 13.8min respectively.
A2.3 Subject Exclusion
GH Clearance study
Subject A, who was the first subject studied for half-life morning studies, was 
excluded as practical problems required readjusting.
Subject G did not attend for third morning (family commitments)
GH signal study
Subject H(l-3) had unusual GH profile during one study night suggesting 
infusion pump/clock timing malfunction and although she attended for 3
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studies, metabolic data was disregarded but one night G H  data was utilised for 
half-life studies.
Subjects who developed hypoglycaemia BG < 2  mmol/1 during use of 
variable insulin clamp with somatostatin infusion included 
Subject K3 and P I (came back for a P4 night).
Subject refusal
Subject N3 did not attend for third occasion as he refused to be a research 
subject.
A2.4 Practical Problems and patient discomfort
Overnight metabolic studies using SRIH and glucagon infusions induced nausea 
and vomiting for 1-6 hours in 5 patients (total of 9(36%) study nights) after 
stopping infusions at 0800h; two patients developed keto-acidosis because of 
persistent vomiting, one of these was found to have Rotavirus ultimately. Both 
glucagon and SRIH decrease gastric motility and cause nausea and vomiting 
and it was difficult therefore to find the exact cause particularly as other factors 
such as morning nausea and one patient had clearly identifiable vomiting 
initiated after removal of intravenous cannula (vasovagal). However, being 
altruistic adolescents, all but one volunteer, returned to complete all profile 
nights and for this I am truly grateful.
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A PPENDIX 3.0 
IN FU SIO N S A N D  ASSAYS
A3.1 Infusions
(i) Recombinant hum an G row th H orm one (r-hGH)
Somatotropin is the internationally approved name for recombinant DNA- 
derived 22k-Da human GH.
G H  stability - Buffer Solution (control) and G H  infusion
Stability of GH as an infusion must be achieved before use in research studies. 
Advice was obtained from Kabi Pharmaceuticals (Stockholm) regarding the 
constitution of Buffer solution.
The Buffer solution was made up as follows: Aminoacetic acid (glycine) 24mg/ml; 
Sodium dehydrogen phosphatefwith 12 molecules water) 0.64904 mg/ml; monosodium 
dihydrogen phosphate (with 1 molecule water) 0.30184 mg/ml.
The GH infusions are described in 2.1.6
(ii) Insulin
Insulin infusion was achieved through a separate cannula inserted in the 
antecubital fossa. The insulin infusion rate was made up to a correction of 0.04 
units per ml by adding 20 units of human actrapid insulin (Novo Laboratories) 
and 2 mis of the subjects blood to 48 mis of 0.9% saline or more dilute at 0.01 
units per ml by adding 5 units of human actrapid insulin to the blood. 
Adjustment of the insulin infusion rate was by syringe pump (Treonic IP3; 
Vickers pump, Basingstoke, Hants, UK).
(iii) Somatostatin infusion (Chapter 2 and 5,6)
During morning studies, a bolus dose of 50pg SRIH was given followed by 
infusion at 50pg / mVhour over 270minutes (section 2.1.4).
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The overnight Somatostatin infusion (30 meg/ml) was made by adding 
1500mcg of a 3mg vial of somatostatin 1-14 (Stilamin, Serono, S.p.A, Rome, 
Italy) dissolved in 2ml water, to 49ml 0.9% saline and infused at a rate of 50-100 
m cg/m 2/h between 19.00-08.OOh by a similar Vickers syringe pump. The 
solution was changed after 6 hours.
(iv) Glucagon infusion (Chapter 6)
The glucagon infusion (Imcg/ml) was 0.5mg of Img vial of glucagon (Novo 
Industri, Bagsvaerd, Denmark) in 10ml 0.9% saline (50mcg/ml) then adding 
1ml of this to 49ml 0.9% saline. The same solution and glucagon was used 
throughout the study and the glucagon was infused through a Vickers syringe 
pump at a rate of Ing/kg/m in between 19.00-08.OOh.
A3.2 Assays
(i) G H
Samples for GH assay were kept at room temperature until the profile was 
complete and then were spun, separated and the plasma was frozen and stored 
at -20°C until assay. Plasma GH concentrations were measured by 
immunoradiometric assay (Netria, St Bartholomew’s Hospital, London) using 
an international reference standard 80/505 and all the samples from subject’s 
overnight profile were analysed in the same batch.
It has been assayed for 30 years in serum or plasma and most immunoassayists 
would not consider GH heterogeneity to be a major factor affecting the validity 
or clinical usefulness of such assays.
Comparison of G H  assays: Plasma G H  was measured by an
immunoradiometric assay (Netria, St Bartholomew Hospital, London) using 
the international reference standard 80/505, and all samples from each patient 
were analysed together in batch. Sensitivity of the GH assay was 0.3 mU/1 
(0.15 micrograms per litre); the inter-assay coefficient of variation (CV) at GH 
concentrations of 3.5, 15.2 and 77.4 m U /L were 9.4%, 7.7% and 10.5%
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respectively and intra-assay CV at G H  concentration of 2.9, 17.7 and 69.4 
m U /L  were 8.0%, 4.9% and 3.4% respectively. Samples from two patients (B,E) 
were also measured with two additional immunoradiometric assays; the 
Tandems-R immunometric kit (Hybritec, Europe) and the Nichols Institute 
Diagnostic (St. Juan, Gapistrano, CA).
The Hybritec IRMA may not detect 20K GH isoforms, whereas the Nicholls 
kit (Sanjuan/Capistrano, CA) may measure the 20K and the 22K G H  forms. 
In addition the Hybritec kit is highly specific for monomeric GH; the inter 
assay co-efficient variation for the Hybritec kit was 10.8% at a serum 
concentration of 5.8 mU/1 (2.9 micrograms per litre). The intra assay co­
efficient of variation at serum G H  levels of 2.8 mU/1 (1.4 micrograms per litre), 
6.2 mU/1 (3.1 micrograms per litre), 26.4 mU/1 (13.2 micrograms per litre) and 
90.4 mU/1 (45.2 micrograms per litre) were 10.6%, 7.8%, 4.9% and 4.9% 
respectively. Sensitivity was 0.5 mU/1 (0.25 micrograms per litre). Standard 
was HS 2443E (NI8) which had been recalibrated to milliunits per litre with the 
first international reference preparation 66/217 (1 micrograms per litre = 2 
milliunits per litre).
Nicholls Kit The intra assay co-efficient at GH concentrations of 3.3, 27 and 
65meg per litre were 8.3%, 4.3%, 3.9%. The inter assay co-efficient of variation 
was 9.7% at a serum concentration of 3.6 micrograms. This precaution was 
taken as the GH samples from G H  half-life studies performed on control 
subjects by Hindmarsh 1989,1990 were assayed by the Tandems-R 
immunometric kit (Hybritec, Europe).
The G H  levels are reported in all my studies are plasma G H  levels 
measured from the N etria kit unless otherwise stated.
(ii) Insulin
For measurement of plasma free insulin, 1.0ml whole blood was added 
immediately to 0.6ml ice-cold 25% polyethylene glycol (PEG, mol. Wt. 6000 
Sigma Ltd, Poole, UK). Samples were stored at 0° to 4°C, then centrifuged at
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3000 rpm for 35minutes and separated within 13 hours (Collins 1985). The 
plasma was stored at -20°C and assayed within 3 months. Assay was by 
double-antibody radioimmunoassay (Guildhay Antisera Ltd., Guilford, UK) 
modified by Morgan and Lazarow (Morgan 1965). Interassay coefficients of 
variation at 12.2 and 47.2 m U /L  were 5.5 and 8.6% respectively.
(iii) Ketones
For ketone measurement 1.0ml whole blood was added immediately to 3.0ml 
of ice-cold 10% perchloric acid (PGA) and mixed. Samples were stored at 0° to 
4°C for 13 hours, then spun and the precipitate discarded. The supernatant was 
neutralised using 2% and 20% potassium hydroxide and 10%PCA. Assays of all 
three metabolites were standard enzymatic techniques (Williamson 1979). Inter- 
and intra-assay CVs for the (30HB assay were 8.3% and 2.2%; and for the 
acetoacetate assay 5.3% and 2.2%, respectively. Lactate inter- and intra-assay 
CVs were 5.1% and 1.0%, respectively.
Glycerol was assayed from the same sample as ketones and the interassay CV 
was 3.4%. As only a few subjects’ profiles had this analysis, I have omitted this 
in final analysis.
(v) N E F A
Samples for free fatty acids (NEFA) were kept in EDTA at room temperature 
until the study was complete then spun, separated and stored at -20°C until 
analysis. Assay was by enzymatic colorimetric kit (Wako Chemicals & Alpha 
Laboratories, Eastleigh, Hants, UK), The inter-assay CV at 0.39mmol/L was 
4.4% and intra-assay CVs at 0.33, 0.62, 0.99 mmol/L were 2.7%, 1.1% and 
1.1%, respectively.
(vi) IGF-1
Serum IGF-1 was measured after acid-ethanol extraction then by double 
antibody RIA by method (Holly 1988).
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A P P E N D IX  4.0 
STATISTICS A N D  ANALYSIS
Statistics is the science of collecting, summarising, presenting and interpretating 
data and of using them to test hypotheses. During the last two decades it has 
assumed an increasingly central role in medical investigations. The reasons are 
many but may be principally that statistics provides a way of organising 
information on a wider and more formal basis than relying on the exchange of 
anecdotes and personal experience; more things are now being quantitatively 
measured in medicine; there is a great deal of intrinsic variation in most 
biological processes.
A full listing of the statistical texts that have been referred to in this Thesis are 
provided in the Bibliography and a summary of the main techniques employed 
are provided in this appendix.
A4.1 C om puting o f data
Between 1989-1993, most of the calculations were done on the Oxford 
University IBM computer with some later usage on the Birmingham University 
Honeywell DPS-8/70M  mainframe computer. The programmes used were 
OXSTAT ver 4 and 5 and SLIDEWRITE and the BMDP Biomedical 
Computer Programs (University of California, Berkley, USA). Post 1993, 
Microsoft Office programmes performed word-processing, data transfer and 
analysis and Stats view and Minitab programmes.
Standard formulae were used for the calculation of means, standard deviations 
(SD) and standard error of the mean (SEM). Student's t-test (paired and 
unpaired), Analysis of Variance and non-parametric tests for non-normalised 
data (Mann-Whitney U, Spearman rank correlation) were used as appropriate. 
The results are plotted graphically by computer programmes updated through 
Microsoft Office programmes.
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A4.2 Normalising data
Group results are given as m e a n S E M  unless otherwise stated. Where SD are 
provided this can be converted to SEM =SD/VN, where N  is number of 
subjects in study. Blood glucose and insulin infusion data were normally 
distributed. Log-transformation normalised the ketone, lipid and plasma free 
insulin data and therefore parametric statistical techniques have been used on 
these log-transformed data.
A4.3 Statistical analysis
Between 1989-1994, analysis using OXSTAT (Oxford University) and 1998- 
2000 the online help facility in Minitab 10.51 was utilised.
(i) Students’ t  test
Student's paired t-test was used for comparisons of mean data between
overnight profiles and at individual time periods.
The statistical method to use to compare two metabolic profiles has been 
discussed by Nattrass (1982). The choice is between:
Students' t test comparing means at each time point. This may show
statistically significant differences at specific time points but not show whether 
there was an overall difference between the profiles, although if the majority of 
individual time points were different then the whole profile would probably be 
different. Also the biological significance of a statistical difference at one or two 
time points during a 12hour-study night is difficult to assess.
A total mean value for a period studied can be calculated for each patient in a 
group and these values then compared between groups
(ii) ANOVA, Analysis of Variance (one way and two way)
Analysis of variance (2-way ANOVA) was used to examine changes with time 
and confirm differences between study nights.
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Two-way analysis of variance with metabolite concentration classified by group 
and time (Armitage, Blackwell Science,UK). It is possible with this method to 
compare the differences in the variance between two groups removing the 
variance due to the time the samples were taken. Each sample value is used in 
this method rather than a derived mean. The significance of the difference 
between groups was calculated from the variance ratio using F-tables.
(iii) M ann-W hitney test
The Mann-Whitney test was used to compare the G H  secretion data between 
puberty groups as this was not normally distributed. The Mann-Whitney test is 
commonly regarded as a test of medians where one median is an estimate that 
of the probability that one variable is less than the other (Altman 1991). 
However, it is a test of both location and shape. Given two independent 
samples it tests whether one variable tends to have values higher than the other. 
However, it is also important to look at distribution differences or spread. I 
have therefore provided the range of GH secretion for each puberty group. 
This will provide the features that are most clinically important. The 
hypothesis that there was no difference between puberty groups can be rejected 
as both median and spread of the difference is different between each puberty 
group.
(iii) Regression and Correlation
Regression functions can be either linear or of higher form. By changing the x 
or y scale non-linear functions are always converted, to linear ones, since the 
mathematical treatment for this is simpler (y = a+bx). The gradient b is 
known as the regression coefficient and is the angle between the regression 
line and the abscissa and can be positive or negative (inclined left or right).
The gradient b shows how many times y is smaller or greater than x. It is 
calculated by dividing the co-variance of the product (x.y) by the variance of
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the individual values x. This relates to the common regression of y to x, 
where y is the dependent variable and x the independent variable.
The opposite regression, x to y, gives as a rule a regression line somewhat 
differently inclined to that of the regression y to x. The measure of the 
mutual behaviour of these two lines gives the correlation coefficient r. This 
is the geometrical mean of the two regression coefficients. The relation 
between the regression coefficient bxy and the correlation coefficient r is given 
by
r  = bxy Sx
Sy
The square of the correlation coefficient is the measure of certainty and 
shows to what extent the independent variable x influences the dependent 
variable. A measure of certainty of 0.5 indicates that 50% of the changes in y 
can be explained as due to changes in x. There is no actual proof that the 
connection is a causal one and the result should be regarded as a pointer to the 
direction in which further investigation would yield direct proof.
(iv) Cross-correlation
Cross-correlation is an iterative technique for establishing whether there are 
statistically coincident recurring waveforms (of any shape) within a data array 
(Matthews 1983). One data array is serially correlated against the other with 
progressive step changes in the tome-relationship between the data. The result 
is dependent both on the relative amplitude of such waves or pulses (e.g. 
whether large pulses of one array are associated with large pulses of the other) 
and on the phase relationships between the arrays (whether one data array is 
time-lagged with respect to the other. It is independent of absolute 
concentrations of hormone.
(v) Probit Transform ation
The probit transformation is useful in all cases where a distribution must be 
tested for normality or where the parameters of a population must be
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determined as exactly as possible from a few values which are known to have 
originated from a normally distributed population. Continuous summation 
(from left to right) of the area under the normal distribution and plotting the 
areas against a linear abscissa yields a sigmoid curve. The values of its ordinates 
correspond to the areas of the normal distribution.
The sigmoid curve may be transformed into a straight line by means of the
probit transformation, whereby the frequency percentages (= areas xlOO) are
converted into corresponding deviations of the normal distribution increased
by the addition of 5 and these are known as prohits. Probits may be obtained
without the need for calculation from tables (Statistical Tables for Agricultural,
Biological and Medical Research, 1953 by RA Fisher and F Yates; published by
Oliver and Boyd, Edinburgh).
Optional Calculations
CF = Cumulative frequency
EP = Empirical probits (derived from statistical tables, Fisher &
Yates 1953)
PP = Provisional P robit This is obtained from the regression
line on probability paper
This calculates mean value and A co-ordinates
A (when x = 0, y=  the minimum PP)
Maximum PP is at maximum C H  concentration
The points of intersection at x provide the provisional probits
Values for the C H  concentrations are then read off
N  = Provisional Probit x cumulative frequency (CF) ratio
W P = working probit is (N 4- m inim um  PP) for each class
WC ™ weighting coefficients is PP x num ber of samples
(vi) Confidence Intervals
The confidence interval is the range on either side of a sample mean, Alpha (a) 
is the significance level used to compute the confidence level. The confidence 
level equals 100x(l-a)% or an a  of 0.05 indicates a 95% confidence level. If a  is 
assumed to equal 0.05, the area under the standard normal distribution curve
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that equals (l-ot), or 95% is 1.96 and the confidence interval is therefore 
calculated as
g ( S D )
Mean (x) ± 1.96 (VN )
A4.4 Missing D ata
Missing data were handled as follows. On only 11 sampling occasions was 
insufficient blood obtained and on a further 9 occasions laboratory problems 
led to the loss of single measurements. The missing values were replaced by 
the mean of the previous and subsequent measurements. In all this amounted 
to 0.3% of the metabolic and hormone data.
Main Statistical References used in this Thesis are provided in Bibliography
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A P P E N D IX  5 
IN SU L IN -V A R Y IN G  CLAM P
Glucose clamping (DeFronzo 1979), whereby a preselected plasma glucose 
concentration is maintained in spite of the action of endogenous or exogenous 
insulin, has become a commonly used physiological tool to examine both 
insulin sensitivity and beta-cell function. Both hyperglycaemic and euglycaemic 
clamps have frequently been used and a variety of algorithms have been 
published (Pacini 1982) which achieve clamping by altering glucose infused. 
However, all these methods use a fixed mathematical formula as a basis of their 
calculation, requiring the insertion of several constants that make some basic 
physiological assumptions about the insulin requirement at the outset. There 
are also disadvantages to such a system of maintenance of blood glucose 
concentration as both hyperglycaemic and euglycaemic clamps are often 
undertaken against a background of high insulin concentration.
These always make some basic physiological assumptions about the insulin 
requirement at the outset with the possibility of biasing the results. An 
unbiased method of similarly using an insulin infusion is therefore needed to 
more accurately measure insulin requirements particularly during adolescence 
when these requirements may be changing substantially. Insulin-varying glucose 
clamping is more difficult but has been used previously in the form of a 
prefixed sliding scale or the Biostator or other algorithm. These cannot be made 
during puberty when insulin resistance is known to change. In assessing Type 
1 diabetes the quantity of insulin required for maintenance of basal state can be 
more informative clinically, and under such circumstances one wishes to vary 
insulin rather than glucose.
Differentiating the GH  Signal, BRP 2002 199
A5.1 Principle o f the program m e developed by M atthew s et al 1989
Minimal models have been utilised for glucose-clamping (Pacini 1982) and most 
of these algorithms for clamping are
New prediction = /[pre-existing state] + /[current data] + /[tim e]
The data for each function(/) are discrete and usually based only on one or two 
readings. The new predictions depend critically on formulae that are 
preconceptions of the way that the body functions or are derived from mean 
approximations of glucose change. Some have used arbitrary ‘factors’ to 
compensate for changing circumstances during a clamp. The computer 
programme developed by Matthews 1989, adopts ‘experience’ rather than 
preconception as the basis of its prediction. By abandoning a fixed algorithm it 
is possible to accumulate many data entries into an internal table or array . The 
data for the internal array are calculated as the change of glucose concentration 
that has occurred against the insulin infusion rate given which caused the 
change. There is a time lag of insulin action that is built into the programme. 
Every new glucose concentration reading is matched with the 20-40min 
previous insulin-infusion datum and inserted into the array. Duplicate data to 
either infusion data or rate of change data that pre-exist in the array are pooled 
using an arithmetic mean and the rank order of infusion data is maintained by 
sequential sorting. If the infusion rates are within 1% of each other, they are 
averaged so that the array in the computer does not linearly increase in size 
throughout the clamp. The initial array is 3 values only and this increases 
progressively throughout the clamp. From this data it is possible to read 
directly, or by linear interpolation, the insulin infusion rate that will be 
required to change the observed glucose concentration to that required. The 
minimal assumption made is therefore that after accumulating data about cause 
and effect, one may then use the knowledge to predict an effect from a cause.
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A5.2 U se o f the Program m e
1. Starting assumptions
In practice an initial assumption is required to establish an infusion rate. The 
basic tenet is that over a short period of time there will be no change of glucose 
concentration if no insulin is given. The array consists of three points only at 
this stage. Once the programme is running even this minimal assumption is 
rapidly abandoned in favour of the accumulated information from successive 
sampling.
2. Adjustments o f array during dam p
The accumulated array of data (rate of change in glucose concentration versus 
insulin infusion rate) is continuously updated and rationalised by averaging, 
sorting and deletion of redundant data.
3. Lag phase
Changes in blood glucose do not occur instantaneously with changes in insulin 
infusion. There are delays in mixing, sampling (dead-space) and assaying the 
blood glucose concentration. The delay can be found in any system by cross­
correlation or simply by checking the time lag (y min) between insulin 
administration and a change in glucose being measured. This data can be used 
by the programme that then assumes that the current glucose concentration is 
consequent on the infusion that was running y min before the reading. 
Inaccuracies in this estimate are not critical because the averaging and ranking 
allows for ‘noise’ in the system.
4. Outliers
Assay points that are outliers (eg an individual poor assay of glucose) cause a 
response in insulin advice immediately. The data are entered by the computer 
in the periphery of the array. If the next glucose value is a non-outlier, the
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central area of the array is utilised again and the outlier has not interfered with 
the near clamp-level part of the array. Thus the overall effect of an outlier is 
small and a noisy assay does not lead to an oscillatory phenomena. There are no 
continuing perturbations from one outlying result.
5. Flexible options
Sample time interval: Because the array is accumulated in terms of
concentration change against infusion rates, it is immaterial, within certain 
limits, what the blood sampling interval actually is. Nevertheless the system 
time-characteristics are constrained by the delay in insulin action and in practice 
10-15min sampling is the shortest time that can be used. The upper limit is 
constrained by the fact that too long a sampling interval will not monitor 
changes adequately, and in practice 30 minutes is probably the longest advisable 
time between samples. The sample interval can be changed easily at any time. 
Reaction speed: The computer prediction for infusion rate can be adjusted to 
correct the current blood glucose concentration to the requested concentration 
over a range between 30 and 60 minutes. Slow reaction speeds are inefficient 
and fast reaction times may cause overshoot. In practice, if one wishes the 
changes to be approximately exponential towards the requested clamp level, 
then an achievement of two-this of the deviation between successive samples 
will achieve this. Thus the reaction speed is set within the programme as being 
1.5times the sample interval. The reaction interval can be lengthened to reduce 
deviations in the infusion rates, or if the blood glucose concentration ‘hunts’ 
about a mean.
Changing the clamp level: The clamp level can be changed at any time to 
allow a change from ‘basal’ to ‘clamp’ period.
Disc storage: Data are accumulated on disc every time the data array is 
updated. Interim and terminal storage and print-outs can be easily requested.
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This method is an effective, cheap and unbiased method of quantifying insulin 
requirement. It has been validated in adolescents with Type 1 (insulin- 
dependent) diabetes (Matthews 1990) and this system has been shown to be 
sensitive maintaining a clamp glucose concentration of 5.3 +0.2 mmol/L (blood 
glucose remained above 3.0mmol/L at all times and no glucose was needed for 
the correction of hypoglycaemia). Thus the insulin infusion rate is equal to the 
insulin requirement for the maintenance of euglycaemia.
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APPENDIX 6 
RAW DATA
A6.1 Illustration of overnight G H  (profiles and deconvolution)
A6.2 Probit Tables
A6.3 G H  signal: IGF-1 and cortisol
D e c o n v o l u t i o n  d a t a
Raw data is displayed by puberty group and sex. Each profile shows secretion rate, 
plasma GH and calculated variable half-life.
Overnight (20.00-08.00h) GH profiles taken at 15 minute intervals were deconvoluted 
by the method of Hindmarsh 1990. Diabetic subjects have normal insuhn regime 
nights (NR) compared with their own respective individual euglycaemic dam p night. 
Control (normal healthy puberty-matched) subjects are displayed by sex and puberty 
group in the following section.
Key
X axis = time in minutes
y  axis = Plots relate to : GH secretion (mU/min) or Hasma GH (mU/L) or HaH-Mfe (mins)
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GH signal study
IGF-1 data
Data for subjects JLMP
(normal IGF-1 value for stage 5 puberty: median 1.11 U/ml (0.53-2.04)
Study Time 
clock time mins
Pulse
mean IGF-1 (SD) 
U/ml
Continuous
mean IGF-1 (SD) 
U/ml
Control
reference
mean lGF-1 (SD)
p value 
(by ANOVA)
20.00h 0 1.21 (0.39) 1.37 (0.59) 0.95 (0.22)
22.00b 120 1.07 (0.04) 1.31 (0.20) 0.99 (0.26)
24.00b 240 1.06 (0.08) 0.96 (0.17) 0.94 (0.12)
02.00b 360 1.12(0.22)* 0.85 (0.24) 0.95 (0.20) p=0.025*
04.00b 480 1.11(0.16)* 0.95 (0.23) 0.92 (0.25) p=0.006
06.00b 600 0.98 (0.26) 1.02 (0.42) 0.99 (0.14)
08.00b 720 0.92 (0.37) 0.94(0.41) 0.96 (0.10)
Subject 
mean ovemigbt 
20-08.00b
Pulse
mean lGF-1 (SD) 
U/ml
Continuous
mean lGF-1 (SD) 
U/ml
Control
reference
mean lGF-1 (SD)
p value 
(paired t test)
J 1.08 (0.12) 1.00 (0.11) 1.10(0.05)
L 0.94 (0.13) 0.78 (0.20) 0.97 (0.21)
M 0.92 (0.21) 1.07 (0.56) 0.89 (0.08)
P 1.34 (0.22) 1.37 (0.17) 0.88 (0.20)
mean 1.07 (0.09)* 1.06 (0.20) 0.96 (0.02) p=0.02*
Data for subject J
GH signal study
Cortisol data
Study Time 
clock time mins
Pulse Continuous Control
reference
p value 
(by ANOVA)
21.00h -60 218 489 219
20.00h 0 145 246 138
21.00h 60 231 131 154
22.00h 120 143 82 76
23.00b 180 102 56 61
24.00b 240 60 40 50
01.00b 300 67 <27 130
02.00b 360 44 83 296
03.00b 420 42 44 131
04.00b 480 155 32 87
05.00b 540 307 183 78
06.00b 600 261 400 376
07.00b 660 434 373 326
08.00b 720 549 462 542
Subject 
mean ovemigbt 
20-08.00b
Pulse Continuous Control
reference
p value 
(paired t test)
J
L
M
P
mean
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